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ABSTRACT 
Telomere attrition during mitosis is thought to be a mechanism for cell 
senescence, which is induced when the mean length reduces below a critical value. 
Oxidative DNA damage has been suggested to cause greater telomere loss per cell 
division. Thus telomere length indicates the cells‘ replicative capacity and ―biological 
age‖. Premature tissue ageing and senescence are major features of cardiovascular 
disease (CVD) and type 2 diabetes (T2D), and as such telomere length might play an 
important role in their pathogenesis. The aim of this thesis was to explore the 
association of telomere length with CVD and type 2 diabetes (T2D) as well as the 
CVD/T2D risk factors determining telomere length. 
The present study showed that telomere length is shorter in CVD and T2D 
patients compared to healthy subjects. As to what determines telomere length, I found 
that at least in the case of CVD, it can in part be partly attributed to inherited short 
telomeres, expressing the family history of the disease. At the same time, in diabetes 
patients I have observed that high oxidative stress, probably induced by the disease risk 
factors in the patients, is associated with greater telomere shortening. The later was 
consistent with the association found between variation in genes regulating reactive 
oxygen species levels, and shorter telomeres. I further examined the possible 
determinants of telomere shortening with in vitro experiments on ageing fibroblasts. In 
this case, the effect of glucose-induced oxidative stress and/or pro-inflammatory 
conditioning on telomere shortening was tested. The results showed that pro-
inflammatory conditioning, partly by inducing an increased cell turnover, aggravates the 
shortening of telomeres in long-term culture. 
Telomere length may prove to be very useful in the management and possibly 
the prediction of CVD and diabetes, representing the contribution to their pathology of 
age, oxidative stress and chronic inflammation.  
 
Total thesis word count: 80,880 
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I. INTRODUCTION 
 
1. IMPACT 
 
1.1 IMPACT OF CARDIOVASCULAR DISEASE 
The years following World War II cardiovascular disease (CVD) replaced 
infectious diseases as the leading cause of deaths. Today more people worldwide die 
from the complications of CVD than from any other cause. According to the World 
Health Organization (WHO), 17.1 million people died from CVD in 2004, representing 
29% of all global deaths. An estimated 7.2 million of these deaths were due to coronary 
heart disease (CHD) and 5.7 million were due to stroke. By 2030 another 23.6 million 
people are expected to die from CVD (WHO, Fact sheet on cardiovascular disease, 
www.who.int). 
More than 190,000 deaths in the United Kingdom (UK), a third of all deaths, 
were caused by CVD in 2007. CVD is also a major cause of premature death (death 
before the age of 75) accounting for almost a third (29%) of premature deaths in men 
and over a fifth (21%) in women (British Heart Foundation (BHF) statistics 2007, 
www.bhf.org.uk). The main components of CVD are CHD and stroke. Around half of 
all CVD deaths are from CHD and about a quarter from stroke. CHD, by itself, is UK‘s 
number one killer and the most common cause of premature death, with approximately 
2.6 million people in the country currently suffering from CHD (BHF, UK CHD 
statistics 2009-10, www.bhf.org.uk). This is illustrated for Europe in figures 1A and 1B. 
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Figure I-1. Percentage of deaths by cause in Europe for 2007 (British Heart 
Foundation (BHF) statistics 2007, www.bhf.org.uk). 
A) In men. 
 
A) In women. 
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Medical care of CVD patients is costly and usually prolonged. By itself the care 
of CHD patients costs the health system of UK around £3.2 billion a year (British Heart 
Foundation, UK CHD statistics factsheet 2009-10, www.bhf.org.uk). Nonetheless, 
estimating the costs of CVD to the health care system underestimates the total cost to 
the society‘s resources. CVD affects people in their peak mid-life years, disrupting the 
future of the families dependent on them and depriving the society of a highly 
productive and experienced working force (International Cardiovascular Disease 
Statistics of the American Heart Association, www.americanheart.org). 
 
1.2 IMPACT OF DIABETES 
According to the International Diabetes Federation (IDF) estimates, 285 million 
people worldwide have diabetes and this number is expected to reach 438 million 
people by 2030, corresponding to the 7.8% of the adult population (IDF Diabetes Atlas, 
Fourth Edition 2009, www.diabetesatlas.org). The increasing prevalence and severity of 
diabetes creates one of the most challenging health problems of our century 
In the UK around 1.9 million people have been diagnosed with diabetes and 
another 600,000 people are estimated to have undiagnosed diabetes. The prevalence of 
diabetes has been continuously increasing also in the UK, as in most countries around 
the world, with estimates reaching 3 million people by 2010 (British Heart Foundation, 
UK CHD statistics factsheet 2009-10, www.bhf.org.uk).  
Diabetes impact on society is very significant. Approximately four million 
deaths in the 20-79 age group are attributable to diabetes in 2010, accounting for 6.8% 
of global all-cause mortality in this age group. These deaths are expected to double 
between 2005 and 2030. For Europe, the mortality percentages attributable to diabetes 
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are shown in figure 2. While the cost of diabetes to the healthcare systems around the 
world is estimated to be very high (around 376 billion US Dollar in 2010), the largest 
economic and social burden is associated with disability and loss of life as a result of the 
disease itself and its related complications (IDF Diabetes Atlas, Fourth Edition 2009, 
www.diabetesatlas.org).  
 
Figure I-2. Percentage of all-cause mortality attributable to diabetes by age and 
sex in Europe for 2010 (IDF Diabetes Atlas, Fourth Edition 2009, 
www.diabetesatlas.org). 
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Despite the significant advances in the prevention and treatment of CVD and 
diabetes in recent years, these still represent the prime health problems around the globe 
with immense impact on society‘s prosperity, rendering the need for deeper 
understanding of their pathology and improvement in their prevention an urgent issue.  
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2 CARDIOVASCULAR DISEASES  
 
2.1 THE CARDIOVASCULAR SYSTEM 
The cardiovascular system consists of the heart, the vessels and the blood. Its 
main function is to transport and distribute essential substances, such as oxygen, 
nutrients, water and electrolytes, to all tissues and to remove byproducts of metabolism. 
The cardiovascular system also serves homeostatic mechanisms such as the regulation 
of body temperature and humoral communication among tissues and organs (Robert M. 
Berne 1993a). 
2.1.1 The heart 
 The human heart is a muscular pump serving two distinct blood circulations, the 
pulmonary circulation, where the blood is impelled towards the lungs for the exchange 
of oxygen and carbon dioxide, and the systemic circulation, where the blood is impelled 
towards all other body tissues. The interior of the heart is divided into four chambers, 
two atria and two ventricles. The atria are responsible for receiving blood from the veins 
leading to the heart and in turn they deliver the blood into the ventricles. During 
contraction the ventricles pump the blood out of heart with enough pressure in order to 
pass through all body tissues and return back to heart. The heart valves are responsible 
for the unidirectional blood flow (Robert M. Berne 1993a).  
2.1.2 The systemic circulation 
The systemic circulation is an extended network of vessels, which consists of a 
series of distributing and collecting large vessels and an extensive system of thin vessels 
with capillary endings which allow the exchange of substances between the intracellular 
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matrix of tissues and the blood. The blood is pushed away from the heart through the 
aorta and its arterial branches. These are progressively divided into smaller arteries and 
even thinner vessels the arterioles which eventually end in capillaries. The blood from 
the capillaries then flows into thin vessels called venules, which drain into larger 
vessels, the veins. The veins progressively increase in size, until the blood is transferred 
back to heart into the right atrium.  
A special part of the systemic circulation is the coronary circulation, a network 
of vessels, which supply with blood the myocardium. The right coronary artery supplies 
blood principally to the right atrium and ventricle, and the left coronary the left atrium 
and ventricle with a partial overlap. The blood from the heart tissues is mainly collected 
by the coronary sinus which returns the blood to the right atrium. Another special 
circulation, again part of the systemic, is the cerebral circulation, which distributes 
blood to the brain tissues. The vertebral arteries in conjunction with branches of the 
internal carotid artery form a network called the circle of Willis, which supplies the 
brain with blood (Robert M. Berne 1993a). 
2.1.3 The vascular wall 
 The vascular wall consists of three distinct layers, which from the inner to the 
outer are the intima, the media, and the adventitia. These layers are separated by two 
elastic laminas. The intima is mainly composed of a single layer of endothelial cells 
facing the lumen and a small amount of sub-endothelial connective tissue. The 
neighbouring endothelial cells are connected with tight junctional complexes. The 
endothelium forms a barrier between the blood and the arterial wall and is a dynamic 
cellular layer regulating a number of functions such as vascular tone, leukocyte 
adhesion and thrombosis. The media is the thickest layer which provides structural 
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support and consists of multiple layers of smooth muscle cells (SMC) held together by 
an extracellular matrix, consisting mainly of elastic fibres, collagen, and proteoglycans. 
The adventitia is composed of a loose matrix of SMC, fibroblasts, collagen and elastin. 
In the adventitia are located vessels nourishing the vascular wall tissues (vasa vasorum) 
and autonomic nerves (nervi vasorum) (M. C. Stuhlinger 2003). 
The walls of arteries are thicker than that of veins in order to withstand the 
higher blood pressure (BP). The arterial thickness and the media composition depend on 
the location, size and function of the artery. For example in large arteries, the media is 
abundant in elastic fibres, while in medium-sized arteries the media is abundant in 
SMCs (M. C. Stuhlinger 2003). 
 
2.2 WHAT IS CARDIOVASCULAR DISEASE 
Cardiovascular disease is an umbrella term for all diseases of the heart and blood 
vessels. The two main diseases in this category are CHD, with the end points of angina 
and myocardial infarction (MI), and cerebrovascular disease, with the end point of 
stroke. Moreover, CVD includes peripheral artery disease, rheumatic heart disease and 
congenital heart disease. CHD, cerebrovascular disease and peripheral artery disease are 
diseases of the blood vessels, mainly caused by the development of plaques on their 
inner wall. This process is described as atherosclerosis. The plaques eventually lead to a 
blockage of the arteries supplying blood to the heart and brain, which is the most 
common reason for MIs and strokes, respectively. MIs and strokes are usually acute 
events, which often cause either fatality or permanent disability (WHO, cardiovascular 
disease, www.who.int).  
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2.3 ATHEROSCLEROSIS 
Atherosclerosis is a chronic vascular disease of medium and large arteries. 
During atherosclerosis a plaque is formed in the inner vascular wall resulting in the 
thickening and remodelling of the wall which obstructs the blood flow. These plaques 
are often vulnerable and therefore may rupture, trigger thrombosis and lead to an 
occlusion of the artery. Depending on its location, the plaque formation in the vascular 
wall can lead to ischemia or infarction of the heart, brain, or extremities (Ross 1999).  
The process of atherosclerosis, from a physiological point of view, aims at 
protecting the endothelium and SMC of the vascular wall from all kinds of insults [e.g. 
mechanical, injury, toxins, viruses, oxidised low density lipoprtotein (LDL)]. 
Essentially, it is an inflammatory response accompanied by the formation of fibro-fatty 
lesions at the site of endothelial damage. When this response is excessive, it becomes a 
disease which may occlude the artery (Ross 1993).   
2.3.1 Stages of atherosclerosis 
The development of atherosclerosis begins with the formation of the ―fatty 
streaks‖, the earliest recognisable lesions. These lesions consist of accumulated lipid-
rich macrophages, called foam cells, under the endothelium, in the intima layer of the 
vascular wall. In the next stage, a lipid-rich necrotic core is built-up, which is 
surrounded by SMCs and covered by a fibrous cap. Monocytes and T lymphocytes, 
some activated, also participate in the composition of the atherosclerotic lesions. The 
fibrous plaques increase in size and can develop in different ways. In some cases 
calcification, haemorrhages into the lesion, ulcers at the luminal surface, or projection 
into the lumen may occur. The increasing volume of the plaque may partially block the 
blood flow and cause ischemia. However, the most crucial point into the development 
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of those atherosclerotic plaques is whether they will evolve into stable plaques with a 
small lipid-rich necrotic core, or in vulnerable plaques with a large lipid-rich necrotic 
core and thin fibrous cap. These vulnerable plaques may rupture and result in a 
formation of a thrombus and the subsequent occlusion of the artery (Ross 1993; Lusis et 
al. 2004) (Figure 3).  
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Figure I-3. The stages of atherosclerosis (Lusis et al. 2004). 
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2.3.2 The process of plaque development 
The endothelium has a major role in the maintenance of vascular homeostasis. 
Although a single-cell layer, it is involved in a number of important functions. 1) It 
regulates the vascular tone by releasing key molecules such as nitric oxide (NO) and 
endothelin, 2) regulates the exchange of substances and cells with the circulation, and 
has the ability to modify (oxidise) lipoproteins during their transportation into the 
vascular wall 3) participates to the inflammatory response, by producing growth factors 
and cytokines and controlling the adhesion of leukocytes, 4) controls thrombogenesis 
and 5) plays an important role in vascular remodelling. Thus, endothelial damage and/or 
dysfunction triggers a number of processes initiating or intensifying the formation of 
atherosclerotic lesions (Ross 1993; Luscher & Barton 1997).  
A prime event in the initiation of the atherosclerotic process is the diffusion 
through the endothelium and accumulation in the intima of lipoprotein particles, mainly 
LDL, but also lipoprotein remnants as well as lipoprotein a [Lp(a)]. When transferred, 
these lipoproteins can be oxidised, if not being oxidised already, and become pro-
inflammatory. A molecule having a substantial contribution to the oxidation of LDL is 
the endothelial derived nitric oxide (NO). Subsequently, as part of an inflammatory 
response, the endothelial cells project specific adhesive glycoproteins on their surface, 
such as the vascular cell adhesion molecule-1 (VCAM-1)], which attach to circulating 
monocytes and T lymphocytes and facilitate their transfer into the intima. The 
endothelial cells also secrete growth factors with the macrophage colony-stimulating 
factor (M-CSF) being the most important among them. Thus, the trapped monocytes 
proliferate and differentiate into macrophages, which then take up the accumulated 
oxidised LDL and become foam cells. The foam cells, as well as the T cells, produce 
cytokines and growth factors [e.g. interleukin 1 (IL-1), tumour necrosis factor α 
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(TNFα), transforming growth factor β (TGFβ) and interferon γ (IFNγ)], which activate 
the migration of SMC to the intima, their proliferation and the secretion of collagen. 
The secreted collagen builds up to form the fibrous cap. The cholesterol-rich foam cells 
and the accumulated SMC are eventually led to apoptosis and necrosis, contributing to 
the enlargement of the lipid-rich necrotic core of the plaque. From then on, continuing 
cell and lipid influx, accompanied by SMC migration to the intima and collagen 
secretion, leads to advanced fibrous plaques (Ross 1993; Lusis et al. 2004) (Figure 4). 
2.3.3 Plaque vulnerability and rupture  
The rupture of a plaque, with the concomitant formation of a thrombus resulting 
in the occlusion of the artery, depends predominantly on the vulnerability of the plaque 
rather than its size. The stability of the plaque is determined by the proportion of the 
fibrous cap to the lipid-rich necrotic core. Vulnerable plaques have thin fibrous caps, 
large lipid-rich necrotic cores and a high concentration of inflammatory cells and 
molecules (Davies et al. 1993). The development of a stable fibrous cap requires SMC 
proliferation and production of extracellular matrix including collagen. Thus, a weak 
fibrous cap is primarily a result of SMC loss due to early apoptosis (Clarke et al. 2006). 
T lymphocytes and macrophages also contribute to the weakening of the fibrous cap. 
The T lymphocytes produce IFNγ, which inhibits the production of matrix by SMCs, 
and the macrophages produce matrix metalloproteinases (MMPs), that degrade SMC 
matrix and eventually lead to the rupture of the fibrous cap. Thus, particularly inflamed 
plaques tend to have thinner caps and are more likely to rupture. Other factors and 
characteristics of the plaque like intimal calcification, ulceration, neovascularisation and 
haemorrhages into the plaque, also contribute to its vulnerability and rupture (Lusis et 
al. 2004) (Figure 4).  
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Figure I-4. The development of an atherosclerotic plaque progressively from left to right (Sanz & Fayad 2008).  
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2.3.4 Thrombosis 
The endothelium plays a critical role in both the thrombotic and coagulant 
activities. It secretes antithrombotic molecules like NO and prostacyclin (PGI2) and 
binds factors preventing coagulation. In addition, the endothelial cell production of 
plasminogen activator and urokinase regulate the balance between coagulation and 
fibrinolysis (Ross 1993). On the other hand, when the endothelial cells are exposed to 
oxidised LDL, they secrete tissue factor, a key protein in the initiation of the 
coagulation cascade and plasminogen activator inhibitor 1 (PAI-1) which prevents 
fibrinolysis (Drake et al. 1989; Latron et al. 1991). In this way, when a plaque ruptures, 
the pro-thrombotic tissue factor and the anti-fibrinolytic PAI-1 are exposed to the blood 
from the circulation resulting in thrombus formation. In the majority of cases, the 
thrombus is lysed and the fracture in the artery resealed, although this leads sometimes 
to an enlargement of the plaque at that site, and only in a small portion of cases the 
formation of the thrombus results in total occlusion of the artery (Libby 2008). 
However, thrombosis constitutes the cause of most of the acute manifestations of 
atherosclerotic disease. The majority of thromboses results from the disruption of the 
plaque‘s fibrous cap, which occurs usually in plaques causing 50% or less stenosis of 
the artery. Because of the critical role of the disruption of fibrous cap in triggering 
artery thrombosis, factors determining the vulnerability of fibrous cap (as described in 
the above paragraph), have attracted a great research interest (Libby 2000).  
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2.4 AETIOLOGY 
Atherosclerosis is a complex multi-factorial disease of the arteries resulting from 
the interactions of various environmental factors with the genetic background of each 
individual (Roy et al. 2009). Dyslipidemia, hypertension, and diabetes mellitus are well-
established risk factors for CVD. Nevertheless, there are several other traditional and 
emerging risk factors contributing to the risk of developing CVD.  
2.4.1 Classical risk factors 
Age: There is undoubtedly a strong and independent contribution of age to the 
occurrence of atherosclerotic CVD. Multivariate analysis of the prospective data in the 
Framingham study shows the independent effect of age on CVD incidence, taking all 
the major risk factors into account. The effect of age on CVD risk was evident even in 
subjects at the low risk category by current risk factor guidelines, pointing out the 
substantial contribution of age to an individual‘s risk for CVD (Kannel & Vasan 2009a). 
CVD is a disease of maturity related to tissue deterioration with age. The concept of 
tissues‘ biological ageing in CVD is discussed in more detail in chapter 5 of  the 
―Introduction‖ (page 83).  
Gender: For many years now, it has become clear that men are more prone to 
CVD than women, especially prior to menopause. This results in the delay of CHD 
onset in women by approximately 10-15 years compared to men, and the greater life 
expectancy in women, which is on average 81 years compared to the 74 years in men. 
However, menopause is considered as the marker for the end of natural protection 
against atherosclerotic CVD (Brochier & Arwidson 1998), suggesting that female 
hormones play a protective role against the development/onset of atherosclerosis.   
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Lipid disorders: Hypercholesterolaemia (total cholesterol >5 mmol/l and/or 
LDL cholesterol >3.0 mmol/l, according to WHO Guidelines for assessment and 
management of cardiovascular risk 2007, www.who.int) is acknowledged as the major 
risk factor for atherosclerosis progression and a powerful predictor of premature CVD 
manifestations. Several large studies have shown the significant benefit of cholesterol 
reduction, in particular LDL cholesterol, in primary and secondary prevention. The 
cholesterol-rich, small dense LDL particles are highly atherogenic as a result of their 
prolonged plasma half-life and low resistance to oxidative stress. These LDL particles, 
upon entrance in the arterial intima, get oxidised and are consequently taken on by 
macrophages, which constitutes a trigger for the initiation and exacerbation of the 
atherosclerotic process (Chapman et al. 1998).  
Another frequent form of lipid disorder, with a recently established association 
with CVD risk, is elevated plasma concentrations of triglyceride-rich lipoproteins 
(triglyceride plasma levels >2 mmol/l, according to WHO Guidelines for assessment 
and management of cardiovascular risk 2007, www.who.int). The triglyceride-rich 
lipoproteins (TRLs) appear to be pro-inflammatory, cause endothelial dysfunction, 
upregulate expression of endothelial adhesion molecules and promote macrophage 
chemotaxis. TRLs are also prone to enter the arterial wall, where they are uptaken by 
macrophages like the oxidized LDLs (Kannel & Vasan 2009b).  
In recent years another lipid disorder, that of low high density lipoprotein (HDL) 
plasma levels (HDL cholesterol <1 mmol/l in men and <1.3 mmol/l in women, 
according to WHO Guidelines for assessment and management of cardiovascular risk 
2007, www.who.int), has attracted great attention. High levels of HDL are associated 
with reduced CVD risk. The mechanism through which HDL confers its beneficial 
effects has been attributed in part to its ability to mediate reverse cholesterol transport, 
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as well as its anti-inflammatory, antiapoptotic, antioxidative, and antithrombotic actions 
(Hausenloy & Yellon 2009). All the above lipid disorders are metabolically linked and 
often appear in combination.  
Diabetes: Diabetes is characterised by hyperglycaemia (fasting plasma glucose 
concentration >7 mmol/l or a 2 hours postprandially >11 mmol/l, according to WHO 
Guidelines for assessment and management of cardiovascular risk 2007, www.who.int) 
and glucose intolerance, due to insulin deficiency or impaired effectiveness of insulin 
action, or both. The development of diabetes is accompanied by elevated BP, 
lipoprotein abnormalities, and inflammation. The risk for CVD is doubled among 
people with diabetes, after adjusting for classic risk factors (Kannel & McGee 1979). 
Approximately 50% of diabetes patients die from CVD complications, such as MI and 
stroke (WHO, Diabetes, www.who.int). The mechanism by which diabetes is involved 
in the pathogenesis of CVD is complex, and involves the direct toxic effects of 
hyperglycaemia and advanced glycation end products (Reusch & Draznin 2007), along 
with the impact of abnormal lipid levels (DeFronzo 2010) and inflammation (Maiti & 
Agrawal 2007), which lead to atherosclerosis. The diabetic state also promotes 
oxidative stress mediated by reactive oxygen species (ROS), which may aggravate the 
atherosclerotic progression (Baynes & Thorpe 1999). Diabetes is described in more 
detail in chapter 3 of the ―Introduction‖ (page 64).  
Hypertension: Hypertension is the term to describe the chronic elevation of 
systemic arterial BP. High arterial BP [systolic blood pressure (SBP) >140 mmHg and 
diastolic blood pressure (DBP) >90 mmHg, according to WHO Guidelines for 
assessment and management of cardiovascular risk 2007, www.who.int] is a leading 
risk factor for CVD. Several major prospective, observational and epidemiological 
studies have shown that lower DBP within the usual range (i.e. 70-110 mm Hg) is 
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associated with lower risk of stroke or CHD. This means that, not only in hypertensive, 
but also among normotensive individuals, lower DBP is related to lower CVD risk. 
More specifically, a 5 mmHg lower DBP is associated with about a one-fifth lower risk 
of CHD and a one-third difference in stroke risk (Collins & MacMahon 1994). 
The deleterious effect of elevated BP on the cardiovascular system appears to be 
mainly due to the mechanical stress placed on the heart and blood vessels. Humoral 
factors and vasoactive hormones such as angiotensin, catecholamines and 
prostaglandins may also play a role in the fibromuscular thickening of the intima and 
media with luminal narrowing of the arteries. Hypertension increases the susceptibility 
of arteries to atherosclerosis and accelerates progression particularly in the coronary and 
cerebral vessels. Moreover, hypertension increases the likelihood of plaque rupture and 
thrombotic occlusion of blood vessels, especially in the brain (Hollander 1976).  
Obesity: Overweight and obesity are defined as abnormal or excessive fat 
accumulation that presents a risk to health. Overweight or obese people, in particular 
with abdominal obesity, have an increased risk of developing CVD (WHO, Obesity, 
www.who.int). An individual with body mass index (BMI) >25 kg/m
2
 is characterised 
as overweight and with BMI >30 kg/m
2
 obese. There are other parameters used in order 
to define central obesity. Waist circumference greater than 102 cm in men and 88 cm in 
women, or waist-to-hip ratio over 1 in men and 0.8 in women denote abdominal obesity, 
which has been shown to significantly increase the risk for CVD (The National 
Research Council, Guidelines on overweight and obesity 1998, 
www.nhlbi.nih.gov/guidelines/obesity). For example, men in the uppermost quintile of 
waist-to-hip ratio have a three times higher risk of developing CHD compared to those 
in the lowest (Rimm et al. 1995). Obesity can contribute to CVD directly by 
aggravating the lipid accumulation per se, but also indirectly by increasing insulin 
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resistance and thus promoting the development of diabetes (Bjorntorp 1991). Obesity, 
like atherosclerosis, was once considered to be simple lipid-storage disease. Nowadays, 
obesity and atherosclerosis are considered as chronic inflammatory states, with 
processes such as inflammatory cell infiltration, cytokine production, and cell death, in 
addition to the lipid accumulation, contributing to the two diseases interplay, and their 
complications (Rocha & Libby 2009). 
2.4.2 Emerging risk factors 
C-reactive protein (CRP): The hepatocyte-derived acute-phase reactant CRP is 
a non-specific marker of systemic inflammation and has been associated with high risk 
for CHD events as well as with increased carotid intima-media thickness, a sub-clinical 
measure of atherosclerosis. The role of CRP in the pathogenesis and risk prediction of 
CVD has attracted an intense research interest, which provided controversial data the 
previous years. However, recent studies and a systematic review of published data show 
that measurement of CRP has limited utility in the screening or prediction of CVD 
(Shah et al. 2009). Once established risk factors have been evaluated to estimate 
absolute risk, CRP concentration appears to provide very modest incremental risk 
information (Hingorani et al. 2009). 
Regarding the implication of CRP in the pathogenesis of CVD, Mendelian 
randomisation studies have shown a lack of concordance between the effect of CRP 
genotypes on CHD risk and CRP levels, which argues against the causality of CRP 
(Casas et al. 2006; Kivimaki et al. 2008; Elliott et al. 2009). It seems more likely that 
the association of CRP with atherosclerosis is a result of reverse causality, i.e. CRP 
levels are altered as a result of atherosclerosis rather than being a cause of it, or 
confounding, i.e. the association of CRP with atherosclerosis arises from the common 
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association of the two with other causative factors (Kivimaki et al. 2008). Although the 
totality of evidence at present favors the interpretation that elevated CRP does not cause 
CVD, a human intervention trial with a specific CRP inhibitor is still missing in order to 
give the final answer (Nordestgaard 2009). 
Homocysteine: Homocysteine is an amino acid synthesised during the 
metabolism of an essential amino acid, the methionine. Circulating levels of 
homocysteine are normally low due to its rapid metabolism and clearance and high 
levels of circulating homocyteine have been suggested to have a causal relationship with 
the development of atherosclerosis (McCully & Wilson 1975). A meta-analysis of 
retrospective data showed that an increase of 5μmol/l was associated with 20-30% 
higher CVD risk (Ueland et al. 2000). The mechanism underlying this association 
remains to be elucidated.    
Fibrinogen: Fibrinogen is a key molecule in the clotting cascade. In the final 
step of the process, thrombin cleaves fibrinogen to produce fibrin, which in turn 
polymerises to produce the structural backbone of a thrombus. Higher levels of 
fibrinogen are considered as a risk factor contributing independently to a higher risk for 
CVD (Heinrich et al. 1994).  
Lp(α): Lp(α) is a circulating lipoprotein which is deposited in the arterial wall 
along with LDL and triglyceride-rich lipoproteins. The contribution of this particular 
lipoprotein to atherosclerosis lies with its ability to interfere with fibrinolysis by 
competing plasminogen (Angles-Cano et al. 2001). Large-scale prospective data have 
demonstrated an independent, continuous and modest association of Lp(a) levels with 
the risk of CHD in a broad range of individuals, with levels of Lp(a) being highly stable 
within individuals across many years and only weakly correlated with known risk 
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factors (Bennet et al. 2008; Erqou et al. 2009). But most importantly, variants in the 
gene of Lp(a) have been strongly associated with both an increased level of Lp(a) 
lipoprotein and an increased risk of CHD, which provides support for a causal role of 
Lp(a) lipoprotein in CHD (Clarke et al. 2009). 
2.4.3 Enviroment - Lifestyle 
Smoking: Smoking and lipid disorders are the two most important risk factors 
for CHD worldwide, accounting for about two-thirds of the population attributable risk 
for a MI. The INTERHEART study showed that the association of smoking with MI is 
graded, without either a threshold or a plateau in the dose response, with smoking even 
five cigarettes per day to increase the risk (Yusuf et al. 2004). There is a large body of 
evidence from prospective cohort studies regarding the beneficial effect of smoking 
cessation on CVD mortality. There are several potential mechanisms by which smoking 
may increase the risk of CVD. Smoking causes damage to the endothelium, abnormal 
lipid levels, increased BP, insulin resistance; increased oxidative stress and decreased 
activity of endothelial NO, all of which promote atherosclerosis. Also, smoking 
activates platelets, increasing the risk of thrombus formation with consequent artery 
occlusion (Erhardt 2009).   
Alcohol: Many epidemiological and clinical studies have shown a U-shaped 
association of alcohol consumption with CVD risk and total mortality in middle-aged 
and elderly men and women (Rehm et al. 2003) (Rimm et al. 1999). A light-to-
moderate consumption confers a lower risk and death rate than that of abstainers, while 
those who drink large amounts have a higher risk and death rate compared to both the 
other two categories (Gaziano et al. 2000). The plausible mechanisms for the putative 
cardioprotective effects include increased levels of HDL (Rimm et al. 1999), prevention 
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of formation and promotion of dissolution of blood clots, reduced platelet aggregation, 
and lowering of plasma Lp(a) concentration (Agarwal 2002). Nonetheless, people who 
drink heavily have a high mortality from all causes and CVD, including sudden death 
and haemorrhagic stroke, which is attributed to increased clotting, rise in LDL 
cholesterol (Rehm et al. 2003) and lower threshold for ventricular fibrillation 
(Greenspon & Schaal 1983).  
Physical activity: Sedentary lifestyle is associated with increased risk of CVD, 
while observational studies have shown that leisure-time physical activity is associated 
with reduced CVD risk and mortality in both men and women and in middle-aged and 
older individuals. The physical activity beneficiary effect on CVD can be attributed to 
improvement of endothelial function as well as contribution to weight loss and 
glycaemic control (Yung et al. 2009; Kokkinos et al. 2011). 
Diet: Atherosclerosis is widely considered to have a nutritional background. In 
several cross sectional studies high dietary intakes of fat, cholesterol and sodium or low 
consumption of fruits, vegetables and fish are linked to CVD risk (WHO Guidelines for 
assessment and management of cardiovascular risk 2007, www.who.int). For example, 
in the INTERHEART study, the daily consumption of fruits and vegetables conferred a 
30% reduction in the odds for MI while the lack of daily consumption accounted for 
13.7% of the population attributable risk for MI (Yusuf et al. 2004).  
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2.4.4 Genetic predisposition 
Complex diseases such as CVD arise due to ineffective maintenance of 
homeostasis within a physiological system. This may be attributed to failure at the 
genetic level, or to exposure to a detrimental environment, but it usually occurs due to 
an interaction between the two. Failure at the genetic level involves mutations altering 
the composition or structure of the proteins encoded for by genes, or the inappropriate 
amount of protein synthesised (Stephens & Humphries 2003). There are some 
monogenic causes of early CVD, such as familial hypercholesterolemia (FH), with a 
frequency for the heterozygous state, approximately 1 in 500 members of the general 
population. In monogenic forms, a single functional mutation in a single important 
homeostatic gene, like the gene coding for the LDL receptor in the case of FH, are 
sufficient to cause the disease. However, the common form of the disorder is polygenic 
and heterogeneous (Humphries et al. 2004). Complex disorders such as atherosclerosis 
are usually the result of several common polymorphisms causing subtle alterations in 
the expression or activity of the encoded proteins which individually are compatible 
with health. However, interaction among several of these polymorphisms combined 
with an adverse environmental influence leads to the development of the disease 
(Hingorani 2001) (Figure 5). 
  
60 
 
Figure I-5. Models representing the mechanism by which common polymorphisms 
influence the susceptibility to a complex disorder such as atherosclerosis 
(Hingorani 2001). 
 
 
 
Many family and twin studies have examined the contribution of genetics in 
CVD and have found heritability to often exceed 50% (Lusis et al. 2004). 
Atherosclerosis is a multistep process involving the interaction of many different key 
pathways, including lipoprotein metabolism, coagulation, inflammation oxidative stress, 
cellular proliferation and tissue remodelling. Variation in genes encoding key proteins 
in any of these metabolic pathways can upset the delicate balance of homeostasis and 
result in the development of the disease (Roy et al. 2009). Over the last 10 to 15 years 
variants, functional variants in genes with a key role in processes involved in the 
pathogenesis of CVD have been investigated for their effect on disease predisposition. 
More recently after the mapping of linkage disequilibrium blocks in the genome has 
become available, single nucleotide polymorphisms (SNPs) tagging the variation in and 
flanking the candidate genes are also being studied followed by investigation for the 
functional variants. The use of the candidate gene approach through association studies 
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in prospective analysis or case control studies has led to the identification of many 
common polymorphisms associated with CVD. Meta-analyses have confirmed the 
association of several of those polymorphisms with CVD, with the best example being 
that of apolipoprotein E gene (APOE). Two common polymorphisms in this gene result 
in the coding of three different isoforms of the protein, the strong effects of which on 
plasma lipids and their modest effects on CHD risk has been confirmed by many 
independent studies.  
The last couple of years, the technological advances have provided the 
possibility for genome-wide screening of cases and controls in order to discover new 
loci associated with CVD. This hypothesis-free approach has confirmed several 
previously identified CVD associated loci, but most importantly has revealed many new 
ones. The discovery of these new loci has triggered further research aiming at 
identifying the functional variants related to the newly identified loci and their 
involvement in processes predisposing to CVD. In this way new directions have been 
given to the research field and also new questions have been raised.  
Table 1 summarises the most important genes that have been associated with 
atherosclerotic CVD.  
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Table I-1. Genes reported to be associated with atherosclerotic vascular diseases 
(CHD, MI, peripheral artery disease, carotid atherosclerosis and ischemic stroke) 
(Roy et al. 2009). 
Pathophysiological processes Susceptibility genes 
LDL metabolism LDLR, LDLRAP1, LRP,LRP6, APOB, APOE, PCSK9, 
CYP7A1, SREBP-2/SCAP, USF1, PSRC1 and CELSR2 
HDL metabolism LCAT, APOA-1, ABCA1, SR-B1, PON, LIPC, CETP 
Triglyceride metabolism LPL, APOA5, APOC-III 
Lipoprotein(a) APO(a) 
Endothelial dysfunction NOS3, MnSOD, KDR 
Oxidative stress CYBA, MPO, EC-SOD, GPX1, GST, UCP2, HO-1 
Inflammation Interleukins: IL-1, IL-1Ra, IL-6, IL-10 
Cytokines and cytokine receptors: TNF-α, TNF-receptor, 
LTA 
Adhesion molecules: selectins, ICAM-I, VCAM-I, 
PECAM 
Chemokines and chemokine receptors: CX3CR1, CCR5, 
CCR2, CXCL12, RANTES, MCP-1 
Eicosanoids: ALOX5, ALOX5AP, LTA4H, LTC4S, 
PTGS1, PTGS2, L-PGDS 
Others: Connexin 37, MEF2A, TLR-4, CRP, TNFS4, 
MHC2TA 
Vascular remodeling TGF-β1, MMP-1, MMP-3,MMP-7, MMP-9, MMP-12 
Arterial thrombosis Hemostatic system: fibrinogen, prothrombin, factor V, 
factor VII, Factor XIII, thrombomodulin 
Fibrinolytic system: PAI-1, TAFI, t-PA 
Platelet surface receptors: glycoprotein IIb/IIIa, Ia/IIa, Ib 
Cell cycle regulators CDKN2A, CDKN2B 
Vascular progenitor cell 
regulators 
CXCL12, GATA2 
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Miscellaneous 
PPARγ, PPARα, thrombospondins, ACE, angiotensin II 
type 1 receptor, angiotensinogen, MTHFR, PDE4D, 
ANRIL, VAMP8, HNRPUL1, KIF6 
 
Although the list of candidate loci has grown with the contribution of genome 
wide association studies (GWAS), the SNPs currently identified only explain a portion 
of the heritability estimate for CVD. Since there is robust evidence for the heritability of 
CVD, the fact that this heritability cannot be explained means that the nature and 
number of genetic factors involved in the disease pathogenesis remains partly elusive. 
Therefore, more genetic factors need to be explored in order to elucidate their 
contribution in the disease heritability. These include rare mutations, telomere length, 
copy number variations and epigenetic modifications such as DNA methylation.  
Genetic research in CVD aim is to reveal a set of genetic factors which could 
improve the risk prediction algorithms by adding information over and above the 
classical risk factors. Improving the sensitivity and specificity of risk prediction is very 
important, since with the use of the current algorithms a large percentage of individuals, 
who go on to develop CVD, is not identified in time to prevent the disease 
complications. Moreover discovering the genetic factors contributing to the disease 
development offers new drug targets and helps to more effective treatment strategies for 
primary or secondary prevention.  
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3 TYPE 2 DIABETES 
 
3.1 THE PANCREATIC ISLETS 
The pancreas serves an endocrine and exocrine function and consists of two 
distinctly different tissues. The bulk of its mass is exocrine tissue, which produces 
digestive enzymes which are delivered to the small intestine to facilitate digestion. 
Scattered throughout the exocrine tissue are clusters of several hundred thousand 
endocrine cells, the pancreatic islets or islets of Langerhans. These endocrine cells 
produce two very important hormones, insulin and glucagon. Insulin is secreted by the β 
cells, which are the majority of cells in the pancreatic islets, and glucagon from the α 
cells. Insulin and glucagon together regulate the uptake, storage and use of exogenous 
glucose mainly, but also free fatty acids and amino acids, in order to cover the energy 
needs of tissues. Insulin is an anabolic hormone promoting the uptake and storage of 
fuels after food intake, while glucagon acts in the opposite way to insulin promoting the 
mobilisation of fuels during fasting or exercise (Cooperstein 1981; Robert M. Berne 
1993b) (Figure 6).  
 
3.2 INSULIN  
Insulin is the major glucoregulatory hormone. It consists of two polypeptide 
chains held together by disulfide bonds and synthesised from a single chain precursor 
proinsulin. The secretion of insulin is stimulated by food intake, gastrointestinal 
peptides, cholinergic and β-adrenergic stimuli. Its release is inhibited by fasting and 
exercise, conditions where fuel mobilisation is required. 
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The regulatory role of insulin is accomplished through its action in various sites 
of the body. Insulin action in the liver leads to inhibition of gluconeogenesis or 
glycogenolysis and glucose release, as well as stimulation of glycogen synthesis. In 
muscle cells insulin signals the inhibition of proteolysis, the stimulation of glucose 
uptake and storage as glycogen. Finally, in adipose tissue insulin inhibits lipolysis and 
ketogenesis and stimulates the glucose uptake from blood (Figure 6). 
 
Figure I-6. The insulin-glucagon balanced regulation of glucose (Diabetes Atlas 4
th
 
edition, IDF 2009, www.diabetesatlas.org).  
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The signal transduction pathway of insulin in the cells of these tissues begins 
with its binding to a plasma membrane receptor with tyrosine kinase activity, called the 
insulin receptor. Insulin binds and activates the tyrosine kinase subunit, which 
phosphorylates intracellular substrates, such as kinases, phosphatases or G proteins, 
which in turn may trigger a number of cascades (Robert M. Berne 1993b). It is now 
established that the phosphatidylinositol 3-kinase in particular plays a pivotal role in the 
signal-transduction pathways linking insulin with many of its specific cellular responses 
(e.g. glycogen synthesis, cell proliferation, differentiation and apoptosis) (Shepherd et 
al. 1998). One of the cellular responses triggered by the activation of 
phosphatidylinositol 3-kinase is the projection to the cell membrane of the facilitated 
glucose transporter member 4 (GLUT4) in order to enhance glucose uptake by muscle 
and adipose tissue cells when circulating glucose levels are increased (Thong et al. 
2005). Thus, insulin signalling in muscle and adipose tissue is important for keeping 
plasma glucose levels within acceptable limits (approximately 3.4-6.4 mmol/l) (Robert 
M. Berne 1993b).  
 
3.3 TYPES OF DIABETES 
Diabetes, also called diabetes mellitus, is a group of heterogeneous disorders 
having as common features hyperglycaemia and glucose intolerance, which arises as a 
result of insufficient production of insulin due to failure of the pancreatic β cells, insulin 
resistance or both. According to the aetiology and the clinical presentation, diabetes is 
classified in two main types, 1 and 2.  
Type 1 diabetes (T1D): T1D, also called insulin-dependent, immune-mediated 
or juvenile-onset diabetes, is caused by complete failure of the β cells of the pancreas, 
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and thus insufficient or null production of insulin. This β cell failure is predominantly 
caused by an auto-immune reaction; the aetiology of which is not fully understood 
(Bloomgarden 2006). T1D can affect people of any age, but typically its onset occurs 
during childhood or adolescence. This form of the disease is severe, with T1D patients 
being dependent on exogenous insulin administration (Diabetes Atlas 4
th
 edition, IDF 
2009, www.diabetesatlas.org and WHO, Diabetes, www.who.int). 
Type 2 diabetes (T2D): T2D, the common form of the disease, is caused by 
insulin resistance and relative insulin deficiency due to relative β cell failure. The onset 
of T2D, in contrast to T1D, usually occurs later in life, during middle-age and 
thereafter. However, T2D can remain undetected for years, with its diagnosis being 
made often from the associated complications or an incidental detection of abnormal 
circulating glucose levels (Table 2). Most T2D patients are not dependent on exogenous 
insulin, like T1D, but may require insulin for control of hyperglycaemia if this is not 
achieved with diet and oral hypoglycaemic agents (Bloomgarden 2006) (Diabetes Atlas 
4
th
 edition, IDF 2009, www.diabetesatlas.org and WHO, Diabetes, www.who.int). 
 
3.4 PREDIABETES CONDITIONS 
Impaired glucose tolerance and impaired fasting glucose are asymptomatic 
conditions preceding diabetes development and are also caused by insulin resistance and 
a low grade of insulin deficiency (Ferrannini et al. 2011). Impaired glucose tolerance is 
characterised by elevated levels of blood glucose two hours after an oral glucose 
challenge, while impaired fasting glucose is characterised by elevated fasting glucose 
levels in plasma (Table 2) (Bloomgarden 2006) (Report of a WHO/IDF Consultation for 
the definition and diagnosis of diabetes, http://www.idf.org/webdata/docs). In both 
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cases the plasma glucose levels are not as high as in developed diabetes; however 
people with prediabetes are at high risk of developing T2D and CVD (Twigg et al. 
2007). This increased risk for CVD in prediabetes is multifactorial, with etiologies 
including insulin resistance, hyperglycemia, dyslipidemia, hypertension, systemic 
inflammation, and oxidative stress (Hsueh et al. 2010). 
 
Table I-2. Diagnosis criteria of diabetes mellitus and intermediate hyperglycemia 
(Report of a WHO/IDF Consultation for the definition and diagnosis of diabetes, 
http://www.idf.org/webdata/docs).  
 
Diabetes 
Fasting plasma glucose 
 
≥7.0mmol/l 
or 2hrs plasma glucose* 
 
≥11.1mmol/l 
Impaired Glucose Tolerance (IGT) 
Fasting plasma glucose 
 
<7.0mmol/l 
and 2hrs plasma glucose* 
 
≥7.8 and <11.1mmol/l 
Impaired Fasting Glucose (IFG) 
Fasting plasma glucose 
 
>6.1 and <6.9mmol/l 
and if measured 2hrs plasma glucose** 
 
<7.8mmol/l 
 
* Venous plasma glucose 2hrs after ingestion of 75g oral glucose load 
** If 2hrs plasma glucose is not measured, status is uncertain as diabetes or 
IGT cannot be excluded. 
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3.5 PATHOGENESIS OF TYPE 2 DIABETES 
T2D mainly rises from the failure of glucose homeostasis maintenance, which 
depends on the balance between the target‘s tissue sensitivity to insulin and the insulin 
secretion from β cells. Insulin resistance alone is not sufficient to disturb glucose 
homeostasis as long as the β cells function normally and secrete insulin in adequate 
amounts, in order to compensate for the defective tissues‘ insulin response. Thus, T2D 
onset requires the development of both insulin sensitivity and insulin secretion 
(DeFronzo & Tripathy 2009). 
3.5.1 Insulin resistance 
Insulin resistance is considered to be the initiating defect, which might occur 
decades before, resulting in β cell failure and overt hyperglycemia. Insulin resistance is 
defined as a reduced, compared to normal, response to insulin of target tissues, such as 
the skeletal muscle, liver, and adipocytes. In particular the response of skeletal muscle 
cells to the insulin signal is mainly responsible for the glucose uptake and glycogen 
synthesis after food intake, determining the postprandial blood glucose levels and the 
time of clearance (Krook et al. 2000). Therefore, the reduced response of skeletal 
muscle to insulin is considered as the hallmark in T2D pathogenesis (Goldstein 2002).  
The molecular mechanism leading to skeletal muscle insulin resistance is 
triggered by high levels of free fatty acids and cytokines as well as glucose itself 
(DeFronzo & Tripathy 2009). There is compelling evidence that an increase in free fatty 
acids causes skeletal and liver insulin resistance (Petersen & Shulman 2002), as shown 
in figure 7.  
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Figure I-7. Fatty acid- and age-induced insulin resistance in: A) skeletal muscle 
cells and B) liver cells. 
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Legend: A) Increased fatty acid availability and/or age-induced decrease in 
mitochondrial β-oxidation in skeletal muscle cells result in high levels of intracellular 
long-chain acylcoenzyme A (LCCoA) and diacylglycerol (DAG). This in turn induces 
serine/threonine phosphorylation of IRS-1 sites, thereby inhibiting IRS-1 
phosphorylation and activation of phosphatidylinositol 3-phosphate (PI3P) signaling. 
This leads to reduced levels of glucose transporter 4 (GLUT4) synthesis and 
consequently to low insulin-stimulated muscle glucose uptake and diminished glycogen 
synthesis. B) Similarly, increased fatty acid availability and/or age-induced decrease in 
mitochondrial β-oxidation in liver cells result in reduced insulin-stimulated IRS-1and 
consequent inhibition of the PI3P signaling. This leads to lower forkhead box protein O 
(FOXO) phosphorylation, which in turn results in lower insulin-stimulated liver 
glycogen synthesis and increased hepatic gluconeogenesis (Savage et al. 2007).  
 
The resistance of adipose tissue cells to the insulin signal for inhibition of 
lipolysis might be the cause of the elevated free fatty acids, which in turn leads to 
skeletal muscle and liver insulin resistance and consequent β cell failure. Thus, adipose 
tissue insulin resistance might precede the skeletal muscle resistance and represent the 
initial trigger in the pathogenesis of T2D (DeFronzo & Tripathy 2009).  
3.5.2 Β cell failure 
Β cell failure is the sine qua non for the development of T2D and involves a 
decrease in β cell mass due to apoptosis as well as a decline of key β cell functions. The 
pathways leading to β cell failure are not yet fully understood. Current evidence 
suggests that β cell failure is a consequence of 'glucolipotoxicity', i.e. a combination of 
hyperglycaemia and high levels of free fatty acids, rather than exposure to each nutrient 
alone (Poitout et al. 2010). Various mechanisms, explaining the effect of the metabolic 
overload (glucose and fatty acids) on β cells, have been proposed. To begin with, 
metabolic overload of the β cell mitochondria results in basal insulin hypersecretion and 
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loss of glucose-stimulated insulin secretion, through upregulation of the pyruvate 
cycling. This metabolic overload might lead to increased production of ROS and altered 
uncoupling protein 2 (UCP2) expression, which might play a role in β cell failure, 
although the exact mechanism has not yet been defined. In addition, the increased 
demand for insulin biosynthesis gradually leads to ER stress, with consequent protein 
misfolding and cell death (Muoio & Newgard 2008). Finally, insulin hypersecretion is 
accompanied by amylin hypersecretion, which accumulates as amyloid plaques at the β 
cell surface inducing severe dysfunction and apoptotic death (Muoio & Newgard 2008). 
Thus, metabolic overload in combination with an increased demand for function are the 
main causes for β cell failure.  
3.5.3 Risk factors 
T2D is often associated with obesity and its occurrence is highly familial. Most 
of T2D risk factors are shared with those for CVD (see chapters 2.3.1.1 and 2.3.3 of the 
Introduction).  
Age: T2D, as well as CVD, is considered an age-related disease, associated with 
tissue deterioration and decline from normal functions in a biologically aged organism. 
The biology of ageing and its possible role in T2D are discussed in more detail in 
chapter 5 of the ―Introduction‖ (page 82). 
Obesity: Excess adiposity is considered the most important risk factor, which 
itself can cause insulin resistance and lead to elevated blood glucose levels. This risk 
increase is mainly conferred by intra-abdominal and intra-hepatic fat depots. 
Accumulation of ectopic lipids in muscle and islets is also involved in the pathogenesis 
of the disease (Joost 2008). Indicative of the effect of obesity is that in the Health 
Professionals Follow-up Study, 56% of the T2D cases could be attributed to a weight 
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gain of 7 kg or greater and 20% to a waist gain of 2.5 cm or greater (Koh-Banerjee et al. 
2004).  
Physical activity and diet: Human cohort studies have provided convincing 
evidence that nutritional and lifestyle variables are independent risk factors for T2D. 
Specifically, sedentary lifestyle can increase almost 3-fold the risk for T2D, while 
physical activity has a protective effect which is independent of the weight reduction. 
Regarding the role of diet, a beneficial nutritional pattern has been identified consisting 
of a high consumption of fruits in combination with a low consumption of red meat, 
beer, soft drinks and white bread. This dietary pattern has been associated with an 
approximately 80% reduction of T2D risk (Joost 2008).  
Sub-optimal intrauterine environment: In recent years, it has become evident 
that a disturbed nutritional environment of the foetus is a risk factor for T2D. There are 
now several human epidemiological studies showing that both a nutrient poor and a 
nutrient abundant intrauterine environment may compromise the adult health of the 
fetus by increasing susceptibility to insulin resistance, glucose intolerance and diabetes 
(Reusens et al. 2007). 
3.5.4 The role of genetics 
There is compelling evidence to support a major genetic component to T2D 
susceptibility (Gloyn & McCarthy 2001). According to the thrifty gene hypothesis, 
certain genetic variants have developed in some populations as a fitness advantage in 
poor nutritional environments, but in an environment of increased food supply these 
same variants now predispose to insulin resistance and diabetes (Carulli et al. 2005). 
The genetic contribution is well recognised in the diverse forms of both juvenile-onset 
diabetes (monogenic) and adult-onset diabetes (complex). Evidence supporting the 
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genetic basis to T2D includes its greater prevalence in particular ethnic groups (Gloyn 
& McCarthy 2001), the higher concordance rate observed in monozygotic than 
dizygotic twins (Newman et al. 1987) and the identification of susceptibility loci by 
GWAS (Zeggini et al. 2007; McCarthy & Zeggini 2009).  
The primary methods used to explore the genetic basis of diabetes were linkage 
analysis (analysis of shared DNA segments inherited from common ancestors coupled 
with phenotypic information) and candidate gene approaches. These approaches 
revealed few genes [e.g. peroxisome proliferator-activated receptor-gamma (PPARG) 
and potassium channel, inwardly rectifying, subfamily J, member 11 (KCNJ11), Table 
3], with most important the breakthrough of the transcription factor 7-like 2 gene 
(TCF7L2) discovery by linkage analysis (Table 3). The TCF7L2 gene has a strong effect 
on the risk for T2D which has been replicated in many ethnicities (Frayling 2007).  
In the past three years, GWAS for T2D in several European populations 
revealed 25 new loci, several of which encode proteins of the cell cycle, and represent 
putative new pathways involved in the pathogenesis of the disease which can also serve 
as new targets for therapeutic interventions (Bonnefond et al. 2010) (Table 3).  
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Table I-3. Genes and loci associated with T2D that have been most replicated (Bonnefond et al. 2010).    
Gene Loci Protein Assumed effect of risk allele 
Candidate gene studies 
PPARG 3p25 Peroxisome proliferator-activated receptor-γ Decreased insulin sensitivity, decreased insulin clearance 
KCNJ11 11p15.1 
K inwardly-rectifying channel, subfamily J, member 
11 
Decreased β-cell function, decreased glucose-stimulated 
insulin secretion (GSIS), decreased insulin sensitivity 
HNF1B 17cen-q21.3 Hepatocyte nuclear factor 1-beta Decreased β-cell function 
WFS1 4p16 Wolfram syndrome 1 (wolframin) Decreased β-cell function, decreased insulin secretion 
GCK 7p15.3-p15.1 Glucokinase (Hexokinase 4) 
Decreased β-cell function, decreased GSIS, increased 
fasting glucose, increased glycated hemoglobin 
Linkage analysis 
TCF7L2 10q25.3 
Transcription factor 7-like 2 (T-cell-specific, HMG-
box) 
Decreased β-cell function, decreased incretin-stimulated 
insulin secretion, decreased GSIS, decreased proinsulin 
conversion, decreased insulin sensitivity, decreased 
disposition index, increased fasting glucose, increased 2h-
glucose 
GWAS for T2D 
CDKN2A/2B 9p21 Cyclin-dependent kinase inhibitor 2A/2B 
Decreased β-cell function, decreased GSIS, decreased 
disposition index 
CDKAL1 6p22.3 CDK5 regulatory subunit associated protein 1-like 1 
Decreased β-cell function, decreased GSIS, decreased 
proinsulin conversion, decreased disposition index 
SLC30A8 8q24.11 Solute carrier family 30 (zinc transporter), member 8 
Decreased β-cell function, decreased GSIS, decreased 
proinsulin conversion, decreased disposition index, 
increased fasting glucose, increased 2h-glucose, increased 
glycated hemoglobin 
IGF2BP2 3q27.2 Insulin-like growth factor 2 mRNA binding protein 2 
Decreased β-cell function, decreased GSIS, decreased 
disposition index 
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Gene Loci Protein Assumed effect of risk allele 
HADA 2p21 Thyroid adenoma associated 
Decreased β-cell function, decreased insulin sensitivity, 
decreased second-phase insulin secretion, decreased 
disposition index, decreased GLP-1 and arginine-
stimulated insulin response 
NOTCH2 1p13-p11 
Neurogenic locus notch homolog protein 2 
(Drosophila) 
NA 
CDC123 10p13 
Cell division cycle 123 homolog (Saccharomyces 
cerevisiae) 
Decreased β-cell function, decreased insulin secretion 
CAMK1D 
 
Calcium/calmodulin-dependent protein kinase type 
1D  
HHEX 10q23 Hematopoietically expressed homeobox 
Decreased β-cell function, decreased GSIS, decreased 
insulin sensitivity, decreased proinsulin conversion, 
decreased disposition index 
IDE 
 
Insulin-degrading enzyme 
 
TSPAN8 12q14.1-q21.1 Tetraspanin 8 
Decreased β-cell function, decreased insulin secretion, 
decreased insulin sensitivity 
LGR5 12q22-q23 
Leucine-rich repeat-containing G protein-coupled 
receptor 5  
ADAMTS9 3p14.3-p14.2 
ADAM metallopeptidase with thrombospondin type 
1 motif, 9 
Decreased insulin sensitivity 
JAZF1 7p15.2-p15.1 Juxtaposed with another zinc finger protein 1 
Decreased β-cell function, increased insulin secretion, 
increased fasting insulin 
IRS1 2q36 Insulin receptor substrate 1 
Increased insulin resistance, decreased insulin sensitivity, 
increased fasting insulin, increased 2h-insulin 
KCNQ1 11p15.5 
K voltage-gated channel, KQT-like subfamily, 
member 1 
Decreased β-cell function, decreased insulin secretion, 
decreased insulin secretion 
FTO 16q12.2 Fat mass and obesity-associated protein 
Increased risk of obesity, increased body mass index, 
increased fat mass, increased triglycerides and cholesterol 
 
77 
 
Worthy of remark is that most of the variants detected with GWAS influence the 
β cell function and insulin secretion, which strongly suggests that susceptibility to T2D 
is mainly caused by genetic defects in β cell function (Billings & Florez 2010; 
Bonnefond et al. 2010; Grarup et al. 2010).  
Similar to the genetics of CVD, the T2D-associated genetic variants discovered 
so far, only explain a small portion of T2D heritability. There is again an issue with the 
―missing heritability‖ which requires new directions in genetic research. These new 
directions include the investigation of rare variants with large effects on T2D risk, copy 
number variations, epigenetic modifications (Billings & Florez 2010; Bonnefond et al. 
2010)and possibly telomere length.   
 
3.6 DIABETES COMPLICATIONS 
Chronic diabetes eventually leads to tissue damage in many organ systems. The 
kidneys, the eyes, the peripheral nerves and the vascular vessels are manifesting with 
the most significant diabetes complications of nephropathy, retinopathy, neuropathy and 
cardiovascular disease. The mechanism by which diabetes leads to these complications 
is not yet fully understood, but hyperglycaemia, abnormal lipid levels and high BP are 
all likely to play a role in accelerating the deterioration of tissues and lead to organ 
damage (Melendez-Ramirez et al. 2010; Stolar 2010). 
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4 THE „COMMON SOIL‟ HYPOTHESIS 
T2D is undoubtedly a major risk factor for atherosclerotic CVD, however 
atherosclerosis may precede the development of T2D, suggesting that rather than 
atherosclerosis being a complication of diabetes, both conditions rise from a "common 
soil." According to the ―common soil‖ hypothesis a certain genetic background 
combined with adverse environmental conditions, perhaps even in uterus, result in 
susceptibility to both diabetes and atherosclerotic CVD. For example, insulin resistance 
is a key risk factor for T2D and some of its features, like high triglyceride levels, low 
HDL levels and hypertension are also documented risk factors for CVD (Stern 1995).  
At the molecular level, both atherosclerosis and T2D development involves 
―cross-talk‖ between different complex processes, including inflammation, glucose and 
lipoprotein metabolism and oxidative stress. In particular, oxidative stress has been 
proposed as the pathogenic mechanism linking insulin resistance with dysfunction of 
both β cells and endothelium, eventually leading to overt diabetes and cardiovascular 
disease. Further support for this hypothesis is provided by pharmacological intervention 
studies aiming at reducing CVD, which used agents with intracellular preventive 
antioxidant activity. Therapy with statins in the WOSCOP study (Freeman et al. 2001), 
with angiotensin-1 converting enzyme inhibitors in the HOPE (Yusuf et al. 2001) and 
CAPP studies (Hansson et al. 1998), and with angiotensin II type 1-receptor antagonists 
in the LIFE study (Dahlof et al. 2002) resulted in a substantial reduction in the 
development of T2D, in parallel to the CVD risk, presumably through an underlying 
common mechanism (Ceriello & Motz 2004).  
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4.1 OXIDATIVE STRESS 
Oxidative stress and consequent damage are considered the main component of 
the ―common soil‖ hypothesis for the pathogenesis of CVD and T2D (Ceriello & Motz 
2004). High oxidative stress is associated with many of the risk factors implicated in the 
pathophysiology of atherosclerosis and diabetes, such as hypercholesterolaemia, renal 
failure, ageing, hypertension, smoking and ageing (Harrison et al. 2003). Oxidative 
stress is caused by high levels of ROS, molecules containing oxygen and having one or 
more unpaired electrons in their atomic structure, which renders them highly reactive. 
These include the hydrogen peroxide (H2O2), the superoxide anion (O2
-
), the hydroxyl 
radical (OH
-
) and the peroxynitrite radical (OONO
-
). One to five percent of inhaled 
oxygen becomes active oxygen species, which are approximately 25,000,000,000 
molecules per cell in a day‘s time (Maritim et al. 2003).  
The mitochondria constitute a major source of cellular ROS, which are produced 
during the final step of nutrient oxidation for energy production. When excessive 
NADH, produced in the citric acid cycle, cannot be dissipated by oxidative 
phosphorylation, the mitochondrial proton gradient increases, and single electrons are 
transferred to molecular oxygen, resulting in the formation of superoxide (Maechler et 
al. 1999). Another major source of ROS is the enzymatic activity of the membrane-
associated NADPH oxidase, whose primary function is to catalyse the transfer of 
electrons from NADPH to molecular oxygen resulting in the generation of superoxide. 
In addition, the enzymatic activity of xanthine oxidase may result in the formation of 
superoxide as byproduct (Droge 2002). Similarly, NO generation, which reacts with O2
-
 
to form OONO
-
, occurs through specific nitric oxide synthase isozymes, including 
mitochondrial nitric oxide synthase (mtNOS), neuronal NOS (nNOS), endothelial NOS 
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(eNOS), and inducible NOS (iNOS). Other sources of ROS, mainly H2O2, include the 
microsomes and peroxisomes (Trachootham et al. 2008). 
Oxidative stress is essentially a redox imbalance which results from a disparity 
between ROS production and antioxidant defences (Maritim et al. 2003). Cells are 
equipped with enzymatic and nonenzymatic antioxidant systems to eliminate ROS and 
maintain redox homeostasis. The antioxidant defences come from endogenous systems 
including uncoupling proteins of the respiratory chain, mitochondrial, cytoplasmic and 
peroxisomal enzymes, which exist to reduce oxidative stress. Of particular importance 
for the antioxidant defence is the conversion of O2
-
 to H2O2 by superoxide dismutase 
(SOD) in the mitochondria and then the further detoxification of H2O2 to form H2O by 
the action of glutathione peroxidase (GPX) in the cytoplasm or the the action of catalase 
in the peroxisome (Trachootham et al. 2008). In specific, the conversion of reduced 
glutathione (GSH) to oxidized glutathione (GSSG), which is catalyzed by GPX is a 
major antioxidant system that reduces a broad range of hydroperoxides. GSH, in 
addition to being a cofactor of various antioxidant enzymes, is the most abundant 
peptide in cells and possesses a plethora of functions. These include direct scavenging 
of HO
-
, singlet oxygen, and regeneration of other antioxidants such as vitamin C and E 
to their active forms (Nakamura et al. 1997). 
Key role in the antioxidant defence play the uncoupling proteins (UCPs), 
especially the ubiquitously expressed UCP2. UCP2 dissipates the electrochemical 
proton gradient generated across the mitochondrial membrane by the electron transport 
chain. As shown in figure 8, superoxide production in the mitochondrial electron-
transport chain activates UCP, which transfers protons to the internal side of the 
mitochondrial inner membrane. This proton leak causes a decrease in mitochondrial 
81 
 
membrane potential, which limits the production of superoxide in an autoregulatory 
feedback loop (Krauss et al. 2005).  
 
Figure I-8. Negative regulation of ROS by activation of UCP2 (Krauss et al. 2005). 
 
Legend: The proton gradient across the mitochondrial inner membrane (H+) is created 
by the export of protons (H+) from the mitochondrial matrix across the inner 
mitochondrial membrane (a), which also leads to electron reductions of molecular 
oxygen at complexes I and III of the mitochondrial electron-transport chain and the 
formation of superoxide (b). When this export of protons increases the membrane 
potential and consequently the production of superoxide in the inner side of the 
membrane also increase. The increased levels of superoxide anions in the inner side of 
the membrane active UCP2, which transfers protons from the mitochondrial matrix 
across the mitochondrial inner membrane (c). This proton leakage, in turn, causes a 
decrease in mitochondrial membrane potential (d), which limits the production of 
superoxide from the mitochondrial electron-transport chain as a result of this 
regulatory feedback meachanism.  
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Uncoupling leads to a higher flow rate through the electron chain and a reduced 
formation of ROS, which protects the cell from high oxidative stress at the cost of 
wasting energy as heat. UCP2 activity is induced by byproducts of lipid peroxidation 
and intra-mitochondrial superoxide (Echtay et al. 2002), serving as a negative regulator 
of ROS generation. The widespread UCP2 tissue distribution is, to some extent, due to 
expression in immune cells which are generators of large amounts of ROS especially 
under conditions of stress. 
In its most severe form, redox imbalance may result in cell death following 
widespread macromolecule oxidation, while more subtle changes appear to play a role 
in modulating a range of signal transduction pathways (Suzuki et al. 1997). All 
molecules are potential targets for ROS (proteins, lipids and DNA), but because of their 
propensity to contain double bonds, unsaturated lipids are more often targeted (Evans et 
al. 2002). Nonetheless, oxidative DNA damage is of particular importance, since it may 
trigger DNA damage response pathways which influence the cell cycle (Zhan et al. 
2010).  
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5. THE BIOLOGY OF AGEING 
Chronological age is a measure of the period of time that an organism exists and 
proceeds at the same rate in all individuals of every species. On the other hand, the 
biological age reflects the physical state of an organism and does not proceed at the 
same rate in all individuals. Biological ageing is a result of tissue deterioration and 
progressive loss of function accompanied by a gradual decrease in fertility and increase 
in the probability of death. This tissue deterioration and loss of function is often 
responsible for the development of age-related diseases, which lead to higher morbidity 
and mortality. 
 
5.1 THE EVOLUTION OF AGEING 
There are different evolution theories to explain how natural selection is 
implicated in the development of the mechanisms governing ageing. One explanation is 
that programmed senescence-associated mortality has evolved in order to limit the 
population size, or enhance the turnover of generations, helping the population to adapt 
in changing environments. However, in the wild mortality is mainly determined by 
extrinsic hazards and occurs in younger ages, long before senescence-associated 
mortality arise (Figure 9A). Thus the evolution of genetic factors leading to 
programmed senescence-associated death appears unlikely. Due to high extrinsic 
mortality, only a small number of subjects in a population reach old ages, and thus, 
natural selection has limited opportunity to act, creating a natural selection ―shadow‖ at 
old ages (Figure 9B). For this reason, not only are genetic factors leading to 
programmed death unlikely to be favoured, but nor will the accumulation of mutations 
with late-acting deleterious effects be opposed by natural selection. Therefore, given 
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that unselected deleterious mutations accumulate, the distribution of these mutations in 
a population is expected to be highly heterogeneous (Kirkwood & Austad 2000).  
 
Figure I-9. Theories for the evolution of biological ageing. A) The theory of 
programmed senescence-associated ageing, B) The theory of natural selection 
shadow in later life, C) The theory of antagonistic pleiotropy, D) The disposable 
soma theory (Kirkwood & Austad 2000). 
 
 
 
In 1957, Williams suggested another theory for the evolution of ageing, that of 
―antagonistic pleiotropy‖ (Figure 9C). According to this theory genes with beneficial 
effects early in life would be favoured by natural selection even if these same genes led 
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to a deleterious effect, such as senescence, later in life. A small beneficial effect of a 
pleiotropic gene early in life, before reproduction, grants a more important fitness 
advantage compared to the disadvantage of a deleterious effect later in life, even if that 
leads to premature ageing and death (Williams 1957). This theory led Kirkwood to 
suggest the theory of ―disposable soma‖ (Figure 9D). This theory is based on the 
concept that metabolic resources are allocated between somatic maintenance and 
reproduction as effectively as possible. In that sense somatic maintenance is required for 
as long as the organism has a reasonable chance to survive in the natural environment. 
Extending the theory of Williams, Kirkwood suggested that an organism will benefit by 
investing any spare resource into preserving a good physiological condition until 
reproduction, rather than into a better repair capacity later on, even though that would 
result in less damage accumulation and slower ageing (Kirkwood 1977). 
 
5.2 MOLECULAR PATHWAYS OF AGEING 
Ageing is no longer thought to be an entropic process of tissue deterioration that 
occurs in a random way. We now know that the ageing process, like all biological 
processes, is subject to regulation by classical signalling pathways and that its role is 
partly genetically determined. Interestingly, ageing research has shown that mutations 
that slow ageing also postpone age-related disease (Kenyon 2010), which raises the 
possibility of combating many age-related diseases all at once by targeting ageing, their 
greatest risk factor. 
Studies in organisms ranging from yeast to primates have revealed specific 
mechanisms that regulate ageing, which involve nutrient sensors and metabolic 
regulation and genome maintenance mechanisms and DNA damage signalling (Kenyon 
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2010). Of great importance is the metabolic flux through the insulin/insulin growth 
factor-1 (IGF-1) pathway and the downstream phosphoinositide 3-kinase (PI3K) 
signalling (Honjoh et al. 2009). Another pathway regulating ageing is the signalling of 
the kinase target of rapamycin (TOR). TOR kinase is a major amino-acid and nutrient 
sensor that stimulates growth and blocks salvage pathways such as autophagy when 
food is plentiful (Kapahi et al. 2004; Kaeberlein et al. 2005). Another important 
pathway is that of AMP kinase, a nutrient and energy sensor that activates catabolic 
pathways and represses anabolic pathways when the cell's AMP/ATP ratio rises (Greer 
et al. 2007). Also, sirtuins, the NAD+-dependent protein deacetylases have been 
demonstrated to play a key role. Sirtuins are important metabolic regulators that respond 
to dietary restriction (Rogina & Helfand 2004). Finally, mitochondria integrity seems to 
be crucial, since decreasing mitochondrial reserves and function has been documented 
in aged human and mouse tissues (Kenyon 2010; Sahin & Depinho 2010). 
On the other hand, the preservation of genome integrity has a great impact in the 
regulation of ageing. Inefficiency of DNA repair (Rossi et al. 2007) or oxidative 
defence systems (St-Pierre et al. 2006), as well as shortened, dysfunctional telomeres 
(Wong et al. 2003) have been shown to accelerate premature ageing and diminish 
lifespan. In particular, there is increasing evidence pointing to age-associated telomere 
damage and p53-mediated DNA damage signalling as the driving force leading to 
senescence and apoptosis of tissue stem cell reserves and age-related tissue 
degeneration (Sahin & Depinho 2010). 
As to what causes ageing, it is widely now accepted that ageing is caused by 
macromolecular damage and a prime candidate for causing this damage are the ROS 
produced during respiration. Evidence supporting this role of ROS comes from resistant 
to oxidative stress mutants who exhibit long lifespan (Sun et al. 2002), as well as from 
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the stress-resistant cells of mammalian species that live long (Kenyon 2005). In 
addition, a moderate inhibition of respiration has been shown to extend the lifespan in a 
wide variety of species (Kenyon 2010).  
 
5.3 CELLULAR SENESCENCE  
The ageing process at the cellular level is expressed through senescence. 
Cellular senescence is seen as permanent growth arrest and appearance of a cell 
phenotype associated with impairment of cellular homeostasis, which under certain 
circumstances may lead to apoptosis. Senescence was first described by Hayflick and 
Moorhead in 1961. They discovered that primary human cells can only divide up to a 
finite number of times in culture. After this cell-specific limit of replications, now called 
the ―Hayflick limit‖, the cells undergo ―replicative‖ senescence. Hayflick and Moorhead 
interpreting their results, suggested that the cells, in a way, remembered how ―old‖ they 
were, i.e. how many times they have divided, linking the phenomenon of limited 
replicative capacity to ageing (Hayflick & Moorhead 1961; Hayflick 1965). However, 
at the time it was unclear how cells remember how ―old‖ they are. In other words, the 
mechanism by which the cells register the number of cell divisions that has occurred 
and the mechanism that controls the trigger of replicative senescence once this cell-
specific limit of replications is reached were unknown.  
It is now widely accepted, at least in humans, that this role is served by the 
progressive shortening of telomeres with cell divisions until they reach a critical length, 
whereby telomere dysfunction is induced. The latter is considered to be the trigger of 
replicative senescence, by activating the tumour suppressor p53 (the role of telomeres is 
described in more detail in chapter 6 of the Introduction, page 92) (Allsopp & Harley 
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1995; Blackburn et al. 2006; Finkel et al. 2007). Stressful stimuli might also induce 
cellular senescence, which can be telomere-dependent or –independent. In the second 
case, cells may undergo an exogenously induced acute growth arrest, which occurs in 
particularly stressful conditions. This phenomenon is called stress or aberrant 
signalling-induced senescence ―stasis‖ and is similar to telomere-dependent replicative 
senescence. However, the telomere-dependent replicative senescence is induced at the 
M1 or M2 phase of the cell cycle, while during ―stasis‖, growth arrest is induced at the 
G1 phase of the cell cycle (Shay & Roninson 2004).  
Senescence has probably developed initially as a mechanism of removal of cells 
which have accumulated genomic damage, protecting in this way against the formation 
of early onset cancers. Thus the evolution of senescence complies with the antagonistic 
pleiotropy theory on the evolution of ageing. According to this theory, natural selection 
would have favoured a mechanism, like senescence, which preserves genomic integrity 
and health in early life, even if the accumulation of senescent cells in later life would 
compromise normal tissue function and lead to ageing and age-related diseases (Shay & 
Roninson 2004).   
 
5.4 EUKARYOTIC CELL DIVISION  
The division of the eukaryotic cell is only a small part of the cell cycle and is 
called the ―M‖ phase. During this phase mitosis (or meiosis in gametes) and cytokinesis 
take place, resulting in separation of the nucleus and cytoplasm respectively. The rest of 
the cell cycle consists of the G1 the S and the G2 phases (Figure 10). During G1 and G2 
phases the cell grows, and during S phase DNA replication occurs. After a successful 
cell division, the new cell enters the G1 phase, where it enlarges and makes new 
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proteins. This phase is critical, as a checkpoint occurs at the end of G1, just before the S 
phase, whereby the cell decides whether the conditions are favorable in order to divide. 
If the conditions are not favorable then the cell enters a non-dividing state called G0. If 
the conditions are favorable the cell decides to commit to the cell cycle and divide, and 
it moves on to the S phase. After the DNA is replicated successfully the cell moves to 
the G2, during which the cell prepares itself for division, and finally at the M phase the 
cell divides (Hunt 2002).  
 
Figure I-10. The cell cycle (University of Leicester, Genetics Education Networking 
for Innovation and Excellence, Virtual Genetics Education Centre, 
http://www.le.ac.uk/ge/genie/vgec/he/cellcycle.html).  
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5.5 THE END-REPLICATION PROBLEM 
Replication of DNA is governed by the interplay of various proteins, with DNA 
polymerase, the enzyme which catalyses the synthesis of new DNA strands, having the 
central role. The first step of the replication is the split of the two antiparallel strands of 
DNA to form the ―replication fork‖. The DNA polymerase can only add 
deoxyribonucleotides to the 3' hydroxyl terminus of a pre-existing strand. Thus, the 5' to 
3' leading strand is synthesized continuously to the end of the DNA molecule using 
DNA polymerase. On the other hand, the 3' to 5' lagging strand cannot be copied 
continuously due to the incapability of DNA polymerase to add deoxyribonucleotides to 
the 5' hydroxyl terminus. Thus, the lagging strand is synthesised in discontinuous 
Okazaki fragments initiated by RNA primers. In the next step, these RNA primers are 
degraded, the internal gaps are filled and the Okazaki fragments are ligated with the 
help of DNA ligase. However, this enzyme can only join two strands together, which 
means that the terminal gaps left from the degradation of the RNA primers cannot be 
filled. Thus, in each DNA replication the terminal region will be left unreplicated 
(Figure 11). This phenomenon is called the ―end replication problem‖.  
In 1971 Olovnikov proposed the ―marginotomy‖ theory (Olovnikov 1971), 
according to which the incomplete replication of the very end sequences of 
chromosomes, during DNA replication provided an explanation for the Hayflick limit 
and the trigger of senescence. These distal ends of chromosomes constitute a special 
structure, called the telomere.  
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Figure I-11. The replication of DNA in eukaryotic linear chromosomes (Reactome, 
Telomere maintenance in Homo Sapiens http://www.reactome.org/cgi-
bin/eventbrowser?DB=gk_current&ID=157579 ).  
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6. TELOMERE BIOLOGY 
 
Telomeres (from the Greek words ―telos‖, meaning ―end‖ and ―meros‖ meaning 
―component‖) are specialised DNA-protein structures at the extreme ends of eukaryotic 
linear chromosomes. Elizabeth Blackburn, Carol Greider and Jack Szostak won the 
Nobel Prize in Medicine in 2009 for discovering the molecular structure of telomeres, 
and how these protect chromosomes from degradation. Their discoveries shed light on a 
basic biological mechanism which stimulated research in a new exciting field aiming to 
explore the role of telomeres in normal ageing, cancer and age-related disease 
pathology.  
 
6.1 TELOMERE STRUCTURE 
The essential DNA sequences of telomeres, in most species, are tandem repeats 
of a short sequence unit. The number of terminal repeats at a telomere displays 
variability between species and between individuals of the same species. The initial 
mammalian telomere length is estimated to be at around 17 kb (de Bono 1998). In 
humans, telomere length is approximately 15 kb in sperm and 10kb in average in 
somatic tissues. The sequence of the tandem repeats is TTAGGG, thus the double-
stranded telomeric DNA, consists of a G rich strand, which is always 5′ to 3′ and a 
complimentary C rich strand. Telomeric DNA is double-stranded for most of its length 
with a 3′ G rich single-stranded overhang of a few to several repeats at the very end 
(150-200 bp). This 3′ single-stranded overhang is usually tucked back invading the 
preceding double-stranded DNA (with a section of the double-stranded DNA also 
invading the preceding one) resulting in the formation of a loop, the so-called ―T-loop‖. 
93 
 
However, in dividing cells with active telomerase, telomeres are in a state of flux 
(Figure 12). Subtelomeric sequences, next to the terminal telomeric repeats, are 
degenerated telomeric sequences which also contain tandem repeats of shared telomeric 
sequences (Blackburn 2001; De Boeck et al. 2009).  
 
Figure I-12. Schematic presentation of telomeres (Salpea & Humphries 2010). 
 
 
 
In all vertebrates, including humans, the distal end of the telomeric DNA is part 
of a non-nucleosomal DNA-protein complex, with various structural and evolutionarily 
conserved DNA binding proteins taking part. The interaction between these proteins and 
the telomeric DNA sequences is essential to the function of telomeres. Two of the most 
important telomeric sequence-specific binding proteins in mammals are telomeric 
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repeat-binding factor 1 and 2 (TRF1 and TRF2). TRF2 contributes to the formation of 
the ―T-loop‖, which has been shown to protect the telomeric structure in vivo. 
Telomeres which do not form the T-loop are prone to non-homologous end-joining, and 
fusion (Blackburn 2001; De Boeck et al. 2009). In addition, the loss of TRF2 has been 
shown to activate the p53 pathway and induce senescence (Smogorzewska & de Lange 
2002), while overexpression results in prevention of chromosomal aberrations 
(Karlseder 2003). On the other hand TRF1 binding to double-stranded DNA blocks 
replication by DNA polymerases (Smucker & Turchi 2001). The proteins which bind 
along the repetitive telomeric sequences assemble additional proteins to form a higher-
order nucleoprotein. For example in humans, the telomeric proteins, TIN2, tankyrase 
and DNA-repair protein Ku, interact with telomeres via TRF1 binding. It has been 
proposed that tankyrase-mediated ADP-ribosylation of TRF1 opens the telomeric 
complex allowing access to the enzyme telomerase (Smith & de Lange 2000), and that 
TIN2 interacts with TRF1 to suppress telomere elongation in cells with active 
telomerase (Kim et al. 2003). A recent study has suggested that another human telomere 
protein Pot1 may bind to the 3′ end of telomeres and stabilise them whilst in a flux or 
―open‖ state during various phases of the cell cycle (Colgin et al. 2003). 
 
6.2 GENETICS OF TELOMERE LENGTH 
The consistent average length differences between species and chromosome arm 
differences within species indicate that mean telomere length is genetically determined 
(de Pauw et al. 2005). Telomeres have chromosome-specific lengths which are very 
similar between homologues of an individual and may differ among individuals. It has 
been suggested that this chromosome-specific pattern of telomere lengths is defined in 
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the zygote. Twin and family studies have provided evidence showing that heritability of 
the inter-individual variation in telomere length ranges from 44% to 80% (Slagboom et 
al. 1994) (Vasa-Nicotera et al. 2005; Njajou et al. 2007). Quantitative trait linkage 
(QTL) studies have mapped putative loci for telomere length to human chromosomes 
3p26.1, 10q26.13, 12q12.22 and 14q23.2 (Vasa-Nicotera et al. 2005; Andrew et al. 
2006; Mangino et al. 2008). Recent GWAS have identified SNPs affecting telomere 
length on chromosome 18q12.2 (Mangino et al. 2009) and chromosome 3q26 at a locus 
which includes TERC, the gene encoding the telomerase RNA component (Codd et al. 
2010). 
 
6.3 TELOMERASE 
In 1984 Carol Greider working with Elizabeth Blackburn discovered the enzyme 
which forms telomeric sequences (Greider & Blackburn 1985). This enzyme prevents 
telomere shortening with cell division, which otherwise takes place due to the end 
replication problem. It is a ribonucleoprotein enzyme containing the rate-limiting 
catalytic unit of reverse transciptase (TERT), which is highly conserved, and a RNA 
primer (TERC), which provides the template for the telomeric repeats to be synthesised 
and to fill in the gap in telomeres left unreplicated during DNA replication. During 
telomerase-dependent replication, the enzyme binds to telomeric sequences serving as 
primers on the 3΄ end of the G-rich strand of telomeres, so that the reverse transcriptase 
TERT elongates the G-rich strand using the TERC RNA as template. The 
complimentary C-rich strand is generated by lagging-strand synthesis, thus a G-rich 
single stranded overhang is always created (Figure 13) (Greider & Blackburn 1989; 
Lingner et al. 1997).  
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Figure I-13. Telomerase-mediated replication (University Medical Center 
Hamburg-Eppendorf, Department of Internal Medicine, 
www.uke.de/kliniken/medizinische-klinik-1/images_content/klinik-med-
I/Telomerase_Abb2.jpg).  
 
 
 
Telomerase is not expressed at the same level in all cell types. All foetal tissues 
have active telomerase at early stages of the development. However, some tissues like 
liver, lung, testis and spleen have active telomerase until the latest foetal age examined, 
while brain and kidney tissues only express it up to the 16
th
 week and heart up to the 
12
th
 week (Ulaner & Giudice 1997). Most importantly, telomerase is active always in 
germ cells. The differentiated cells of somatic tissues in most cases do not express 
telomerase. Nonetheless, there is a low activity of telomerase in hematopoietic 
progenitor cells, activated lymphocytes (Hiyama et al. 1995), the basal layer of skin 
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(Harle-Bachor & Boukamp 1996) and cells of the premenopausal endometrium (Brien 
et al. 1997). This low activity though, is not sufficient to maintain the telomere length as 
long as in germ lines (Figure 14).    
 
6.4 TELOMERE FUNCTION 
Jack Szostak and Elizabeth Blackburn in 1982 revealed that telomeres constitute 
a fundamental mechanism offering protection to chromosomes from degradation 
throughout different species (Szostak & Blackburn 1982). More specifically, telomeres 
protect chromosome ends against cellular exonucleases and non-homologous end-
joining, while distinguishing integer chromosome ends from DNA breaks. We now 
know that telomeres‘ biological function goes beyond the protection of chromosome 
ends from degradation or fusion, playing an important role in the cell‘s ageing process 
(Blackburn et al. 2006).  
In somatic cells, where the enzyme telomerase is not expressed, the very end of 
telomeres is left unreplicated due to the end-replication problem. Thus the length of 
telomeres becomes shorter with each cell division, and once the length reduces below a 
critical value, the Hayflick limit, replicative senescence is induced (Sozou & Kirkwood 
2001). Telomere length constitutes a mechanism of normal cell senescence (Allsopp & 
Harley 1995). This normal cell senescence is induced, at the cell cycle checkpoint M1, 
when the critically short length compromises the telomeric structure inducing DNA 
damage signaling pathways. Mutations or transformation events may allow cells with 
DNA damage (such as critically short telomeres) to escape the M1 checkpoint and 
extend their lifespan (de Lange 2001) (Figure 14). Another checkpoint exists later in the 
cell cycle, at M2, whereby the cells that escaped M1 usually undergo crisis at M2. In 
98 
 
rare cases of mutations, cells might also escape the M2 checkpoint and become 
immortal. There is an additional checkpoint later on at the G2 phase of the cell cycle, 
which is also sensitive to critically short telomeres (Jin et al. 1996). The regulator of the 
senescence response pathway to critically short telomeres is p53 (Itahana et al. 2001). 
 
Figure I-14. The telomere hypothesis of cellular senescence and immortalization 
(Royle et al. 2009).  
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Immortality may be induced when cells, that do not normally have active 
telomerase, express this enzyme and elongate their telomeres (Figure 14). This 
telomerase-dependent immortalization occurs in the majority of human cancers. 
Nevertheless, in 10-15% of human cancers, cell immortalization is achieved through 
another pathway that does not require the acivity of telomerase, the alternative 
lengthening of telomeres (ALT) pathway (Figure 14). In this case telomeres are 
elongated through homologous recombination between telomere repetitive DNAs. The 
ALT phenomenon has been observed only in cancer and genetically modified 
organisms, but it is possible that it represents the dysregulated version a normal process 
(Cesare & Reddel 2010).  
A potential mechanism for telomere-mediated senescence is the transcriptional 
silencing of genes adjacent to telomeres. According to this postulated mechanism, 
called the ―telomere positioning effect‖, when the length of telomeres becomes very 
short, it causes the reversible silencing of certain adjacent gene/s. The telomere 
positioning effect has been shown in Saccharomyces cerevisiae but there is little 
evidence suggesting that this mechanism exists in humans (Wright & Shay 1992; Tham 
& Zakian 2002).  
 
6.5 TELOMERE HYPOTHESIS IN AGEING  
Telomere shortening in somatic tissues ―counts‖ the number of cell divisions 
and induces senescence at a critical length. In this way the length of telomeres 
represents the replicative history and capacity of the cells, serving as a ―mitotic clock‖. 
The theory that telomere length is a mitotic clock regulating the cellular lifespan was 
proposed by Harley in 1992 (Harley et al. 1992). Since then, this theory has been 
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supported with increasing evidence. Telomere length has been shown to decrease with 
ageing of cells both in vivo and in vitro. More importantly, initial telomere length has 
been shown to predict the replicative capacity of cell culture generated from a wide 
range of donor ages. The donor age has also been shown to correlate with the cells 
telomere length (Allsopp et al. 1992; Vaziri et al. 1994; Chang & Harley 1995).  
The rate of telomere shortening in telomerase negative cells is not only 
dependant on the number of cell divisions, but also on DNA damage. The processing of 
telomere ends to reconstitute 3‘ single-strand overhangs results in telomere loss due to 
the fact that DNA repair mechanisms, particularly for single-stranded DNA damage, are 
less efficient in telomeric DNA than elsewhere in the genome. The resulting 
accumulation of single-strand breaks along the telomere leads to additional DNA 
damage-dependent shortening during replication (Richter & von Zglinicki 2007). 
Hence, telomere shortening could serve as an indicator of replicative history and 
cumulative genomic damage of somatic cells (Petersen et al. 1998; Serra et al. 2000). 
Therefore, the length of telomeres indicates the replicative capacity and cumulative 
genomic damage of somatic cells, reflecting the tissue‘s ―biological age‖.  
In recent years, the role of telomere length in the pathology of CVD and 
diabetes, where tissue ageing and senescence play major roles, has attracted a 
continuously growing research interest. 
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7. TELOMERE LENGTH IN CARDIOVASCULAR DISEASE AND DIABETES 
 
7.1 TELOMERE LENGTH IN CARDIOVASCULAR DISEASE 
As discussed previously (paragraph 2.4.1 of the ―Introduction‖, page 51), CVDs, 
including ischaemic heart disease, heart failure, cerebrovascular disease, aortic 
aneurysms and renal vascular disease, are all diseases of maturity, closely related to 
ageing. CVDs mainly arise from the failure to preserve vascular wall homeostasis and 
normal function. This is usually a result of vascular tissue deterioration and impaired 
regenerative capacity during the ageing process. The accelerated age-associated changes 
in vascular structure and function lead to a number of pathologies, causally related to 
the early development of CVDs; These include endothelial dysfunction (Celermajer et 
al. 1994), atherosclerotic plaque progression (Eggen & Solberg 1968), arterial stiffening 
and remodeling (Lakatta 2003) as well as impaired angiogenesis (Rivard et al. 1999) 
and defective vascular repair (Weinsaft & Edelberg 2001).  
 At the cellular level, vascular ageing and the related pathologies possibly 
arise from the depletion of vascular progenitor cell reserves which impairs the tissue‘s 
regenerative capacity and the accumulation of senescent endothelial and vascular SMCs 
(VSMCs) (Erusalimsky 2009). Senescent cells undergo distinct changes in gene 
expression that cause impairment of cellular function. Vascular endothelial and VSMC 
senescence and consequent dysfunction have been shown to contribute to atherogenesis. 
Specifically, senescent endothelial cells, which display impaired NO production and 
overexpress proteins such as interleukin-1α, intercellular adhesion molecule 1 and PAI-
1, characterise the pro-inflammatory and pro-thrombotic phenotype of the endothelium 
during atherogenesis (Samani et al. 2001; Minamino et al. 2002). 
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As expected from the description of telomere length as a marker of tissues 
biological ageing and a mechanism of cellular senescence (paragraph 6.4 of the 
―Intorduction‖, page 97), marked telomere shortening has been detected in endothelial 
cells of vascular regions susceptible to atherosclerosis (Chang & Harley 1995), while 
telomere shortening-induced SMC senescence has been shown to contribute to the 
development of atherosclerotic plaques (Matthews et al. 2006). Taking these together, it 
can be hypothesised that telomere length could serve as an indicator of vascular 
biological ageing associated with CVD development.  
Previous studies have demonstrated an association of telomere length with 
health and longevity (Terry et al. 2008), atherosclerosis (Samani et al. 2001), vascular 
ageing as reflected by arterial stiffness (Benetos et al. 2001) and other degenerative 
diseases, such as dementia and Alzheimer (Honig et al. 2006). In this last study, mean 
telomere length was shorter among patients dying during follow-up than in those 
surviving. As a result, CHD patients have mean leukocyte telomere length (LTL) 
equivalent to that of 11 years older healthy subjects (Brouilette et al. 2003), which 
reflects the biological ageing of the vascular wall (Figure 15).  
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Figure I-15. Schematic presentation of LTL decrease with age in CHD cases (solid 
line) and controls (dashed line). The double line illustrates the biological age gap 
between cases and controls. 
 
 
 
Short telomeres may be a primary abnormality that renders the organism more 
susceptible to CVD. However, reduced leukocyte length in CHD patients may also be a 
consequence of increased cell turnover induced by chronic inflammatory response 
underlying atherogenesis (Serrano & Andres 2004) or faster shortening due to oxidative 
stress caused by CHD risk factors (Aviv 2002).  
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7.2 TELOMERE LENGTH IN TYPE 2 DIABETES 
T2D is also considered an age-related disease in terms of its onset and 
progression. Premature cell senescence has been postulated as an important cause and 
consequence of T2D and its complications (Sampson & Hughes 2006). The β cell 
senescence and apoptosis is an indispensible condition for the pathogenesis of T2D. On 
the other hand the complications of the disease are a consequence of senescent 
phenotypes in various tissues and organs, including the kidneys, the eyes, the peripheral 
nerves and the vascular vessels. Thus, it can be speculated that telomere shortening may 
be the underlying mechanism leading to senescence of beta cells and the onset of the 
disease, and/or to senescent phenotypes in other tissues contributing to the worsening of 
the disease.  
These shorter telomeres can be either attributed to shorter length at birth in 
individuals predisposed to diabetes or to accelerated telomere loss during cell division 
caused by T2D risk factors in prediabetic conditions, or both. In support of this, shorter 
telomeres have been observed in circulating epithelial progenitor cells in patients with 
metabolic syndrome (Satoh et al. 2008) and in other conditions of high oxidative stress, 
such as smoking and obesity (Valdes et al. 2005).  
Accelerated shortening of telomeres during diabetes may also be the underlying 
mechanism leading to telomere-dependent genomic instability and consequent 
development of epithelial cancers, senescent retinal and renal phenotypes (expressed as 
diabetic retinopathy and nephropathy), as well as senescent vascular endothelial and 
smooth muscle cells (expressed as endothelial dysfunction and accelerated 
atherogenesis), all contributing to T2D complications (Sampson & Hughes 2006).  
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7.3 MECHANISMS  
As described earlier (paragraph 6.2 of the ―Intorduction‖, page 94), telomere 
length is documented to have a strong hereditary component (Graakjaer et al. 2004). 
More specifically, Graakjaer et al. (Graakjaer et al. 2004) demonstrated that any length 
alteration during the lifespan impacts equally on genetically identical chromosomes. 
Therefore, mean telomere length at a certain point in lifetime will be a function of the 
telomere length inherited at birth and the rate of shortening during life. 
Increased oxidative stress is associated with many of the risk factors implicated 
in the pathophysiology of atherosclerosis including diabetes, hypercholesterolaemia, 
ageing, hypertension and smoking (Harrison et al. 2003). Diabetes, in specific, is 
characterised by increased oxidative stress (Orie et al. 2000) and oxidative DNA 
damage (Sampson et al. 2006). Telomeres are particularly prone to oxidative damage at 
the GGG sequence and consequent single-strand breaks. Telomere ends tend to 
reconstitute their 3‘ single-strand overhangs when broken, thus the accumulation of 
single-strand breaks along telomeres leads to an additional, DNA damage-dependent, 
shortening during replication (Richter & von Zglinicki 2007). Therefore, the rate of 
telomere shortening is considered to depend on the balance between intracellular 
oxidative stress and antioxidant defence. Thus, it can be speculated that increased 
oxidative DNA damage in CVD and T2D leads to telomeric DNA damage in many cell 
types, resulting in telomere loss accelerated at cell division, and consequently to 
senescent phenotypes in multiple cell types (Sampson & Hughes 2006). 
Finally, chronic inflammation is an important feature characterizing and 
preceding both CVD and T2D (Pillarisetti & Saxena 2004; Hulsmans & Holvoet 2010). 
Pro-inflammatory cytokines released in chronic inflammation may lead to a more rapid 
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shortening of telomeres most likely through increased cell turnover (Serrano & Andres 
2004) but also through the enhancement of free radical production (Hulsmans & 
Holvoet 2010). 
 
8. GENERAL HYPOTHESIS 
Despite the significant advances in identifying risk factors for CVD and T2D, 
these do not completely explain the inter-individual variability related to predisposition 
for premature disease. CVD and T2D development is clearly associated with ageing, but 
chronological age does not reflect the physical state of an organism and does not 
proceed at the same rate in all individuals. Thus there is a need for a marker of 
biological age in evaluating the risk for CVD and T2D and telomere length could serve 
as such. 
As described earlier, CVD and T2D are thought to arise from a ―common soil‖ 
of metabolic abnormalities. This common soil of abnormalities includes oxidative stress 
but lately chronic inflammation is also considered to be part of it. My hypothesis is that 
these abnormalities might lead to accelerated telomere shortening during life and 
extended cell senescence implicated in the pathogenesis of both diseases. Moreover, 
since there is a strong genetic component in determining telomere length, familial 
predisposition to CVD or T2D might in part arise from inherited short telomeres at birth 
leading earlier to senescent phenotypes and disease development.   
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8.1 WORKING HYPOTHESES: 
1)  Telomeres will be shorter in patients with CVD and/or T2D where premature tissue 
ageing and senescence are major features of the disease. 
2)  The short telomeres in patients are due to:  
a) shorter lengths at birth in those predisposed to CVD/T2D 
b) faster shortening during life due to oxidative stress caused by CVD/T2D risk factors. 
c) faster shortening during life induced by the underlying chronic inflammatory 
response. 
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II. GENERAL METHODS 
 
1. GENERAL STOCK SOLUTIONS  
I. 1M MgCl2: 20.33gr MgCl2 dissolved in 100ml in dH2O. 
II. 1M Tris pH 8.0: 12.11gr Tris, made up to 100ml in dH2O, Corrected pH to 8.0 and 
autoclaved. 
III. Sucrose lysis mix: 109.54gr sucrose, 5ml 1M MgCl2, 10ml 1M Tris pH7.5, 10ml 
Triton-X-100, made up in 1000ml in dH2O and stored at 4
o
C. 
IV. 0.5M Na2EDTA: 37.22gr EDTA, made up to 200ml in dH2O. Adjusted with NaOH 
to pH 8.0. 
V. 10%SDS: 10gr Sodium dodecyl sulphate, made up in 100ml in dH2O. 
VI. Nuclear lysis mix: 1ml 1M Tris-HCl pH8.2, 2.34gr NaCl, 0.4ml 0.5M Na2EDTA pH 
8.0, 10ml 10%SDS, made up to 90ml in dH2O.  
VII. 5M Sodium perchlorate: 70.24gr sodium perchlorate, made up to 100ml in dH2O. 
VIII. TE buffer pH 7.6: 1.21gr Tris, 0.37gr EDTA, made up to 1000ml in dH2O. 
All reagents were supplied by Sigma (Poole, UK).  
  
109 
 
2. DNA EXTRACTION 
 
2.1 DNA EXTRACTION FROM WHOLE BLOOD WITH THE SALTING-OUT 
METHOD 
2.1.1 Protocol 
DNA was extracted from 5ml of potassium-EDTA or citrated anti-coagulated 
peripheral blood using the salting out method described by Miller with minor 
modifications (Miller et al. 1988). Before starting the extraction process in batches of 24 
samples, the samples identification codes were carefully logged and entered into a 
database. This DNA extraction process involves several steps, which are described 
below:  
1) Cell and nuclear lysis: Blood samples (10ml) were thawed and transferred 
into a labeled 30ml polypropylene tube. Twelve ml cold (4
o
C) sucrose lysis buffer 
(15ml) were added to each tube and mixed by hand inversion. Tubes were centrifuged at 
4
o
C for 10 min at 1300g (Sorvall RC5 centrifuge using rotor SA-600). The supernatant 
was carefully discarded without disturbing the pellet; then the pellets were re-suspended 
in 20ml of sucrose lysis buffer. The samples were subsequently centrifuged for a further 
10 minutes. Following centrifugation, the supernatant was discarded, and the pellet was 
re-suspended in 2ml of nuclear lysis buffer. 
2) Deproteinisation: In the re-suspended pellet of the previous stage, 1ml of 5M 
sodium perchlorate was added and the sample was mixed by inversion. Samples were 
then left on a shaker for 15 min. 
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3) DNA extraction: In each tube, 2ml of cold chloroform (-20
o
C) was added and 
the sample was mixed by inversion. Samples were then centrifuged at 1300g for 3min at 
room temperature. Following addition of cold chloroform, the DNA from each sample 
had been partitioned into the upper aqueous phase within each tube. This upper aqueous 
phase was then transferred into a fresh 30ml polypropylene tube without disturbing the 
organic phase.  
4) Precipitation and washing: Ten ml of cold (-20
o
C) 100% ethanol was added 
slowly in each tube and then mixed by inversion in order to precipitate the DNA. DNA 
from each tube was then ―spooled‖ using a sterile Pasteur pipette. The ―spooled‖ DNA 
was washed in 70% ethanol and transferred into a sterile labeled microtube containing 
1ml Tris-EDTA (TE) buffer.  
5) Dissolving the DNA: The microtubes were then sealed and incubated at 37
o
C 
overnight. The samples were then placed in a cold (4
o
C) cabinet where they were left for 
a period of at least four weeks to allow complete dissolution of DNA.  
Troubleshooting: In cases where no visible DNA was precipitated after the 
addition of 100% ethanol, the samples were placed in the freezer overnight at -20
o
C. 
After that the samples were centrifuged at 1500g for 15 mins. The supernatant was 
discarded and a small DNA pellet was left. The tubes containing this small pellet of 
DNA were left to air dry before adding 0.5ml of TE buffer. Then the samples were left 
overnight at 37
o
C before re-suspending and transferring the contents into labeled 
microtubes. The samples were then placed in a cold (4
o
C) cabinet where they were left 
for a period of at least four weeks to allow complete dissolution of DNA.  
Handling of DNA samples: Stock DNA samples were checked for quality and 
purity and then were standardised to a concentration of 15 ng/μl, and aliquoted into 96-
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well deep Abgene‘s arrays. These ―Stock Arrays‖ were stored at -20oC. Working arrays 
were also generated and stored at 4
o
C. 
2.1.2 Standardisation of DNA stock arrays 
The process of standardisation to 15 ng/μl is described below:  
1) Transfer of DNA: An array sheet from the database of the study sample was 
prepared. 250μl original DNA was transferred from microtubes into 0.8ml labeled 96-
well Abgene‘s arrays. Two people were required during the process of array making in 
order to double check that the ID numbers matched those of the prepared array sheet.  
2) Preparing 1/10 dilution for the measuring samples‟ absorption: The 96-
well array was spun-down at 3000rpm for 1 min before opening. Ten l from each DNA 
sample was pipetted out into the corresponding well of a 96 well Costar UV plate 
containing 90l dH2O and mixed by re-suspending. Four no template controls were kept 
in wells 12E, 12F, 12G and 12H. The plate was then spun-down, before being placed in 
the plate reader. 
3) Measuring absorption at 260nm and 280nm: This was performed using the 
Tecan GENios plate reader and the Magellan 3 software package. The 260/280nm filter 
slide was inserted into the excitation port. The corresponding absorption at 260 and 
280nm was then recorded for each well in the plate and exported.  
4) Extracted DNA quality control: The quality and purity of the extracted 
DNA was checked by the absorbance ratios of DNA/protein and DNA/organic 
contaminants, as measured with the Tecan GENios plate reader. DNA absorbs at 
A260nm, protein at A280nm, thus the samples with values of A260/280nm ratio lower 
than 1.8 were excluded from further analysis. Furthermore, organic contaminants absorb 
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at 230nm (e.g. carbohydrates, peptides, phenol or other aromatic compounds), thus DNA 
samples with values of A260/230 ratio lower than 1.8 were also excluded from further 
analysis. 
5) Standardisation to 15 ng/μl stock arrays using the Beckman Coutler 
Biomek 2000 Robot (Beckman-Coulter, High Wycombe, UK): After excluding the 
DNA samples that had not pass the quality control, the concentration data of each array 
from the plate reader were imported into the Robot. The Robot‘s software calculated the 
volume of DNA required for achieving a concentration of 15ng/l when adding 750l of 
10mM Tris pH 8.0 dilution into each well. If any of the DNA volumes were above 
200l, then the volume was halved and respectively only 375l of 10mM Tris pH 8.0 
dilution was added to the respective wells of the array. If any of the DNA concentrations 
were near 15ng/l, then the DNA was transferred neat. The new Abgene 0.8ml arrays 
and lids were labeled before placed to the robot. This way stock arrays, standardised to 
15 ng/μl, were created and stored at -20oC. 
6) Creating Working Arrays: Working arrays were made in labelled Matrix 
ScreenMate plates using Matrix ScreenMate cap mats. The stock array was spun-down 
before opening and 20 μl of DNA were transferred to the bottom of the working arrays 
using filtered tips. Using filtered tips, 40 μl of 3 mM Tris pH 8.0 was also added to each 
well in order to create a 1/3 dilution of the stock array i.e. a 5 ng/μl concentration in the 
working array (other dilutions can also be created following the same procedure). The 
working array was then left overnight to equilibrate before use.  
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2.2 DNA EXTRACTION FROM C ULTURED HUMAN CELLS 
 Total DNA was extracted from cultured cells (normal human dermal fibroblasts) 
using the PUREGENE DNA kit (Qiagen, West Sussex, UK) with a minimum starting 
material of 200,000 cells per sample. To purify the DNA, this kit uses a modified 
salting-out precipitation method, which leads to a high purification and quality of DNA 
needed for sensitive downstream applications, such as PCR. This method was chosen for 
the extraction of DNA from the cultured fibroblasts of the experiment described in the 
―Fourth Result Chapter‖ (pages 317-354). The reason was mainly that with this method 
both high and low molecular DNA (like mitochondrial DNA) could be yielded, since 
one of the aims of the cell experiment of Result Chapter 4 was to also measure the 
mitochondrial DNA copies. In contrast, the in-house salting-out method, as used for the 
whole blood samples, included the ―spooling of DNA‖, which resulted in the extraction 
predominantly of high molecular DNA. This kit was also chosen due to other advantages 
which include the possibility of interruption and storing the partially purified samples 
during the DNA isolation via convenient stopping points and the possibility of parallel 
processing of multiple samples; useful advantages in order to meet the high demands of 
a large scale cell experiment, such as the one carried out in the present thesis (described 
in the ―Fourth Result Chapter‖, pages 317-354).   
First, the sample of fibroblasts in PBS was centrifuged at 13,200 rpm for 5 
seconds and the supernatant was discarded carefully, leaving approximately 20 µl 
residual liquid with the pellet. The pellet was resuspended in 150 µl Cell Lysis Buffer 
with the use of vortex. After adding 0.75 µl of RNase A Solution and mixing the 
solution by inverting 25 times the cells were incubated at 37°C for 8 minutes (up to 1 
hour is possible). Subsequently the cells were incubated on ice for 1 min and 50 µl 
Protein Precipitation Solution was added and mixed by vortex. The samples were then 
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centrifuged for 1 min at 13,200 rpm. In the following step only the supernatant was 
poured into a new tube, where 150 µl isopropanol were added and mixed in order to 
remove the proteins by precipitation. The samples were then centrifuged for 1 min at 
13,200 rpm and the supernatant was discarded. Following this, the DNA was washed 
with 150 µl of 70% ethanol by inverting several times, and centrifuged for 1 min at 
13,200 rpm. The supernatant was discarded. After air drying (for 15 min), the DNA was 
dissolved in 25 µl of DNA Hydration Solution and incubated at 65°C for 1 hr. The DNA 
concentration was measured using the Nanodrop ND-8000 (Nanodrop Technologies, 
USA), a full-spectrum UV/Vis 8-sample spectrophotometer. The same quality control 
was performed for these samples (described in pargraph 2.1.2 of the ―General methods‖, 
page 111) and the samples that did not meet the criteria were excluded from further 
analysis. Once the DNA concentration had been determined, DNA samples were stored 
for short-term at 4°Cand for long-term at -20°C. 
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3. RNA EXTRACTION FROM CULTURED HUMAN CELLS 
 Total RNA was extracted from cultured cells (normal human dermal fibroblasts) 
soon after the cells were harvested (minimum starting material: 200,000 cells per 
sample) using the RNeasy Mini Kit 250 (Qiagen, West Sussex, UK). Such kits, due to 
the simplicity of their method, are useful alternatives to time-consuming and more 
hazardous methods, like the alcohol precipitation or methods involving toxic reagents 
such as phenol and/or chloroform. This kit is also designed for parallel processing of 
multiple samples, providing purified RNA that is ready for use in applications such as 
cDNA synthesis and real-time RT-PCR.  
In the first step, the sample of fibroblasts in PBS was centrifuged at 13,200 rpm 
for 5 sec and the supernatant was completely removed by aspiration. Buffer RLT was 
then added to the pellet of fibroblasts at a volume dependent on the number of cells 
included in the sample (e.g. 350 µl for 200,000 cells). The samples were then vortexed 
for 10 sec to enhance the lysis of the cells, and, therefore, to maximise the RNA yield. 
One volume of 70% (v/v) ethanol was added to the homogenised lysate and mixed well 
by pipetting. Subsequently, the whole solution was transferred to an RNeasy spin 
column, placed in a 2 ml collection tube and centrifuged for 15 sec at ≥10,000 rpm. The 
flow-through was discarded and the collection tube was reused in the next step. For the 
first washing step, 700 µl of Buffer RW1 was added to the RNeasy spin column which 
was centrifuged for 15 sec at ≥10,000 rpm. The flow-through was discarded again and 
500 µl of Buffer RPE was added to the RNeasy spin column which was centrifuged for 
15 sec at ≥10,000 rpm for a second wash. The flow-through was discarded, the 
collection tube was reused and the membrane was washed once more with 500 µl of 
Buffer RPE. In contrast to the previous washing step, this time the sample was 
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centrifuged for 2 min at ≥10,000 rpm. This step ensured the drying of the spin column 
membrane, so that no ethanol was carried over during the RNA elution. Then the 
RNeasy spin column was placed in a new 1.5 ml collection tube and 40 µl of RNase-free 
water was directly added to the spin column membrane. After a rest period of about 1 
min the samples were centrifuged for 1 min at ≥10,000 rpm in order to elude the RNA. 
RNA quality and concentration were assessed using the Nanodrop ND-8000 
spectrophotometer (Labtech, East Sussex, UK). RNA samples with A260/A280 or 
A260/A230 ratio below 1.8 were excluded from further analysis. The samples of good 
quality were immediately stored at -80°C. 
 
3.1 CDNA SYNTHESIS 
cDNA was synthesised by reverse transcription of total RNA extracted from 
cultured cells (normal human skin fibroblasts) using the Superscript III Reverse 
Transcriptase (Invitrogen, Paisley, UK) and random hexamer primers (Rd(N)6, GE 
Healthcare, Little Chalfont, UK), according to the manufacturer‘s instructions. In brief, 
10 μl RNA (100ng), 1 μl random hexamer primers (50-250 ng) and 1 μl of dNTP mix 
(10 mM of each) were mixed together in a nuclease-free eppendorf tube. The reaction 
was incubated at 65°C for 5 min and cooled quickly on ice. In the next step, 4 μl first-
strand buffer (5x) and 1 μl of 0.1M Dithiothreitol (DTT) and 1 μl of Superscript III 
reverse transcriptase (200 units) were added and the mixture was first incubated at 25°C 
for 5min and then at 42°C for 1 hr. The reaction was stopped by incubation at 70°C for 
15 min. In order to remove completely the RNA from the newly synthesised cDNA, 1 
μl E.coli RNase H (EPICENTRE Biotechnologies, distributed by Cambio Ltd., 
Cambridge UK) was added to each sample, which were then incubated at 37°C for 20 
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min. The synthesised cDNA was subsequently used as a template for amplification in 
real-time PCR. 
 
4. POLYMERASE CHAIN REACTION (PCR) 
The Polymerase Chain Reaction (PCR) is based on the self-replicating nature of 
DNA, which allows short primers to be used in order to initiate synthesis of a target 
sequence in the presence of a DNA polymerase. As shown in figure 1, during the first 
step of the PCR, the double stranded DNA is heated up to a high temperature for a short 
period of time in order to denature DNA into single strands (denaturation step). Then a 
period of lower temperature follows, during which the primer oligonucleotides anneal to 
the complementary bases on the single strands of DNA, flanking the DNA target 
sequence (annealing step). Then the polymerase initiates the synthesis of a new 
complimentary strand at the 5‘ end of each primer using trisphosphate 
deoxyribonucleotides (dNTPs: dATP, dCTP, dGTP and dTTP) (extension step). This 
process is repeated many times during a PCR, resulting each time in the synthesis of 
new pieces of double stranded DNA. During the second cycle of this process, extension 
can occur on both the genomic DNA strands but also on the newly synthesised DNA 
pieces which are shorter and are limited in length precisely to the target sequence. In the 
end, this technique allows the use of a small initial amount of DNA to produce a large 
amount of copies of a specific sequence of interest. Typically, the DNA polymerase 
used in PCRs is derived from the bacterium Thermus aquaticus (Taq), which is not 
denatured by the fluctuating temperatures of the PCR. 
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Figure II-1. Schematic presentation of polymerase chain reaction (Source: Florida 
museum of natural history website, 
http://www.flmnh.ufl.edu/cowries/amplify.html). 
 
 
P1: Forward primer, P2: reverse primer 
 
 Theoretically, each cycle of a PCR results in the doubling of the target sequence. 
In practice this exponential increase in the PCR product occurs only for a limited 
number of cycles while the reagents are still in excess. After a number of cycles the rate 
of amplification reaches a plateau phase, due to a number of reasons including the 
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saturation of the amplified target sequence, the eventual failure of the DNA polymerase 
and the consumption of dNTPs. After the plateau phase is reached subsequent cycles 
lead to eventual formation of primer-dimmer and non-specific products.  
There are two kinds of PCR depending on the purpose it serves. These are the 
―end-point PCR‖ and the ―real-time PCR‖. The purpose of multiplying a specific 
sequence of interest using PCR is to facilitate its study. If the aim of the study is to 
detect a specific sequence and thus its multiplication will allow its determination, then 
the end-point PCR is employed. In this case, once the reaction is completed the PCR 
product is determined by either sequencing or gel electrophoresis or high resolution 
melting. Generally, methods that can determine the length or the base consistency of a 
PCR product are used depending on the purpose of the study. The end-point PCR is 
used for many applications such as the detection of mutations or polymorphisms, the 
detection of infectious agents and  DNA fingerprinting. 
On the other hand, when the target sequence needs to be quantified, then real-
time PCR is employed. In a real-time PCR the amplification of the PCR product is 
measured in each cycle by the fluorescence emitted from a DNA intercalating 
fluorescent dye or from fluorescent probes. Through the monitoring of the amplification 
in each PCR cycle, the exponential phase of the PCR can be determined. Then at this 
phase the rate of amplification of the sequence of interest is compared to that of a 
control target sequence and the relative concentration is estimated. The real-time PCR 
also has many applications, such as the quantitation of mRNA expression levels and the 
measurement of mean telomere length, which will be described in detail in the ―First 
result chapter― of the present thesis (pages 149-210).   
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4.1 REAL-TIME PCR 
 During the real-time PCR or quantitative PCR (qPCR), the fluorescence emitted 
during the reaction is recorded in each cycle. This fluorescence emission is proportional 
to the PCR product generated, thus by recording the amount of fluorescence produced it 
is possible to detect when the exponential phase of the reaction occurs. At this phase the 
rate of the fluorescence increase correlates directly to the amount of the initial target 
sequence. Usually a threshold of the fluorescence is set, and the earliest cycle that a 
sample reaches this threshold (Ct value, Figure 2), the higher is the number of initial 
copies of the target sequence in that sample relatively to the others in the same PCR run. 
This way the relative starting amount of copies of the target sequence is determined 
relatively to a control sample (normalised) in a real-time PCR.  
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Figure II-2. Schematic presentation of the fluorescence signal during real-time 
PCR. 
 
 
The real-time PCR can provide quantification of the starting concentration of the 
target sequence either in relation to a reference sequence or absolute quantification. In 
the second case a standard curve is constructed by serial dilution of a DNA sample of 
known concentration which is included in the same PCR run. The methods of analysis 
of real-time PCR data are described in the ―First result chapter‖, paragraph 2.3 (pages 
164-168).  
An important aspect of the quantification of a target sequence with real-time 
PCR is the amplification efficiency. In theory, during the exponential phase of the PCR 
reaction the amount of the target sequence is doubled in each cycle. In reality this is not 
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quite true because the efficiency of the reaction is not 100%. The conditions of the 
reaction and the purity of samples are factors that play a major role in determining the 
performance of a PCR. Thus it is very important when optimising a real-time PCR to 
achieve as close to 100% efficiency as possible. This can be examined by carrying out a 
standard curve of serial dilutions of a DNA sample; the efficiency (E) can be calculated 
by the slope (M) of the curve with the formula: 
E = 10
-1/M
 
From the standard curve, it can also be examined whether there is a linear correlation 
between the serial dilutions and the amount of target sequence copies measured, which 
indicates the accuracy of the quantification using the real-time PCR data. Thus, 
examining these estimates of a standard curve is considered a quality control of real-
time PCR.  
 
4.2 PCR FLUOROGENIC CHEMISTRIES 
The detection of the PCR products is performed by the generation of a 
fluorescent signal from different kind of chemistries. These chemistries include 
intercalating fluorescent dyes such as SYBR Green, TaqMan probes, Molecular 
Beacons and Scorpions.  
Intercalating fluorescent dyes: Such dyes (e.g. SYBR green) are the simplest 
chemistry for detecting the DNA product in real-time PCRs. These dyes exhibit little 
fluorescence when in solution, but emit a strong fluorescent signal upon binding to 
double-stranded DNA. Thus, as the number of copies of DNA increases during the 
reaction, the fluorescent signal increases. The advantages of such dyes are that they are 
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inexpensive, simple and sensitive; major disadvantages are the lack of specificity, since 
such dyes will bind to any double-stranded DNA generated during the PCR reaction and 
the need for extensive optimization (Gudnason et al. 2007).   
TaqMan probes: Generally, fluorescent probes are pieces of DNA, labelled 
with a fluorescent dye, which are complimentary to the specific sequence of interest. 
The most commonly used type of these probes is the TaqMan. The TaqMan technology 
is based on the 5‘ nuclease activity of the DNA polymerase to hydrolyse an 
oligonucleotide which has been hybridised to the target sequence (Holland et al. 1991). 
The TaqMan probes are labelled with a fluorescent dye -the ―reporter‖- at the 5‘ end, 
and a molecule capable of quenching the reporter‘s fluorescence -the ―quencher‖- at the 
3‘ end. This coupling of reporter and quencher prevents the emission of fluorescence. 
During PCR the TaqMan probe binds to the sequence of interest, and when the DNA 
polymerase acts to replicate the sequence where the probe is already bound to, the 5‘ 
nuclease activity of the polymerase cleaves the probe (Figure 3). This cleavage of the 
probe by the polymerase physically separates the reporter and the quencher and allows 
the fluorescence emission. Therefore, the fluorescence increases in each PCR cycle 
proportionally to the amount of probe cleaved, which is in turn proportional to the 
amount of target sequence copied. (Heid et al. 1996).  
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Figure II-3. TaqMan principle (source: (Koch 2004)).  
 
 
(R): Fluorescent reporter, (Q): Quencher molecule, (hν): Excitation light  
 
The advantages of TaqMan probe technology are that little optimisation is 
required compared to the intercalating fluorescent dyes, and that it can be used for 
multiplex assays. However, these probes are expensive, with a separate probe designed 
for each target sequence.  
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Molecular beacons: These are another commonly-used type of fluorescent 
probe, which are also small pieces of DNA, complimentary to the sequence of interest 
and labelled with a fluorescent reporter and a quencher molecule on opposite ends. 
These probes when free (not hybdridised) in solution are fold on to themselves forming 
a hairpin stem, which brings the reporter and quencher into close proximity and 
prevents fluorescent emission. When the probe binds to the sequence of interest, it takes 
up a linear confirmation and the reporter and quencher are separated. This results in the 
desired increase in fluorescence. Molecular beacon probes are not cleaved by the 
polymerase but are just set free again and rebind to the target sequence in the next PCR 
cycle (Kostrikis et al. 1998). 
Scorpions: The Scorpion probes are single oligonucleotides, specific for the 
sequence of interest, which again have a fluorescent dye attached to the 5' end and a 
quencher molecule at the 3' end. The Scorpion probes, when they are not hybridised, 
maintain a hairpin loop configuration which prevents fluorescence emission. The 3' 
fraction of the Scorpions contains a sequence which is complementary to the extension 
product of the primer. This sequence is linked to the 5' end of a specific primer 
(Scorpion primer) through a non-amplifiable monomer. After extension of the Scorpion 
primer, the specific probe sequence is able to bind to its complementary sequence 
within the extended PCR amplicon, thus causing the opening of the hairpin loop. This 
brings apart the fluorescent dye form the quencher and allows the fluorescence emission 
(Whitcombe et al. 1999). 
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4.3 TAQMAN TECHNOLOGY APPLICATIONS 
4.3.1 Determination of expression levels by TaqMan assays. 
Relative quantification of the mRNA of the genes of interest was performed with 
Taqman probes, after amplification and detection with the ABI prism 7900HT sequences 
detection system (Applied Biosystems, Cheshire, UK). The reverse transcribed cDNA 
was used as the template for real time PCR. 
TaqMan probes and primers: Forward and reverse primers and probes for the 
genes of interest and selected housekeeping genes were ordered and supplied on demand 
from Applied Biosystems, Cheshire, UK. The probes used for the housekeeping genes 
were: ubiquitin C (UBC) (Hs00824723_m1), beta actin (ACTB) (Hs99999903_m1) and 
glyceraldehydes-3-phosphate dehydrogenase (GAPDH) (Hs99999905_m1). All probes 
were labeled at the 5‘ end with 6-carboxyfluorescein (FAM), and at the 3‘ end with a 
non-fluorescent quencher.  
Real-time PCR protocol: Each PCR reaction had 5l volume and consisted of 
2.5l Taqman Gene expression master mix (Applied Biosystems, Cheshire, UK), 0.25l 
of (20x) assay on demand probes (containing the relevant primers), 1.25l of RNase free 
water and 1l of cDNA template. The thermal cycling was performed as follows: 50oC 
for 2 min, 95
o
C for 10 min, followed by 40 cycles of 95
o
C for 15 sec and 60
o
C for 1 
min. The raw data of the real-time PCR were analysed with the S.D.S.2.1 Applied 
Biosystems software. The cycle threshold (Ct) was automatically set at the beginning of 
the exponential phase of each of the PCR amplifications, in each well on the 384-plate. 
The fractional PCR cycle number, at which the fluorescence emitted from a particular 
well rose above the threshold, was defined as the well‘s Ct value. Each sample was run 
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in triplicate and the mean Ct value used for analysis. The lower the Ct value, the higher 
the amount of cDNA –and therefore mRNA- in the sample tested.  
Relative expression analysis: The relative quantification of the genes‘ of interest 
cDNA was performed using UBC, ACTB and GAPDH cDNA as endogenous control 
(housekeeping genes), to normalise for differences in total amounts of DNA that may be 
present in the samples. The BestKeeper software (Pfaffl et al. 2004) was used to check 
the stability of the three housekeeping genes. The software estimated the correlation 
between the expression of a particular housekeeping gene and a BestKeeper index 
(geometric mean of all the housekeeping genes) in a repeated pair-wise correlation 
analysis. Coefficient of correlation of 0.885 (p<0.001) for UBC, 0.973 (p<0.001) for β-
actin and 0.936 (p<0.001) for GAPDH were observed, indicating that the amplification 
profiles of all three housekeeping genes were stable. Therefore all three were used for 
standardising the expression levels (mRNA levels) of the target genes. The difference in 
Ct values of the gene of interest with the housekeeping genes was the basis for the 
relative expression analysis. The amount of mRNA of the target genes in the unknown 
sample was normalised to the housekeeping genes and then it was expressed relatively to 
a control sample included in the run. The relative quantification analysis was performed 
using the REST software (Pfaffl et al. 2002) which is based on the method of analysis 
described by Pfaffl (Pfaffl 2001). 
4.3.2 TaqMan Genotyping 
The TaqMan technology is also used for allelic discrimination of a gene variant. 
The genotyping of all the gene variants investigated in the present thesis was performed 
using the TaqMan technology. The method involves the inclusion of two TaqMan 
probes specific for each variant‘s allele and labelled with different fluorescent reporter 
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molecules. The allele-specific probes each contain a short sequence complementary to 
the allele and the surrounding sequence being investigated, a fluorescent reporter dye 
(labelled either VIC or FAM for each allele) at the 5‘ end, and a non-fluorescent 
quencher at the 3‘ end. During the PCR cycle, the pair of forward and reverse primer 
pair anneal to the target sequence DNA, along with the respective allelic probe. The 
DNA polymerase (AmpliTaq Gold DNA Polymerase, Applied Biosystems) replicates 
the disassociated DNA strands up to the allele-specific probe. If the probe is annealed to 
the correct allele for which it is fully complementary, then the 5‘ to 3‘ exonuclease 
activity of polymerase acts and cleaves the fluorescent dye molecule attached to the 5‘ 
end of the probe. Therefore as the amplification of the target sequence increases during 
the PCR cycles, so does the emission of VIC or FAM fluorescence depending on the 
genotype of the DNA sample. The ABI prism 7900HT sequences detection system 
(Applied Biosystems, Cheshire, UK) is able to detect the fluorescence in each sample 
post-PCR and determine the levels of VIC and/or FAM and thus determine the genotype 
of each DNA sample. In this way the Taqman method allows the high-throughput 
genotyping in 384-well plates. 
Protocol: The 96-well working arrays of standardised DNA were used to create 
384-well plates of standardised DNA for genotyping with the TaqMan method. Using 
the Beckman Coutler Biomek 2000 Robot (Beckman-Coulter, High Wycombe, UK), 
DNA was transferred from four 96-well DNA plates to one Thermofast 384-well PCR 
plate (ABgene, Surrey, UK) and down-diluted to a 1.25 ng/μl DNA concentration with a 
final volume of 4μl. A data sheet detailing the samples layout in the plate and the unique 
plate identifier code was prepared and the plate was left to dry out overnight, and then 
stored at room temperature in a sterile paper bag.  
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Forward and reverse oligonucleotides and their respective labelled probe pairs 
were ordered using the ‗Assay by Design‘ online service provided from Applied 
Biosystems (www.appliedbiosystems.com). A master mix consisting of 2.5 μl TaqMan 
Genotyping Master Mix (Applied Biosystems, Cheshire, UK), 0.125 μl of 40x Assay by 
Design, 2.375 μl Sigma dH2O per sample was prepared and a 5 μl aliquot was added to 
each well using an 8-channel pipette. A clear plastic lid (ABgene, Surrey, UK) was 
applied to seal the plate and prevent excess evaporation and the plate was spun-down. 
Then the plate was place on the Thermohybaid (Basingstoke, UK) and the following 
PCR profile was run: 95
0
C for 10 min, 95
0
C for 15s and 60
0
C for 1min for 40 cycles.  
Allelic discrimination analysis: After the completion of the PCR run, the plate 
was ―read‖ on the ABI prism 7900HT sequences detection system, and the SDS v2.1 
(Applied Biosystems) software was used for the allelic discrimination. More 
specifically, the SDS v2.1 assigns genotypes automatically to each well of the plate by 
detecting the VIC or FAM fluorescence intensity. For example, in a homozygote DNA 
sample for the allele corresponding to the FAM probe, only this colour fluorescence will 
be detected and the software will call the sample homozygous for the respective allele. 
In a heterozygote DNA sample the machine will detect both probe‘s colours and thus 
will call it heterozygote. Figure 4 shows an example of the allelic discrimination plot 
produced by the software. The wells emitting only FAM fluorescence are shown on the 
top left corner of the plot and correspond to homozygotes for the mutant allele (CC) of 
that variant, those emitting both VIC and FAM are clutered in the middle of the plot and 
correspond to the heterozygotes (AC), and finally the wells emitting only VIC 
fluorescence are clustered at the bottom right corner of the plot adn correspond to the 
wild-type homozygotes (AA). The software creates also a text output file with the 
genotypes assigned automatically to each well of the plate. This text file was converted 
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from 384-well to four 96-well plates in Microsoft Excel, and merged with the study 
database.  
 
Figure II-4. Allelic discrimination plot. 
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5. TAGGING SNPS – HAPLOTYPE ANALYSIS 
 Having the technology for high throughput genotyping, genetic studies are now 
focusing in studying the whole variation across a gene of interest or across a greater 
genomic region, instead of single candidate variants. It is possible to identify the genetic 
variation without genotyping every SNP in a chromosomal region. This can be achieved 
with the genotyping of ―tagging‖ SNPs and the subsequent haplotype mapping. The 
tagging SNPs are SNPs accounting for the whole variation in a specific genomic region. 
The selection of such SNP-markers is based on the linkage-disequilibrium of genetic 
variants in a chromosome region, which is essentially the non-random association of 
alleles at two or more loci. Due to this phenomenon several variants of a chromosome 
area are ―linked‖, and therefore have a high probability to exist and be inherited 
together in individuals of a particular ethnic group. The pattern of linkage 
disequilibrium varies across the genome (Reich et al. 2001), nonetheless studies suggest 
that discrete regions of high linkage disequilibrium, i.e. linkage disequilibrium blocks, 
exist and are characterised by limited haplotype diversity (Cardon & Abecasis 2003; 
Alper et al. 2006). Thus, there is no need to genotype all the variants located in a 
linkage disequilibrium block; instead, genotyping one of these variants accounts for -or 
―tags‖- the variation of the whole block. This way, selecting and genotyping only a set 
of tagging SNPs -one SNP for each block of linkage disequilibrium- is sufficient for 
identifying the whole variation of that chromosome area and inferring its common 
haplotypes (Johnson et al. 2001). 
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5.1 GENOME VARIATION AND LINKAGE DISEQUILIBRIUM DATABASES 
The HapMap Project: The project is a multi-country effort among Japan, US, 
Canada, Nigeria, China and UK to provide researchers with information on genes 
affecting health and disease. The information generated by the project was released into 
the public domain. The aim of the project was to determine the common genetic 
variants that occur in human beings,to describe where these variants are located in the 
human DNA, and how they are distributed among people within populations and among 
different populations. The project has genotyped over six million SNPs in trios of two 
parents and an adult child from the Centre d‘Etude du Polymorphisme Humain (CEPH) 
samples, the Yoruban (West African) samples (YRI), the Japanese samples (JPT), and 
the Chinese samples (CHB). The data browser built by this project provides information 
on SNP genotype frequencies, the genome architecture and linkage disequilibrium 
blocks, as well as recombination rates. The HapMap data can be accessed at 
http://www.hapmap.org/. All data can be downloaded to and analysed with a specially 
designed software, called Haploview. 
Haploview: Haploview is designed to provide a comprehensive set of tools for 
haplotype analysis (Barrett et al. 2005). Haploview currently provides marker quality 
statistics, linkage disequilibrium haplotype block analysis, population haplotype 
frequencies, single marker association statistics, tagging SNPs selection and 
visualisation of the results in a user-friendly format. As shown in Figure 5, the linkage 
disequilibrium plot generated by Haploview shows the extent and pattern of the degree 
of linkage disequilibrium between the SNP-markers with the background colour 
denoting a scale of logarithm of odds (LOD) score for linkage disequilibrium.  
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Figure II-5. An example of Haploview linkage disequilibrium plot with a selected 
set of tagging SNPs.  
 
  
134 
 
Legend: This figure shows a linkage disequilibrium (LD) plot generated by 
Haploview. On the top of the picture there is a schematic presentation of the gene of 
interest, showing also the position of the selected SNPs in this genomic region. In the 
large triangle, below the rs numbers of the selected SNPs, each square’s color denotes 
the degree of linkage disequilibrium between the SNPs found at the end of the line of 
squares starting from this particular square. E.g The degree of linkage disequilibrium 
between the SNPs rs1748197 and rs10889347 is very high as denoted by the bright red 
color of the square, which means that these two SNPs are in almost complete linkage 
disequillibrium. In the case of the rs4915846 and rs4145257, the blue color of the 
square denotes a low degree of linkage diseqilibrium between them.  
 
Haploview is fully compatible with data downloaded from the HapMap project 
and the Perlegen Genotype Browser and can analyze thousands of SNPs in thousands of 
individuals. Haploview is available for download from: 
http://www.broad.mit.edu/mpg/haploview/. 
Genome Variation Server (GVS): The GVS database provides a quick access 
to all genotype data found in both the dbSNP and HapMap databases but also from 
several other genome projects. The current version of the GVS database contains 4.5 
million variations with corresponding genotype data. The GVS includes a set of analysis 
tools which provides the researcher with data on linkage disequilibrium blocks in the 
chromosome area of interest, and the set of tagging SNPs needed for identifying the 
variation in a region of interest, based on the combined genotype data of several 
genome projects. The GVS also provides visualisation tools like linkage disequilibrium 
plots. The GVS database is hosted by the SeattleSNPs Program for Genomic 
Applications (PGA) and is available online at http://gvs.gs.washington.edu/GVS/. 
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5.2 HAPLOTYPE DATA ANALYSIS 
THESIAS: The objective of the THESIAS program is to test the haplotype 
effects in association studies with unrelated individuals. This program is based on a 
maximum likelihood model (Tregouet & Tiret 2004) and is linked to a stochastic 
version of the EM algorithm (Tregouet et al. 2004). Thus, THESIAS allows the 
simultaneous estimation of haplotype frequencies and of their associated effects on the 
phenotype of interest. Quantitative, qualitative, categorical and survival analysis as well 
as covariate-adjusted haplotype effects and interactions analysis can be carried out. 
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6. HUMAN CELL CULTURE  
Cell culture was performed in a specially-built tissue culture suite, which is a 
protected environment with air filtration and two door locks before entry. Gloves and 
cell culture dedicated laboratory coats were worn at all times. Sterility was maintained 
by handling all open culture media, culture-ware and liquids within a class II 
microbiological safety cabinet with unidirectional laminar flow (Envair UK Ltd). 
Surfaces and equipment for use within the laminar flow hoods were cleaned with 70% 
ethanol solutions. All solutions and materials used in the laminar flow hoods had been 
previously sterilised by autoclaving. Cell contaminants, such as media used for growth, 
were removed to 1% Virkon-containing vessel and stored for at least twenty-four hours 
before disposal. Galaxy R CO2 incubators (Wolf Laboratories) humidified and set to 
5%CO2, 37
o
C were used for cell incubation. The cells cultured in these conditions were 
Normal Human Dermal Fibroblasts (NHDF) from juvenile foreskin for the purposes of 
the work described in the ―Fourth result chapter‖ (pages 317-354).  
 NHDF cells were cultured first in T-75 and then transferred in T-175 tissue culture 
flasks (Sarstedt, Nümbrecht, Germany). The NHDF cells were purchased from 
PromoCell GmbH (Heidelberg, Germany) and were cultured in fibroblast growth 
medium lacking ascorbic acid (FGM –AA) (PromoCell GmbH, Heidelberg, Germany) 
supplemented with 2% Foetal Calf Serum (FCS).  
 
6.1 GROWING OF HUMAN CELLS 
Each flask of cultured cells was viewed everyday under the inverted microscope 
and when it reached >80% confluence, the cells were split into new flasks. First the 
media was removed by aspiration, the monolayer of cells was washed with magnesium 
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and calcium free phosphate buffer saline (PBS) for at least 30 seconds to remove any 
serum containing medium, which contains trypsin inhibitors. The cells were detached 
using the Sigma-Aldrich detach kit for fibroblasts (Sigma-Aldrich, Steinheim, 
Germany). In more detail, the PBS was removed by aspiration and a minimal volume of 
trypsin, which digests the cell adhesion proteins, was added (i.e. 4 ml for a T-175 flask). 
The trypsin solution was incubated with the cell monolayer for 2 min at room 
temperature and then 2 ml of trypsin inhibitor (TNS), provided with the kit, were added. 
The cell suspension was transferred to a sterile 15 ml conical centrifuge tube and 
centrifuged at 1,000 rpm for 5 min. After discarding the supernatant, the cells were 
diluted in 10 ml of fibroblasts growth medium. 40% of the cells harvested (i.e. 4 ml of 
the re-suspended cells in medium) were seeded into a new T-175 flask where 22 ml of 
fibroblast growth medium were also added. The rest (60%) of the cells harvested were 
used for DNA and RNA and all other required measurements, according to the 
experiment carried out. The number of cells was calculated in a 1 in 10 dilution by the 
cell counter Sysmax CDA-500 (Norderstedt, Germany) in order to estimate the 
population doublings using the following formula:  
PD=[Ln(number of cells harvested)–Ln(number of cells seeded)] / Ln2 
 
6.2 FREEZING OF HUMAN CELLS 
Cells were frozen for long-term storage in a way that prevented senescence and 
reduced the risk of contamination. For this purpose, the cryoprotective agent 
dimethylsulfoxide (DMSO), was used in conjunction with medium and the cells were 
stored at -70°C or lower. DMSO properties include the decrease of the cells‘ freezing 
point and the gradual freezing process of the cells. These properties reduce the risk of 
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ice crystal formation and cell damage. From the cells harvested a small portion 
(~100,000 cells) was re-suspended in growth medium containing 10% DMSO (v/v), 
mixed thoroughly and stored in 2 ml cryovials. These cryovials were then placed in a 
special case that allows the gradual freezing of the cells in a -70°C freezer overnight. 
The next day the cryovials were moved into liquid nitrogen for long-term storage. 
 
6.3 MEASUREMENT OF CELL CULTURE APOPTOSIS AND NECROSIS 
Assay principle: The percentages of apoptosis and necrosis of the cultured cells 
were assessed using the Annexin-V-FLUOS-Staining Kit (Roche Diagnostics GmbH, 
Penzberg, Germany) and flow cytometry. This method is based on the translocation of 
phosphatidylserine at the cell surface during the early stages of apoptosis (Creutz 1992; 
Fadok et al. 1992). The phosphatidylserine moves from the inner part of the plasma 
membrane to the outer layer, and becomes exposed at the external surface of the cell, 
where it can be specifically recognised by macrophages (Fadok et al. 1992). The 
recognition and phagocytosis of apoptotic cells protects organisms from the exposure to 
cellular compounds leading to inflammation, which mostly accompanies necrosis. 
Annexin V is a Ca
2+
-dependent phospholipid-binding protein with a high affinity for 
phosphatidylserine. Thus it can be used as a probe for phosphatidylserine translocation 
to the outer part of the cell membrane and therefore for the detection of apoptotic cells 
(Vermes et al. 1995). On the other hand, necrotic cells also expose phosphatidylserine 
due to the loss of membrane integrity, and need to be differentiated form the apoptotic 
cells. This can be achieved with the use of proidium iodide, a DNA stain which is used 
for dye exclusion tests. Necrotic cells lose their integrity completely and leak, exposing 
their DNA molecules to external factors. Propidium iodide (PI) stains the exposed DNA 
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of necrotic cells allowing the discrimination of necrotic cells from the apoptotic ones. 
Annexin V-Fluorescein and PI staining emit at different wavelengths (i.e. Annexin V-
Fluorescein at 518 nm and PI at 617 nm), thus a specific and easy discrimination of the 
two cell states can be performed with the use of flow cytometry.  
Procedure: Before each experiment, an Annexin-V-FLUOS labeling solution a 
PI labeling solution and a combination of Annexin-V-FLUOS and PI labeling solution 
were prepared according to the manufacturer‘s protocol. In the next step ≥6x105 cells 
were washed with PBS and distributed in 3 different sterile tubes. These were 
centrifuged at 1,000 rpm for 5 min and the three cell pellets were re-suspended in 100 µl 
of the pre-prepared Annexin-V-FLUOS labeling solution, 100 µl of the pre-prepared 
Proidium iodide labeling solution and 100 µl of the pre-prepared Annexin-V-
FLUOS/Proidium iodide labeling solution. After incubation at room temperature for 15 
min, 0.5 ml Incubation Buffer per 10
6
 cells was added and the cells‘ fluorescence was 
analyzed on the flow cytometer.  
Flow cytometry: a FACSCalibur (Becton-Dickinson) flow cytometer using 
488nm excitation with a 530nm filter for fluorescein detection and a 585nm filter for PI 
detection. Electronic compensation of the instrument was performed before each 
measurement. A FACSCalibur flow cytometer (Becton-Dickinson, Franklin Lakes, 
USA) was used for the flow cytometry analysis. The excitation wavelength was set at 
488 nm, with a 530nm filter for green fluorescence (Annexin V-Fluorescein) detection 
and a 585nm filter for red fluorescence (PI) detection. The emitted fluorescence was 
collected on FL1 and FL2 channels, respectively. In each measurement, a total of 5000 
cells were analyzed. Data were acquired and analysed with the Cellquest Pro software 
(Becton Dickinson Biosciences, Oxford, UK).  
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To exclude cellular debris from the analysis and to establish the cells‘ size, 
forward (indicating the size of cells) and side (indicating the granularity of cells) 
scatters were used. Since for the detection of apoptotic and necrotic cells a dual labeling 
was used, there was a need for electronic compensation of FL2 (detecting the PI 
fluorescence), in order to exclude overlapping of the two emission spectra. Thus for 
each sample a measurement with Annexin-V-Fluorescein labeling alone and a 
Porpidium iodide labeling alone were acquired before analysing the cells‘ with dual 
labeling, as shown in figures 6A and 6B, respectively. The compensation level was 
increased to the point that the cells incubated with Annexin V-Fluorescein only did not 
emit fluorescence detected by the FL2 and vise versa.  
 
Figure II-6. A) Cells from the same flask with (on the left) and without (on the 
right) Annexin V-Fluorescein labeling. The cells shifted into the gate R1 are 
Annexin V-Fluorescein positive i.e. apoptotic cells. B) Cells from the same flask 
with (on the left) and without (on the right) PI labeling. The cells shifted into the 
gate R2 are PI positive i.e. necrotic cells. 
A) 
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B) 
 
FSC-H: forward scatter (indicating cell size); FL1-H: green fluorescence (Anexin V-
Fluorescein) collected in channel 1.FL2-H: red fluorescence (PI) collected in channel 2. 
 
The percentage of apoptotic and necrotic cells was determined with the dual 
labeled cell samples. Plots of FL1 against FL2 revealed the Annexin V-Fluorescein 
positive (apoptotic) and PI positive (necrotic) cells as shown in figure 7. The events 
accumulating at the bottom right quadrante represent the early apoptotic cells, events at 
the top right quadrante represent the late apoptotic cells and events at the top left 
quadrante represent the necrotic cells. The cells at the bottom left quadrante are not 
stained with either probe, thus these are the viable cells. The percentage of early or late 
apoptotic and necrotic cells were calculated from the events counted in each of the 
quadrantes of the FL1-Fl2 plot.  
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Figure II-7. Plots of FL1 against FL2 showing the distribution of the cells 
according to their fluorescent signals. The left plot shows cells which have not been 
stained, and the right plot shows cells with the double staining of Annexin V-
Fluorescein and PI. 
 
 
FL1-H: green fluorescence (Anexin V-Fluorescein) collected in channel 1.FL2-H: red 
fluorescence (PI) collected in channel 2. 
 
6.4 MEASUREMENT OF INTRACELLULAR REACTIVE OXYGEN SPECIES 
Assay principle: Intracellular ROS content was measured using the fluorescent 
probe 2‘,7‘-dichlorodihydrofluorescein (H2DCFDA) (Invitrogen, Molecular Probes, 
Inc., Eugene, USA). Chemically reduced and acetylated forms of 2′,7′-
dichlorofluorescein (DCF), such as the H2DCFDA, are widely used as cell-permeate 
indicators for a large range of ROS (e.g. hydrogen peroxide, peroxyl radical and 
peroxynitrite anion) (Oyama et al. 1994; Jakubowski & Bartosz 2000). These 
derivatives passively diffuse into cells, where the intracellular esterases cleave off the 
diacetate group and this yields a charged form of the dye (H2-DCF) which is better 
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retained by the cells compared to the parent compound. In the presence of cellular ROS, 
H2-DCF is rapidly oxidised to the highly fluorescent DCF (figure 8) (Keston & Brandt 
1965; Cathcart et al. 1983). The fluorescence produced can be detected by a flow 
cytometer using excitation sources and filters appropriate for fluorescein.  
 Procedure: The H2DCF-DA indicator was reconstituted in 100% ethanol 
shortly before performing the measurement to avoid any photo-oxidation. Before 
applying the ROS measurements to the cell experiments, the optimal working 
concentration and incubation time was determined empirically. The cells harvested after 
trypsinisation were washed with PBS, collected by centrifugation at 1000 rpm for 5 
min, re-suspended in PBS buffer containing the H2DCFDA at a 10μM concentration 
and incubated for 10 min at room temperature (15–25°C). Then the buffer was removed 
and cells were returned to pre-warmed PBS to recover for approximately 10-15 min. 
The fluorescence intensity was determined in a sample of cells with and one without 
prior exposure to the fluorescent dye. A sample of cells incubated with 5-(and-6)-
carboxy-2',7'-dichlorodihydrofluorescein diacetate (carboxy-DCFDA) (from Molecular 
Probes, Invitrogen, Oregon, USA) was used as positive control.  
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Figure II-8. Measurement of cellular ROS with H2DCFDA. 
H202, OH
-·
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 Flow cytometry: The samples were then analysed on the FACSCalibur (Becton-
Dickinson) flow cytometer using 488nm excitation with a 530nm filter for fluorescein 
detection (green fluorescence). The emitted fluorescence was collected on FL1 channel. 
In each measurement, a total of 5000 cells were analyzed. Data were acquired and 
analysed with the Cellquest Pro software (Becton Dickinson Biosciences, Oxford, UK).  
As previously described for the Annexin V-Fluorescein / PI staining, cellular 
debris was excluded from the analysis using the forward and side scatters. In addition 
the ROS cellular content was determined only in viable cells. The apoptotic and necrotic 
cells, as detected with Annexin-V/PI staining from the same cell samples, were 
excluded from the measurement of ROS content. More specifically, using cell samples 
stained with Annexin V-Fluorescein and PI, the viable cells could be detected in the 
respective FL2-to-FL1 plot, as shown in figure 9. Thus, for each sample of cells 
incubated with H2DCFDA the viable cells were gated in the FL2-to-FL1 plot and only 
these cells were used for the quantification of fluorescence intensity.  
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Figure II-9. FL2-to-FL1 plot of cells: a) without staining, b) with double staining of 
Annexin V-Fluorescein staining  and PI. In panel b, the cells at the bottom left 
quadrante are not stained with either probe, thus these are the viable cells, while 
the cells shifting to the lower right or the two upper quadrantes are apoptotic or 
necrotic. The viable cells in the lower left quadrante of panel b were gated (R3) 
and only these were then used for the ROS measurement.  
 
 
FL1-H: green fluorescence (Anexin V-Fluorescein) collected in channel 1.FL2-H: red 
fluorescence (PI) collected in channel 2. 
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 After having determined the viable cells only in the samples incubated with 
H2DCFDA, then their fluorescence intensity was measured at FL1. In the forward-to-
FL1 scatter plot (figure 10a), the number of cells shifted on the FL1 axis, which are the 
cells emitting fluorescence due to H2DCFDA oxidation, was calculated. Then a 
histogram of the fluorescence of these cells was drawn in order to calculate the 
fluorescence intensity emitted by those cells (figure 10b). The fluorescence intensity 
was calculated as the delta between the mean fluorescence intensity in the channel of 
the treated cells stained with dye and that of the same cells without dye staining. Thus, 
the ROS content is estimated by the FL1 fluorescence intensity [as calculated in figure 
10b by the distance between the peaks of the slopes of cells with and without 
fluorescence emission] multiplied by the number of viable cells emitting this 
fluorescence [as calculated in figure 10a by the number of cells shifting on the FL1 
axis]. 
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Figure II-10. a) Plot showing the cells shift on the FL1 axis due to the green fluorescence emission from the H2DCFDA dye 
oxidation by intracellular ROS . b) Histogram of the fluorescence emitted by cells with oxidised H2DCFDA dye. 
 
  
 
FSC-H: forward scatter (indicating cell size); FL1-H: green fluorescence (Anexin V-Fluorescein) collected in channel 1.  
 
a) b)
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III. FIRST RESULT CHAPTER: “TELOMERE LENGTH MEASUREMENT” 
 
1. SELECTION OF A METHOD FOR QUANTITATIVE ANALYSIS OF MEAN 
TELOMERE LENGTH  
Until recently, the traditional method of measuring telomere length in samples of 
total human genomic DNA was the mean terminal restriction fragment (TRF) length 
estimation with Southern blotting. However, this method has certain drawbacks; it requires 
large amounts of DNA (3-5 µg per sample) and time (3-5 days per assay) (personal 
communication with Scott Brouilette, March 2007). These drawbacks render very difficult, 
and sometimes impossible, the application of this method in large clinical/population 
studies, or large-scale experiments, or experiments with specific cell types where the 
number of samples is large and the available amount of DNA restricted. Another important 
disadvantage is that TRF analysis also measures the highly variable sub-telomeric region 
which may cause artificial inter-individual variability in the mean telomere length 
estimation. The sub-telomeric region includes restriction site polymorphisms or length 
polymorphisms and this may confound the identification of primary factors accounting for 
inter-individual variation in the mean length of the true telomeric repeat sequence.  
Recently, methods that allow multiple samples to be compared for their relative 
content of pure telomeric repeats have been developed (Lansdorp et al. 1996; Bryant et al. 
1997; Nakamura et al. 1999). However, the quantitative PCR-based method introduced by 
Cawthon in 2002 is the simplest, more rapid and the only one allowing a high throughput 
processing of large numbers of DNA samples without requiring viable cells as starting 
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material (Cawthon 2002) compared to the other recent methods. This high throughput PCR-
based method appears to be valid and fast and requires considerably less DNA compared to 
TRF analysis, thus it widens the possibilities for research in the field of telomere biology. 
PCR-based methods, previous to Cawthon‘s method, had been designed for the 
quantification of telomere lengths in specific chromosome arms, using primers for that 
specific chromosome region. These methods were complex and did not provide the 
researcher with a global estimate for telomere length. Amplifying the pure telomeric 
hexamer repeats has always been a problem due to the repetitive nature of telomeric 
sequences and the generation of primer dimer-derived products. Cawthon (Cawthon 2002) 
managed to overcome this problem and design a set of primers which specifically amplified 
telomeric hexamer repeats (TTAGGG) without generating primer-dimer products (Figure 
1). Each primer when it is hybridised to telomeric sequences is designed such that every 
sixth base is a mismatch (red arrows) and a full-match at the last five bases of the 3′-end 
(blue arrows) in order to allow DNA polymerase to extend. The last six bases on the 5′-end 
of each primer cannot base pair with the telomere sequence when the rest of the primer is 
optimally hybridised. The complements of these 5′-sequences are generated at the 3′-ends 
of all products that are completed in each cycle of the PCR, thereby blocking those 3′-ends 
from initiating DNA synthesis in the middle of telomere amplification products in 
subsequent cycles. When the primers are hybridised to the  other primer, even with the 
strongest possible hybridization as shown in the lower part of Figure 1, then four 
consecutive paired bases are followed by two mismatched bases (purple arrows) which 
prevents DNA polymerase from acting to extend the 3‘-end of each primer. This eliminates 
the possibilities for primer-dimer formation, which can confound the estimation of PCR 
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product generated in a cycle of real-time PCR. This is of particular importance in the case 
of using SYBR Green dye which binds any double-stranded DNA product.  
 
Figure III-1 A) Hybridisation of telomere primers to genomic telomere sequences. B) 
Possible hybridisation of telomere primers to each other.  
 
 
 
Using of the set of primers designed by Cawthon the PCR product expected is the 
sum of the lengths of the two primers, a 76bp product, at a copy number proportional to the 
number of primer-binding sited and thus proportional to the length of the telomere.  
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The quantification of telomere repeats with the quantitative PCR method is based on 
the principle that longer telomeres have more potential primer-annealing sites, thus there 
will be an increase in fluorescence, and a decrease in the number of cycles needed to reach 
a given threshold, compared to a shorter telomere. According to Cawthon (Cawthon 2002), 
the relative telomere length for each DNA sample is determined as the factor by which the 
sample differed from a reference DNA sample in its ratio of telomere repeat number to 
single gene copy (SCG) number. For each sample two quantitative PCRs, one for the 
telomere repeats and one for a SCG, are required. The SCG provides the sample-to-sample 
normalisation for the copies of the genome included in the sample. Thus the T/S ratio is 
equal to one when the tested DNA has the same amount of telomere repeats per genome as 
the reference DNA. The result is then normalised by using a reference DNA in every run, 
as a calibrator. 
Below, I describe the adaptation –including optimisation and validation- of 
Cawthon‘s method in our laboratory in order to use it for the purposes of the present thesis.  
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2. ADPTATION OF CAWTHON‟S PCR METHOD IN OUR LABORATORY 
 
2.1 APPLICATION ON THE ROTORGENE MACHINE 
The Rotor-Gene
®
 real-time PCR machine (Corbett Research Ltd, Cambridge, UK) 
was bought by our laboratory and used for telomere length estimation. This machine is the 
most suitable for applications such as the telomere length quantification for the following 
reasons. The Rotor-Gene employs a unique centrifugal rotary design instead of the micro-
plate which is employed in common PCR machines. PCR tubes are placed into a rotor 
which spins tubes past a single excitation light source and a single detector, in a chamber of 
moving air. This means that there is minimal optical and temperature variation between 
tubes, enabling high precision in real-time PCR quantification. In addition, as the rotor 
spins continuously at 400 rpm, high-speed data acquisition is possible (Corbett Rotor-Gene 
6000 manual, Version 1.7, http://www.qiagen.com/corbett/support/default.aspx). This 
unique design eliminates the well-to-well variability, increasing the accuracy of 
measurements. In the case of methods attempting to detect small differences as the telomere 
measurement, accuracy is a key advantage.  
In addition, this machine offers the possibility to perform high resolution melting 
post-PCR, which allows the identification of the PCR product. With the temperature 
increase during high resolution melting, the double-stranded DNA disassociates at a certain 
temperature characteristic for same length and base content PCR products. Therefore, when 
the PCR generates only a specific product, during high resolution melting analysis the 
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entire amount produced will melt/disassociate at a specific temperature. This way the PCR 
specificity can be ensured after each run.  
Finally, this machine offers the possibility to perform a comparative quantification 
analysis of the real-time PCR data, which is the most advantageous method of analysis, 
since it accounts for the differences in the efficiency of every reaction and does not require 
performing a standard curve in each run.  
 
2.2 OPTIMISATION OF TELOMERE AND SINGLE COPY GENE PCRS 
Telomere PCR optimisation: The primer concentrations and the reaction 
conditions for the telomere PCR were determined empirically, using the protocols 
described by Cawthon (Cawthon 2002) and Brouilette (Brouilette et al. 2007) as a guide.  
The primers for the SCG PCR were adapted from Cawthon‘s protocol: 
Telomere primer 1 (forward): 
GGTTTTTGAGGGTGAGGGTGAGGGTGAGGGTGAGGGT 
Telomere primer 2 (reverse): 
TCCCGACTATCCCTATCCCTATCCCTATCCCTATCCCTA 
A crucial step in optimising a PCR is the determination of the best primer 
concentrations. These concentrations were determined using 16 different combinations, as 
shown in table 1, in order to detect the lowest primer concentration giving the highest 
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fluorescence, the lowest nonspecific amplification and take-off of the amplification at the 
earliest cycle.  
 
Table III-1. The combinations of different primer concentrations that were used for 
the telomere PCR optimisation: 
 
Telomere primer 2 (reverse) concentration (nM) 
Telomere primer 1 
(forward) 
concentration (nM) 
 A (300) B (600) C (900) D (1200) 
I (135) 135/300 135/600 135/900 135/1200 
II (270) 270/300 270/600 270/900 270/1200 
III (540) 540/300 540/600 540/900 540/1200 
IV (810) 810/300 810/600 810/900 810/1200 
A duplicate of a sample and a no-template control was run for each of the above primer 
combinations. 
The minimum non-specific amplification, the maximum fluorescence and the 
earliest take-off (the first point to be 80% below the peak fluorescence level) were achieved 
with the combination of 135nM of telomere primer 1 and 900nM of telomere primer 2 as 
shown in figure 2. 
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Figure III-2. A) The amplification plot generated from the telomere PCR when testing 
the primer combinations of table 1. B) Amplification plot showing only the duplicate 
and the NTC of the 135nM / 900nM primer combination. 
A) 
 
B)  
 
 
A variety of ready-to-use quantitative PCR mixes was also tested in order to achieve 
the best PCR quality. Also, after testing different amounts of template (10ng, 20ng, 30ng 
and 40ng), it was shown that the 30ng of template are the optimal amount. Regarding the 
cycling profile, a higher annealing temperature of 60
o
C, which could theoretically increase 
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the specificity of the PCR, was tested, but it did not prove to ameliorate the efficiency nor 
the specificity of the PCR. Thus the 58
o
C suggested by Cawthon was adapted in the end.   
The telomere PCR assay was finally optimised at the following conditions. The 
final reaction volume was 25 μl consisting of 1 x SYBR Green, 1 x qPCR mix (2x 
SensiMix NoRef DNA kit, Quantace, London, UK), 30 ng of template, telomere primer 1 at 
135nM concentration and telomere primer 2 at 900nM. The cycling profile was: 95
o
C 
incubation for 10 min, followed by 22 cycles of 95
o
C for 15 sec and 58
o
C for 120 sec.  
As shown in figure 3, under these PCR conditions, the exponential phase of the 
telomere reaction begins very early (5-8 cycles), the maximum fluorescence reaches a 
satisfactory level and the no-template controls (NTCs) amplification level remains much 
lower than that of the DNA samples. 
 
Figure III-3. A representative amplification plot of the optimised telomere PCR. 
 
NTCs 
Threshold 
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High resolution melt (HRM) analysis: High resolution melt (HRM) analysis is a 
"closed-tube" technique for characterization of PCR products. The HRM technique detects 
different PCR product based on different melting temperatures (Tms). The PCR products 
are differentiated according to their dissociation behaviour as they transit from double 
stranded DNA (dsDNA) to single stranded DNA (ssDNA) with increasing temperature 
(White & Potts 2006).  
Prior to performing a HRM analysis, a target sequence must first be amplified by 
PCR in the presence of a dsDNA intercalating fluorescent dye (e.g. SYBR Green or LC 
Green). The dye does not interact with ssDNA but actively intercalates with dsDNA and 
fluoresces brightly in this state (White & Potts 2006). Initially, the fluorescence is high in a 
melt curve analysis because the sample starts as dsDNA, but the fluorescence decreases as 
the temperature is raised and DNA dissociates (melts) into single strands. The midpoint of 
the melt phase, at which the rate of decrease in fluorescence is greatest, defines the 
temperature of melting (Tm) of the particular DNA fragment. PCR products can be 
discriminated according to their sequence, length, GC content and strand complimentarity 
(White & Potts 2006). HRM is also used to detect single base sequence variations such as 
SNPs or to discover unknown genetic mutations (Gundry et al. 2003). 
In order to ensure the specificity of the telomere PCR, the melting profile of the 
PCR product is always examined, after the PCR reaction is completed, on the Rotor-gene 
machine by high resolution melting (72-95°C). As shown in figure 4, the melting curve of 
the telomere PCR product has only a single peak at ~80.5
0
 C indicating that there is a 
specific in length (76bp) and base consistency PCR product. The NTCs appear to have 
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generated a negligible amount of PCR product, indicating that there no contamination 
and/or primer-dimmer formation occurred during PCR. 
 
Figure III-4. Melting curve of telomere PCR product. 
  
 
SCG PCR optimisation: As single copy gene, Cawthon suggests the use of the 
acidic ribosomal phosphoprotein PO (36B4 or RLP0), which encodes acidic ribosomal 
phosphoprotein PO and is located on chromosome 12. I tested two single copy genes, the 
36B4 and the glyceraldehyde-3-phosphate dehydrogenase gene (GAPDH), which is widely 
used as a housekeeping gene.  
The primers and PCR conditions used for the 36B4 were adapted from Cawthon‘s 
protocol (Cawthon 2002) and for GAPDH from Martin-Ruiz‘s version of Cawthon‘s 
protocol (Martin-Ruiz et al. 2004):  
NTCs 
Peak 
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36B4 primer u (upstream): 
CAGCAAGTGGGAAGGTGTAATCC 
36B4 primer d (downstream): 
CCCATTCTATCATCAACGGGTACAA 
GAPDH primer f (forward): 
AAATCCCATCACCATCTTCC 
GAPDH primer r (reverse): 
GCTGAGTACGTCGTGGAGTC 
 Both SCG PCRs displayed optimal performance at the conditions described in 
Cawthon‘s and Martin-Ruiz‘s protocols. The exponential phase of both gene‘s PCR 
reaction began early enough, the maximum fluorescence reached a satisfactory level and 
the NTCs amplification level remained much lower than that of the DNA samples (figure 
5). In addition, both SCG‘s PCR produced a single product of the expected length as shown 
by the melting curves in figure 6. The melting temperature of the 74bp product of the 36B4 
PCR was ~81
o
C and that of the 210bp product of the GAPDH PCR was ~84.5
o
C, as 
expected (figure 6). 
 In order to select the best SCG for the telomere length assay, the inter-assay 
variability in estimating the relative amount of 36B4 or GAPDH copies was tested. The 
relative amounts of 36B4 and GAPDH copies in respective PCR runs were measured in 
duplicate for ten randomly selected DNA samples on two consecutive days. There was a 
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significant linearity between the estimates of 36B4 and GAPDH relative concentration 
obtained on the two different days. However, this linearity was higher for the 36B4 
estimates (R
2
=0.79, p=0.001 for 36B4 vs. R
2
=0.53, p=0.001 for GAPDH, figure 7).  
 
Figure III-5. A) The amplification plot of 36B4 PCR. B) The amplification plot of 
GAPDH PCR. 
A) 
 
B) 
 
  
36B4
GAPDH
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Figure III-6. A) Melting curve of 36B4 PCR product. B) Melting curve of GAPDH 
PCR product. 
A) 
 
B) 
 
 
36B4
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Figure III-7. Linear regression graph between the telomere length estimates of the same 10 samples measured on two 
consecutive days. 
 
 
 
 
36B4 GAPDH
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Since the use of 36B4 offers a greater reproducibility to the method, it was chosen 
as the best SCG. The primer concentrations for the 36B4 PCR were optimised at 300/500 
nM and the cycling profile as: 95
o
C incubation for 10 min, followed by 30 cycles of 95
o
C 
for 15 sec and 58
o
C for 60 sec. The final reaction volume was optimised at 25 μl consisting 
of 1 x SYBR Green, 1 x qPCR mix (2x SensiMix NoRef DNA kit, Quantace, London, UK), 
30 ng of template and the respective primer concentrations.  
 
2.3 METHOD OF ANALYSIS OF QUANTITATIVE PCR DATA  
Next, the best method of analysis of the raw data from each of the telomere and 
SCG PCRs had to be chosen. The methods of relative quantification include the method of 
the standard curves, the ΔΔCt method, the Pfaffl method and the comparative quantification 
(CQ).  
The standard curve method: In this method, a standard curve for each of the 
telomere and the SCG PCR is run with the unknown samples and the relative concentration 
in each run is calculated based on the standard curve (Cawthon 2002). This method is based 
on the consistency of the dilution series generating the standard curve. The major 
disadvantage of this method is the need of a standard curve in each run, which reduces the 
number of samples analysed per run.  
The ΔΔCt method: This method is very commonly used in quantitative PCRs. 
Assuming that the efficiency of each PCR reaction is 100%, and thus the PCR product is 
doubled in each cycle, the formula 2
-ΔΔCt
 gives, relative to a calibrator, the concentration of 
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PCR product in each reaction (Livak & Schmittgen 2001). The ΔΔCt is determined as 
following: 
ΔCt= Ct (calibrator) - Ct (unknown sample) and ΔΔCt= ΔCt (telomere) - ΔCt (SCG) (Livak 
& Schmittgen 2001). 
The disadvantage of this method is the assumption that the amplification efficiency is 100% 
in all PCR runs, which is not true in most cases.   
The Pfaffl method: Pfaffl (Pfaffl 2001) introduced in 2001 a new method of 
analysis for relative quantification which takes into account the efficiencies of the two PCR 
runs (for example the telomere and the SCG PCR run). In order to estimate the efficiency 
of each PCR, a standard curve is run at least once. The relative quantification of telomere 
repeats is calculated as following: 
Telomere repeats per SCG copy =  
Efficiency of telomere PCR 
ΔCt (telomere)
 / Efficiency of SCG PCR 
ΔCt (SCG)
 (Pfaffl 2001) 
The disadvantage of this method is that, although it does not assume that the two different 
PCRs (telomere and SCG) are 100% efficient, it does assume that that the amplification 
efficiency of each sample‘s reaction within a PCR run is always the same. 
The comparative quantification analysis (CQ): The Rotor-Gene 6000 software 
from Corbett Research Ltd, Cambridge, UK offers an new alternative method of analysis 
for relative quantification. The method first determines the ―take-off‖ value for each 
sample. To calculate the take-off point, the second derivative of the raw data is taken in 
order to identify the peak reaction velocity. This is the peak of the exponential reaction and 
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occurs shortly after the take-off of the reaction. The take-off point cannot be determined 
exactly, but is estimated by finding the first point to be 80% below the peak level (figure 8). 
Based on the take-off point and the reaction efficiency, the method calculates the relative 
concentration of each sample compared to the calibrator (reference DNA sample). The 
following steps are taken to calculate the relative concentrations: 
1)  The take-off points of each sample are calculated by examining the second derivative 
peaks. 
2)  The average increase in raw data, four points following the take-off, is calculated and 
used to estimate the amplification efficiency. 
3)   Outlier amplifications are removed to account for noise in background fluorescence. 
4)   The non-outlier amplifications are averaged to become a run ―average amplification‖. 
5)   The average take-off point is calculated for all replicates of the calibrator (reference 
DNA sample). 
6)   The relative concentration for a sample is calculated as:  
 
Amplification 
(Calibrator Take-Off—Sample Take-Off)
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Figure III-8. Plot of the second derivative of the amplification. 
 
 
The quantity of telomere repeats is calculated as the relative concentration in the 
telomere PCR of each experimental sample. Similarly the relative quantity of the SCG is 
calculated as the relative concentration in the SCG PCR of each experimental sample. The 
samples are run in duplicates and the average relative concentration of each duplicate is 
considered. The ratio of these relative concentrations (T/S ratio) is the relative telomere 
length and should be proportional to the average telomere length.  
T/S ratio = relative concentration of Telomere repeats / relative concentration of Single 
copy gene copies. 
Peak level 
Take-off level 
80% 
Take-off cycle 
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The advantage of this method is that the amplification efficiency of every sample 
within a run is estimated, and based on that, the relative concentration of each sample is 
calculated compared to a reference DNA (calibrator) included in every run. Importantly, the 
amplification efficiency of the reference DNA sample is also estimated and taken into 
account when each unknown sample‘s relative concentration is normalised to that of the 
reference DNA. Thus, no assumption of equal or constant efficiencies in each PCR reaction 
is made, and no standard curve is required in each run. This way the accuracy of the 
method and the number of samples included in each run are maximised. Nevertheless, this 
CQ method of analysis is only suitable for ratio comparisons and in order to detect a trend 
without allowing an absolute quantification as the standard curve method would allow. The 
restriction of the method is that it is based on the use of the same sample in each run as 
calibrator otherwise the results would nto be comparable between runs.  
However, since the CQ method can serve the pruposes of the present studies (i.e. 
the comparison of T/S ratios) and given its advantages regarding the measuremnts‘accuracy 
and cost-efficiency, the CQ was chosen as the method of analysis for all telomere assays in 
the present thesis.  
Finally, in each run of 32 samples, a reference sample and a no-template control, all 
in duplicate, were included. If the duplicate T/S ratio values of a sample differed more than 
6%, the sample‘s measurement was repeated in duplicate in another run in order to obtain a 
more accurate and reliable estimate of telomere length. The specificity of all PCRs was 
determined by melting curve analysis. All analyses were processed blinded to case-control 
status of samples.  
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3. VALIDATION OF THE ADAPTED PCR METHOD IN OUR LABORATORY 
 
3.1 QUALITY CONTROL – STANDARD CURVES 
In order to ensure the validity and accuracy in determining the relative 
concentration of the PCR product in quantitative PCRs, such as the one for the telomere 
and SCG estimation, a standard curve needs to be performed. The criterion is the linearity 
between the template concentration series and the relative copies of PCR product measured 
in a standard curve analysis. 
Thus, a dilution series (1.25 ng/μl - 160 ng/μl, two-fold dilution, eight points) was 
run after optimization for both the telomere and the 36B4 SCG PCRs. For both assays, 
linearity (R
2
>0.98) over this range of input DNA was observed (figure 9A and 9B, 
respectively). Furthermore, both PCRs displayed greater than 91% efficiency, as calculated 
from the slope of the respective standard curves.  
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Figure III-9. Standard curves of A) Telomere PCR and B) SCG (36B4) PCR. 
A) 
 
B) 
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3.2 REPRODUCIBILITY OF THE METHOD 
In order to test the reproducibility of the method, ten randomly chosen DNA 
samples were run in duplicate on two consecutive days. There was a significant linearity 
between the mean telomere length measurements obtained on the two different days in 
linear regression analysis (R
2
=0.79, p=0.001, figure 10). Moreover, the reproducibility was 
also assessed with Spearman‘s non-parametric test of pair-wise correlation that looks at the 
ranking of each sample. The correlation of the lengths‘ ranking as measured on the two 
different days was significant (Spearman coefficient=0.82, p=0.004). The coefficient of 
variation of the telomere length estimates in the repeated measurements of the same sample 
was 5.6%, which is similar to the 5.8% inter-assay coefficient of variation observed by 
Cawthon (Cawthon 2002).  
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Figure III-10. Linear regression graph between the telomere length estimates of the 
same 10 samples measured on two consecutive days (R
2
=0.79, p=0.001). 
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3.3 COMPARISON WITH THE TRADITIONAL METHOD FOR TELOMERE 
LENGTH MEASUREMENT 
To validate the telomere length assay, 32 DNA samples of subjects aged 24 to 54 
years from the Cardiovascular Sciences Department, Leicester University DNA bank were 
measured in duplicate with the quantitative PCR method in our laboratory. These T/S ratios 
were then compared to measurements obtained by the conventional TRF analysis in 
Leicester University, as previously described (Samani et al. 2001). The DNA samples from 
Leicester University DNA bank and their TRF estimates were kindly provided by Professor 
Nilesh Samani and Dr Scott Brouilette.  
A significant positive correlation between the telomere length measurements 
obtained with the two different methods was found by linear regression analysis (R
2
=0.61, 
p<0.0001, figure 11). A certain deviation from the telomere length as estimated by TRF 
analysis was expected. The PCR-based method measures the length of pure telomeric 
repeat sequences. Subtelomeric regions mainly constitute of degenerated telomeric 
sequences which also contain stretches of pure telomeric sequences (Blackburn 2001; De 
Boeck et al. 2009). Thus the PCR-based method measures the pure telomere length, 
propably along with a small portion of subtelomeric sequences. In contrast TRF analysis 
utilises probes that hybridise to a range of subtelomeric sequences (Baird 2005), thus the 
resulting measurement includes the highly variable length of the subtelomeric region.  
Nevertheless, the level of linearity between the measures obtained by the PCR 
method as adapted in our laboratory (T/S ratios), and the measures obtained by TRF was 
similar to that observed by Cawthon (R
2
=0.68) (Cawthon 2002) and Brouilette (R
2
=0.65) 
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(Brouilette et al. 2007). Thus, the PCR method as adapted in our laboratory can be 
considered valid. 
 
Figure III-11. Correlation of the PCR-based method with the conventional TRF 
analysis. 
 
 
 
trf: mean telomere length in kilobases as measured by TRF analysis. 
ratio: mean telomere length expressed as T/S ratio as determined by the PCR-based 
method. 
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4. ADAPTION OF ABSOLUTE QUANTIFICATION OF TELOMERE LENGTH 
USING THE PCR METHOD 
The PCR method for telomere length determination estimates the relative amount of 
telomeric repeats per genome relatively to that of a reference DNA sample and does not 
give an absolute value (e.g. bp). The only way to translate the relative telomere estimation 
by the PCR method, i.e. the T/S ratios, to bp was through their correlation to the respective 
TRF values. More specifically, the correlation observed between the T/S ratios of the PCR 
method and the TRF values in the set of 32 samples, was described by a regression function 
[TRF(bp) = 2.54 + 4.58xT/Sratio] (see ―First result chapter‖, paragraph 3.3, page 173). 
This function was used later in order to translate the T/S ratios measured in the present 
thesis study samples to bp values. However, this translation could only give a rough 
estimate of the corresponding bp values. The R
2 
of the regression was 0.61, which meant 
that only a proportion of variability in the T/S ratio data set was accounted for by this 
regression model. In addition, with this relative determination of telomere length by the 
PCR method, the results in our study samples were not directly comparable to those of 
other laboratories. Thus, it was considered important to try improving the method from a 
relative to an absolute quantification, since an estimate of absolute telomere length in bp 
would be far more useful. This became feasible with a modification of the PCR method 
introduced by O‘Callaghan et al. (O'Callaghan et al. 2008). I tried to adapt this method in 
our laboratory.  
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4.1 PRINCIPALS OF ABSOLUTE QUANTIFICATION USING THE PCR 
METHOD 
 The original version of the PCR method estimated the telomeric repeats per genome 
in the tested DNA sample compared to a reference DNA. More specifically, in a telomere 
PCR, the amount of telomeric repeats of a sample relative to a reference DNA are 
calculated, and then in a SCG PCR, the copies of the SCG relative to the reference DNA 
are also calculated. The ratio of these two relative concentrations gives the estimate of 
telomere length. 
T/S ratio = relative concentration of Telomere repeats / relative concentration of Single 
copy gene copies. 
 In order to modify this method to an absolute quantification, O‘Callaghan 
(O'Callaghan et al. 2008) suggested performing the calculation of the telomere repeats or 
the SCG copies relative to standard synthesised oligonucleotides. By replacing the 
reference DNA in the telomere PCR with an oligonucleotide of known telomere repeats, 
and also in the SCG PCR with a synthesised oligonucleotide mimicking the genomic SCG 
(36B4) sequence, an absolute quantification of the telomere length can be carried out. Thus, 
a synthesised 84 bp oligonucleotide containing 14 TTAGGG repeats was used as calibrator 
in the telomere PCR, and a synthesised 75 bp oligonucleotide containing the SCG genomic 
sequence was used as a calibrator in the SCG PCR.  
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Synthesised calibrator for the telomere PCR: 
5’TTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGTTAGGGT
TAGGGTTAGGGTTAGGGTTAGGG3’. 
Synthesised calibrator for the SCG (36B4) PCR: 
5’CCCATTCTATCATCAACGGGTACAAACGAGTCCTGGCCTTGTCTGTGGAGACGGAT
TACACCTTCCCACTTGCTG3’. 
 
4.2 OPITMISATION OF THE USE OF SYNTHESISED 
OLIGONUCLEOTIDENUCLEOTIDES AS CALIBRATORS 
First, for the use of the two synthesised oligonucleotides as calibrators, I had to 
determine the concentrations for which these two oligonucleotides would create 
amplification profiles similar to those of DNA samples, since for the same concentration 
these synthesised oligonucleotides would contain thousands more copies of the PCR target 
sequence compared to the DNA samples. For this reason a series of standard curves with a 
large range of dilution series of these synthesised oligonucleotides were performed, in order 
to define the optimum concentration to be used.  
The best-fit concentrations for these oligonucleotides were detected in the following 
standard curves: 
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Figure III-12. Telomere PCR standard curve with a dilution series (2.4 - 0.01875 
pg/μl, two-fold dilution, eight points) of the synthesised 84 bp oligonucleotide. 
 
Red points: represent DNA samples at the concentration used in the telomere assay. 
Blue points: represent the dilution series of the synthesised oligonucleotide 
 
 Using the standard curve of figure 12, the concentration of 0.2pg/μl was chosen for 
the telomere synthesised calibrator. For this concentration the synthesised oligonucleotide 
contained a similar number of telomere repeats to that contained in an average DNA 
sample.  
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Figure III-13. SCG PCR standard curve with a dilution series (0.0032 - 0.000025 
pg/ul, two-fold dilution, eight points) of the synthesised 75 bp oligonucleotide. 
 
Red points: represent DNA samples at the concentration used in the telomere assay. 
Blue points: represent the dilution series of the synthesised oligonucleotide. 
 
 Using the standard curve of figure 13, the concentration of 0.0004pg/μl was chosen 
for the SCG synthesised calibrator. For this concentration the synthesised oligonucleotide 
contained a similar number of SCG copies to that contained in a DNA sample. 
 Next, the specificity of the PCR product generated when using as template the 
synthesised telomere calibrator and the SCG synthesised calibrator had to be determined. 
Thus, high resolution melting analysis was performed after the telomere and the SCG PCR 
respectively, using the synthesised calibrators in the optimised concentrations and various 
DNA samples.   
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Figure III-14. Melting curves including the synthesised calibrators and DNA samples 
of: A) the telomere PCR products and B) the SCG PCR products. 
 
 
  
A) Telomere PCR melting curve:
B) SCG PCR melting curve:
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oligo- calibrator
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 As shown in figure 14A the melting profile of the PCR product generated when 
using as template the synthesised telomere calibrator is similar to that of DNA samples; 
although the melting curve is more sharp, probably due to the greater variation in telomeric 
repeat sequences of the DNA samples compared to a synthesised oligonucleotide.  
Similarly, when using the SCG synthesised oligonucleotide as template the PCR product is 
the same as that generated by DNA samples, as indicated by the melting curves of figure 
14B.  
 
4.3 CALCULATIONS FOR THE ABSOLUTE TELOMERE LENGTH 
QUANTIFICATION 
 In each of the telomere and the SCG quantitative PCRs I had to calculate the 
absolute amount of telomere repeats and SCG copies according to the synthesised 
calibrators used: 
Telomere PCR: The telomere repeats in the unknown sample is calculated 
relatively to the synthesised oligonucleotide according to the following formula: 
Telomere repeats in the unknown sample = 
Amplification 
(Calibrator Take-Off—Sample Take-Off)
 x Telomere repeats contained in the synthesised 
oligonucleotide used as calibrator. 
Each reaction contained 5pg (0.2 pg/μl reaction concentration x 25μl reaction 
volume) of this synthesised 84 bp oligonucleotide, thus the number of template molecules 
is: [(5x10
-12/MW)/ x Avogadro‘s number] molecules. 
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Thus, the amount of telomeric hexamer repeats in bp contained in the 5 pg of this 
oligonucleotide in each reaction is: 
[(5x10
-12/MW)/ x Avogadro‘s number] x 84 bp = 9.48x106 kb. 
Therefore the value of the relative concentration of the unknown sample in the 
telomere PCR multiplied by the 9.48x10
6 
kb of telomeric repeats contained in the 
calibrator, gives the absolute measure of telomeric repeats in the unknown sample. 
SCG PCR: The diploid genome copy number in the unknown sample is calculated 
relatively to the synthesised oligonucleotide according to the following formula: 
Diploid genome copy number in the unknown sample = 
Amplification 
(Calibrator Take-Off—Sample Take-Off)
 x SCG copy number contained in the 
synthesised oligonucleotide used as calibrator. 
Each reaction contained 0.01pg (0.0004pg/μl reaction concentration x 25μl reaction 
volume) of this synthesised 75 bp oligonucleotide, thus the number of template molecules 
is: [(0.01 x10
-12/MW) x Avogadro‘s number] molecules or SCG copies. 
Therefore the value of the relative concentration of the unknown sample in the SCG 
PCR multiplied by the 2.64x10
5 
of SCG copies gives the absolute measure of aploid 
genome copies in the sample. Since this method will be used for human DNA samples, this 
final number has to be divided by two in order to give the absolute estimate of diploid 
genome copies.  
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In the end, the T/S ratio calculated by the CQ analysis when using the synthesised 
oligonucleotides as calibrators will have to be multiplied by [9.48x10
6 
kb / (2.64x10
5 
/ 2)] 
in order to give the absolute estimate of telomere length per diploid genome in bp.  
Using these synthesised calibrators and performing after the CQ analysis the above 
calculations, I measured in a set of 25 DNA samples the absolute estimate of telomere 
length per diploid genome. The results ranged from 95-165 kb, which was in accordance 
with the values reported by O'Callaghan (O'Callaghan et al. 2008). . This estimate refers to 
the sum of the 92 telomeres of 46 chromatids contained in diploid cells of G0 phase, since 
lymphocyte DNA was used. In addition, O'Callaghan reported that the values obtained by 
the absolute quantification were consistently ~7 kb shorter compared to the TRF values for 
the same DNA samples. This discrepancy is expected when considering that the TRF 
overestimates mean telomere length since it also measures the sub-telomeric region (Baird 
2005). Taking this into account, the range of telomere lengths observed here (90-165 kb) is 
close to the mean telomere lengths estimated by TRF analysis that have been reported in 
the literature (Demissie et al. 2006; Tentolouris et al. 2007; Hunt et al. 2008).  
Finally, in order to ensure the validity of this modified method I tested its 
reproducibility. Thirteen randomly selected DNA samples were measured in duplicate on 
two consecutive days and subsequent linear regression analysis showed that the repeated 
measurements correlated significantly (R
2
=0.64, p=0.001).  
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4.4 PROBLEMS IN THE APPLICATION OF THE ABSOLUTE 
QUANTIFICATION 
 After the validation of this modified PCR method for absolute quantification, it was 
used for the telomere length determination in familial hypercholesterolaemia (FH) study 
samples, in parallel to the original relative quantification. This was achieved by adding in 
each PCR run the reference DNA and the respective synthesised calibrator. However, both 
the synthesised calibrators, and especially the SCG one, displayed a much less than optimal 
amplification and melting profiles, while all the DNA samples displayed normal profiles. 
This indicated that the problem in these reactions was with the quality of the template. The 
reactions having as template the synthesised oligonucleotides had generated lower 
maximum fluorescence and their PCR products had low melting curves (Figure 15). Taking 
these into account, it was concluded that the synthesised oligonucleotides had been 
degraded, which was probably due to their very low concentration.  
 I also examined the possibility of self-annealing (possibly forming homo-duplexes 
or hairpins) of these synthesised oligonucelotides, since they contained self-complimentary 
sequences. To prevent the self-annealing from happening, the synthesised oligonucleotides 
before the PCR reaction were incubated for two minutes at 70
0 
C with 5% dimethyl 
sulfoxide [(CH3)2SO] (DMSO), a polar aprotic solvent which inhibits secondary structures 
(Quijada et al. 1997). However, this did not resolve the problem, and the less than optimal 
cycling and melting profiles appeared again with the synthesised oligonucleotides. 
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Figure III-15. Melting curves of FH DNA samples and the synthesised calibrators of: 
A) Telomere PCR products and B) SCG PCR products. 
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 Considering that the most possible explanation was that the oligonucleotides were 
degraded, these were stored in aliquots of high concentration up until their use; once diluted 
into the necessary concentration for the PCR reaction, the leftover was discarded. 
Nevertheless, this handling did not prove sufficient to prevent the degradation problem. 
With the synthesised oligonucleotides being often degraded and thus generating less PCR 
product for the same template concentration, any calculation of the telomere length based 
on these calibrators would be biased and false. For this reason, I considered this 
modification of the original PCR method unreliable and thus it was not used for acquiring 
estimates of telomere length in the present thesis.  
 An alternative to overcome this problem and yet acquire an estimation of telomere 
length in kb using the qPCR method is to use a DNA sample of known telomere length in 
kb as the standard according to which all samples are normalised and calculated. However, 
since the measurement of the standard‘s DNA telomere length in kb will be provided by 
TRF, the estimate will include the subtelomeric length. This means that while qPCR only 
measured the pure telomeric sequences the translation into kb using the length of the 
standard DNA will produce an overestimation of the true telomeric length. Nonetheless, the 
unknown samples‘ telomere lengths will be comparable since they are normalised to the 
same reference DNA. This alternative of using a DNA sample of known telomere length in 
kb has been recently used by other researchers (Martin-Ruiz et al. 2004; Collerton et al. 
2007; Terry et al. 2008) and can provide a good estimate of the telomere length measured 
by qPCR in kb.  
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5. ADAPTION OF MULTIPLEX MONOCHROME QUANTITATIVE PCR 
(MMQPCR) FOR TELOMERE LENGTH MEASUREMENT 
 In 2009, while the present thesis was in progress, Cawthon published a further 
improved multiplex version of the PCR method (Cawthon 2009), suggesting that this assay 
was more accurate, and also offered the possibility of higher throughput at lower cost. In 
the original quantitative PCR method, for each sample the telomere repeats were calculated 
in a telomere PCR reaction and the SCG copies in a another PCR reaction for the SCG. 
This way the relative to a reference DNA T/S ratios were calculated.  Multiplexing the two 
different PCR reactions required for the measurement of telomere length would eliminate 
the inter-assay variation due to DNA pipetting, since both PCRs would occur in the same 
reaction for each DNA sample. Multiplexing the assay, and thus decreasing the reactions 
needed in half, also increases the throughput and lowers the cost, since this uses less 
reagents, DNA template and less set-up time is needed. A further advantage of Cawthon‘s 
multiplex assay is that it does not require the use of two fluorescent dyes for the detection 
of the two different PCR products, but it is based on the use of a single fluorescent DNA-
intercalating dye. This adds to the simplicity of the method and the lowering of the cost. 
Therefore, I tried to adopt this improved version of the PCR method in our laboratory.  
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5.1 PRINCIPLES OF THE MMQPCR METHOD  
The crucial problem that Cawthon had to overcome, in order to design a multiplex 
reaction for measuring the relative copy numbers of two different DNA target sequences 
with the use of a single DNA-intercalating dye, was the accumulation of the fluorescent 
signal from both the PCR products. The design of such a multiplex reaction was based on 
the theory that the fluorescent signal generated from the first, more abundant target 
sequence (telomere repeats) would be collected at early cycles, when the signal from the 
second, less abundant target sequence (SCG) would still be at baseline. The fluorescent 
signal generated from the second target sequence (SCG) are collected at a much higher 
temperature than the melting temperature of the first PCR (telomere) product, which would 
become single-stranded and consequently its fluorescent signal would reach the baseline 
(Cawthon 2009). For this theory to be applied successfully, it is required that the multiplex 
reaction involves two target sequences of rather different abundance. Since this is the case 
for the telomere repeats and the SCG in a DNA sample, multiplexing the two respective 
PCRs is feasible.  
The collection of each of the PCR products at different temperature levels, with the 
parallel melting of the first PCR product, is achieved through the design of the two sets of 
primers. Firstly, both sets of primers are designed to generate short length PCR products. 
Secondly, GC-clamps are added on both ends of the PCR product generated from the less 
abundant target sequence i.e. the SCG, in order that its melting temperature is raised much 
higher than that of the telomere PCR product (Cawthon 2009). The set of primers for two 
different SCGs, albumin (ALB) and hemoglobin beta (HBB): 
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ALBu (upstream): 
CGGCGGCGGGCGGCGCGGGCTGGGCGGaaatgctgcacagaatccttg 
ALBd (downstream): 
GCCCGGCCCGCCGCGCCCGTCCCGCCGgaaaagcatggtcgcctgtt 
Expected PCR product: 98bp. 
HBBu (upstream): 
CGGCGGCGGGCGGCGCGGGCTGGGCGGcttcatccacgttcaccttg 
HBBd (downstream): 
GCCCGGCCCGCCGCGCCCGTCCCGCCGgaggagaagtctgccgtt 
Expected PCR product: 106bp. 
Specifically for the telomere target sequence, Cawthon designed a new set of 
primers (TELg and TELc) which would ensure the generation of a short, fixed-length 
product. New set of telomere primers: 
TELg (forward): 
ACACTAAGGTTTGGGTTTGGGTTTGGGTTTGGGTTAGTGT 
TELc (reverse): 
TGTTAGGTATCCCTATCCCTATCCCTATCCCTATCCCTAACA 
Expected PCR product: 79bp. 
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The TELg is able to anneal on genomic telomere sequences and initiate DNA 
synthesis, whereas the TELc primer anneals to genomic telomeres but cannot initiate DNA 
synthesis due to a mismatched base at its 3′ terminus (figure 16A). In following cycles, 
TELc can hybridise along extensions of the TELg primer but can only initiate DNA 
synthesis when hybridised in a certain configuration shown in figure 16B, where the 3′ 
terminal base of TELc is fully matched. In this way a single, fixed-length PCR product is 
generated. Moreover, when the primers anneal to each other as shown in figure 16C, TELg 
and TELc have multiple mismatches, including at their 3′ terminal bases, and thus primer 
dimer formation is inhibited. 
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Figure III-16. A) Hybridisation of new telomere primers to genomic telomere sequences. B) Extension of a fixed-length 
PCR product initiated by the new telomere primers. C) Hybridisation of new telomere primers to each other. 
 
A)
B)
C)
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5.2 MMQPCR OPTIMISATION  
The reagents and the reaction conditions for the multiplex reaction were empirically 
determined using the protocol described by Cawthon (Cawthon 2009). The following 
parameters of the protocol were tested and changed: 
Reagents and template of the qPCR reaction mix: The ready-to-use SensiMix 
qPCR mix (2x SensiMix NoRef DNA kit, Quantace, London, UK) which was used as for 
the original version of the method, was also used for the MMQPCR. Nevertheless, 
additional reagents were added to the ready-to-use qPCR mix in order to achieve a better 
quality and efficiency in the multiplex reaction. Since the SCG primers contained GC-
clamps, the use of a reagent that reduces the formation of secondary structure caused by 
GC-rich regions would improve the amplification of these DNA sequences. Betaine has 
been suggested to be such a reagent (Henke et al. 1997), thus after testing it was added to 
the final multiplex qPCR mix. Moreover, I assumed that the amount of fluorescent dye 
contained in the ready-to-use PCR mix might not be sufficient, since the multiplex reaction 
includes two PCR reactions and the generation of two PCR products. Thus, I tested whether 
the reaction required extra amount of fluorescent DNA-intercalating dye (i.e. 2x or 3x 
instead of 1x SYBR Green in the final reaction). The results in figure 17 showed that the 
extra amount of SYBR Green was necessary in order to have a satisfactory level of 
maximum fluorescence (i.e. 2x SYBR Green in the final reaction).  
 Another important point of the optimization is to determine the minimum amount of 
DNA template needed in order to achieve a good PCR quality. Thus 20ng and 30ng of 
template were tested and it was shown that 20ng is sufficient.  
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Figure III-17. DNA samples run with and without extra SYBR Green added in their 
PCR reaction mix. A) Second derivative of the amplification from the channel 
collecting the telomere PCR fluorescence. B) Second derivative of the amplification 
from the channel collecting the SCG PCR fluorescence. C) Melting curve of the 
multiplex PCR products. The melting profile of the MMQPCR consists of two curves 
of which, the one at lower temperatures corresponds to the melting of the shorter, 
telomere PCR product, and the other at the higher temperatures corresponds to the 
longer SCGs products. 
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 Selection of the SCG: Both the ALB and the HBB single copy genes were tested in 
order to select the best SCG. As shown in figures 18A and 18B, the HBB amplification had 
a higher peak and earlier take-off compared to that of the ALB. Examining the melting 
profiles of the two single copy genes in figures 18C and 18D, it is evident that there is no 
non-specific amplification generated from the HBB primers. This can be concluded from 
the flat NTCs of the HBB PCR reaction. Also the HBB amplification seem to compete less 
with the formation of the telomere PCR product compared to the multiplex reactions with 
the ABB as SCG. This can be concluded from the lower first melting peak in the melting 
profile of the reactions with ABB as SCG compared to that with the HBB.  
 Although the differences were not great, the HBB was chosen as the best SCG.  
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Figure III-18. DNA samples run with ALB or HBG as SCG. A) Second derivative of the amplification from the channel 
collecting the SCG PCR fluorescence. Samples with ALB and HBB as SCGs are included. B) Second derivative of the 
amplification from the channel collecting the SCG PCR fluorescence. Samples with HBB only as SCGs are included. C) 
Melting curve of the multiplex PCR products including samples with ALB and HBB as SCGs. D) Melting curve of the 
multiplex PCR products including only samples with HBB as SCGs. 
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Optimisation of the cycling conditions: Higher annealing temperatures in the 
amplification cycles for both the telomere and the SCG templates were tested (i.e. 50°C 
instead of 49°C at stage 2 and 63°C instead of 62°C at stage 3). Theoretically, more strict 
annealing temperatures potentially increase the specificity of the PCR, which could 
improve the separation of the two target sequences‘ amplification.  
Both the combinations of cycling conditions resulted in optimal amplification and 
melting profiles as shown in figure 19. The exponential phases of the two target sequences 
amplification were well separated, with a six to seven cycles difference between them, and 
the melting curve consisted of two clear peaks as expected by the telomere and the SCG 
PCR products, respectively. Therefore, the decision of which combination of cycling 
conditions is the best was based on which one leads to higher reproducibility of 
measurements. Nineteen randomly selected samples were measured on two consecutive 
days using both cycling profiles. Linear regression analysis showed that the cycling 
conditions as in Cawthon‘s protocol (Cawthon 2009) lead to a higher linearity between 
repeated measurements of telomere length, compared to the profile with the higher 
annealing temperatures (figure 20). Thus, the cycling profile as suggested by Cawthon was 
chosen.  
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Figure III-19. Amplification and melting profiles of the MMQPCR products with: A) 
Cycling conditions as suggested by Cawthon. B) Cycling conditions with higher 
annealing temperatures. 
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Figure III-20 Linear regression graphs between the telomere length estimates (T/S 
ratios) of the same 19 DNA samples measured on two consecutive days. A) Cycling 
conditions as suggested by Cawthon. B) Cycling conditions with higher annealing 
temperatures. 
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Final MMQPCR conditions: The MMQPCR assay was finally optimised at the 
following conditions. A final reaction with volume of 25μl consisting of 2x SYBR Green, 
1x qPCR mix (2x SensiMix DNA kit, Quantace), 1M of Betaine (Sigma, Aldrich, UK), 20 
ng of template, telomere primers Telc and Telg at 900nM and HBB primers at 500nM. 
With a cycling profile of:  
Stage 1 (1 cycle): at 95°C for 15 min.  
Stage 2 (2 cycles): at 94°C for 15 s and at 49°C for 15 s. 
Stage 3 (32 cycles): at 94°C for 15 s, at 62°C for 10 s, at 74°C for 15 s and signal 
acquisition at channel A (collecting the telomere PCR amplification signal). This was then 
followed by 10 s at 84°C and 15 s at 88°C with signal acquisition at channel B (collecting 
the SCG PCR amplification signal).  
Figure 21A shows the signal from channel (A) which collects the telomere 
amplification fluorescence and 21B the signal from channel (B) recording the fluorescenc 
from the SCG amplification. The telomere amplification takes-off very early at 15-16 
cycles, while the SCG amplification take-off level is approximately at 22-23 cycles. This 
means that the exponential phase of each target sequence‘s amplification is well separated 
from the other target sequence. Both reach a satisfactory level of maximum fluorescence, 
while the NTCs amplification level remains much lower than that of the DNA samples. In 
figure 21B, the NTCs during the cycles of the telomere‘s amplification exponential phase 
remain flat, and only in later cycles come up. This means that any non-specific 
amplification involving the telomere primers happens later when it does not interfere with 
the measurement of the telomere PCR product fluorescence. Regarding the specificity of 
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the two amplifications in this multiplex PCR, the melting, in figure 21C, shows that there 
are only two amplicons produced of the expected length. The two distinct peaks during 
melting indicate a specific telomere product of 79bp melting at ~77.5
0
C and the specific 
SCG product of 106bp which melts at ~89.5
0
C. The NTCs appear to have generated a 
negligible amount of SCG primer product. The telomere primer-generated amplification in 
the NTCs is produced after the genomic telomere sequences‘ amplification has reached the 
plateau phase, which is evident in the fluorescence plot of figure 21A. 
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Figure III-21. A) Amplification signal of the telomere MMQPCR in channel (A), B) Amplification signal of the HBB 
(SCG) MMQPCR in channel (B), and C) Melting profile of both the MMQPCR products. 
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5.3 VALIDATION OF MMQPCR ADAPTION 
 
5.3.1 Quality Control – Standard Curves 
In order to ensure the validity in determining the relative concentration of the 
two PCR products in MMQPCR a standard curve analysis for a dilution series was 
performed. In this case, the linearity between the template concentration series and the 
relative copies of telomere and SCG PCR product, as measured in parallel in a 
MMQPCR reaction, was tested. 
Thus, a dilution series (1.25 ng/μl - 160 ng/μl, two-fold dilution, eight points) 
was run after optimization of the MMQPCR. The relative concentrations of both PCR 
products –the telomere repeat copies and the SCG copies- as measured in the same 
multiplex reaction, linearity (R
2
>0.99) over this range of input DNA was observed 
(figure 22A and 22B, respectively). Furthermore, both target sequences‘ amplification 
displayed ~100% efficiency, as calculated from the slope of the respective standard 
curves.  
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Figure III-22. Standard curves of A) Telomere PCR and B) SCG (HBB) PCR. 
A)  
 
B) 
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5.3.2 Reproducibility of the MMQPCR method 
Nineteen randomly chosen DNA samples were measured on two consecutive 
days with the MMQPCR assay as optimised in our laboratory. A significant linearity 
between the mean telomere length measurements obtained on the two different days was 
observed in linear regression analysis as shown in figure 20A (R
2
=0.89, p<0.001). 
Moreover, the reproducibility was also assessed with Spearman‘s non-parametric test of 
pair-wise correlation; and the correlation of rankings of the two repeated measures was 
found significant correlation (Spearman coefficient=0.89, p<0.001). The coefficient of 
variation of the telomere length estimates in the repeated measurements of the same 
sample was 4.5%, which is slightly better compared to that of the original qPCR 
method. This inter-assay coefficient of variation was higher compared to the 3.13% 
observed by Cawthon with the MMQPCR assay, however Cawthon‘s assays also 
displayed a 5.22% intra-assay variability (Cawthon 2009), which is eliminated when the 
samples are run on a rotor as in the present experiments.  
5.3.3 Comparison with the traditional TRF method for telomere length 
measurement 
To validate the assay, the 32 DNA samples of subjects (aged 24 to 54 years) 
from the Cardiovascular Sciences Department, Leicester University DNA bank (see 
―First result chapter‖, paragraph 3.3, page 173) were also measured in using the 
MMQPCR method as adapted in our laboratory. The T/S ratios obtained were then 
compared to the TRF values obtained by the conventional TRF analysis in Leicester 
University, as previously described (Samani et al. 2001).  
Linear regression analysis showed a significant positive correlation between the 
TRF values and T/S ratios measured with the MMQPCR assay (R
2
=0.53, p<0.0001, 
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figure 23). As described also in paragraph 3.3 of this result chapter (174) a certain 
deviation from the telomere length as estimated by TRF analysis is expected. However 
this correlation of the TRF values with the T/S ratios measured using the MMQPCR 
was weaker than that observed with the T/S ratios measured using the original qPCR 
method (R
2
=0.63). One possible explanation could be that the MMQPCR assay is more 
accurate than the original qPCR method, thus it measures more accurately the length of 
pure telomeric sequences and this increases the deviation from the TRF values which 
also measure the highly variable sub-telomeric region. Nonetheless, the correlation of 
MMQPCR telomere lengths with those obtained by TRF analysis was also weaker 
compared to that observed by Cawthon (R
2
=0.844). Cawthon on the other hand 
performed this comparison using a greater number of samples (95 vs. 32 samples used 
in the present thesis) (Cawthon 2009). 
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Figure III-23. Correlation of the MMQPCR with the conventional TRF analysis. 
 
trf: mean telomere length in kilobases as measured by TRF analysis. 
mqpcr: mean telomere length expressed as T/S ratio determined by the MMQPCR. 
 
Then, I tested the correlation between the T/S ratios obtained with the original 
qPCR method and the MMQPCR using the same 32 DNA samples of the Leicester 
University DNA bank. Linear regression analysis showed that these T/S ratios 
correlated significantly (R
2
=0.47, p<0.001, figure 24), although this association was not 
very strong, as it would be expected.  
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Figure III-24. Correlation of the MMQPCR with the original qPCR method. 
 
 
 This not so strong correlation between the T/S ratios estimated with the original 
qPCR assay and the MMQPCR is puzzling, since both assays measure the mean copy 
number per genome of pure telomeric repeat sequences. Unfortunately, Cawthon in his 
article has not examined this correlation in order to compare.  
Nevertheless, the MMQPCR as adapted in our laboratory can be considered 
reliable since it is highly reproducible and valid taking into account that its 
measurements correlate significantly with those obtained by the original qPCR assay 
and with those obtained by TRF analysis. Moreover, this assay has certain advantages 
compared to the original qPCR. It requires less DNA template, which is very important 
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in the case of large study samples where the available DNA is restricted. Also, it 
requires fewer reactions per sample which reduces significantly the cost and time 
required. 
The reproducibility and reliability of the method can be improved by using a set 
of three DNA samples as references, instead of one, as standards according to which all 
unknown samples are normalised. Thus, three DNA samples of known telomere length 
can be used as internal standards in each batch of samples for calculating the T/S ratios. 
Then the T/S ratio of each standard DNA will be divided by the average T/S ratio for 
the same DNA sample measured in ten runs, in order to obtain a normalising factor. The 
average normalizing factor for all three DNA standards can then be used to correct the 
measured T/S ratio of each unknown DNA sample. This modification for minimizing 
the inter-assay variability has been used in the study of Lin et al (Collerton et al. 2007; 
Lin et al. 2010). In addition, if these three reference DNA samples used as standards are 
DNA samples of known telomere length in kb as measured by TRF, then a very good 
estimate of the unknown samples‘ telomere length in kb can be obtained using the 
MMQPCR method.  
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IV. SECOND RESULT CHAPTER: “TELOMERE LENGTH IN 
CARDIOVASCULAR DISEASE AND T2D DIABETES PATIENTS”. 
 
1. TELOMERE LENGTH IN CORONARY HEART DISEASE PATIENTS  
 
1.1 INTRODUCTION 
The first aim of the present thesis was to test the hypothesis that CVD and T2D 
is associated with shorter mean telomere length. The main disease representing CVDs is 
CHD, with the major endpoint of MI. There is growing evidence of an association 
between telomere length and CHD (Serrano & Andres 2004), where age- and sex-
adjusted mean LTL of CHD patients was ~300 base pairs (bp) shorter than that of 
healthy subjects, and this difference was not accounted for by other CHD risk factors in 
a study of 203 cases and 180 controls. In the same study, the risk of MI for subjects in 
the lowest quartile of LTL was ∼3 times higher compared with subjects in the highest 
quartile (Brouilette et al. 2003). Most importantly, prospective studies have supported 
the causative role of telomere length in the development of CHD (Brouilette et al. 2007; 
Fitzpatrick et al. 2007). The prospective West of Scotland Primary Prevention Study 
(WOSCOPS) with 484 CHD patients and 1058 controls revealed that individuals in the 
middle and the lowest tertiles of LTL were at higher risk of developing CHD compared 
to those in the highest tertile (Brouilette et al. 2007).  
In this chapter, I examine the association of telomere length with CHD in cases 
of different disease aetiology, including both the common polygenic form of CHD and 
for the first time, CHD caused by monogenic familial hypercholesterolaemia (FH). 
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While, in general, CHD has a multifactorial origin, in some rare cases it has a 
monogenic cause such as FH. FH is an autosomal co-dominant disorder which leads to 
high levels of LDL-cholesterol and if untreated to early CHD (Thorogood et al. 2009). 
Heterozygous FH has been estimated to affect about one in 500 of the British 
population (Neil et al. 2000). I also aimed at investigating whether telomere length 
would be predictive of post-operative mortality, by examining a sample of CHD cases 
consisting of patients undergoing a first elective coronary artery bypass graft (CABG) 
surgery.  
For pragmatic reasons, most of the population studies are using LTL (LTL), 
measured in DNA samples extracted from whole blood. Wilson et al. (Wilson et al. 
2008) have shown that LTL is a good predictor of vascular wall telomere length. Thus, 
in the present thesis shorter LTL was taken as a surrogate marker of telomere length in 
vascular wall tissue.  
 
1.2 METHODS 
1.2.1 Subjects 
Hypercoagulability and Impaired Fibrinolytic function MECHanisms 
predisposing to myocardial infarction (HIFMECH) study. The HIFMECH study 
consists of 598 male survivors of a first myocardial infarction aged <60 years 
(excluding patients with familial hypercholesterolaemia and insulin-dependent diabetes 
mellitus) and 653 population-based control subjects of the same age and region, 
recruited from four centers in Europe: Stockholm in Sweden and London in England 
were designated North Europe and Marseille in France and San Giovanni Rotondo in 
Italy were designated South Europe. In all, a total of 598 post-infarction patients and 
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653 controls were included in the study. Patients and control subjects were examined in 
parallel in the early morning after an overnight fast. Post-infarction patients were 
investigated 3 to 6 months after the acute event. Blood samples were obtained from the 
antecubital vein after an overnight fast, collected into citrate (3.8% citrate, 0.129 mol/L) 
and centrifuged at 2500g for 30 minutes at 4°C. Detailed description of the study can be 
found in the study of Juhan-Vague et al. (Juhan-Vague et al. 2002).  
The HIFMECH investigators include: Stockholm: A Hamsten (co-ordinator), S 
Boquist, C-G Ericsson, P Lundman, A Samnegård, A Silveira, P Tornvall. London: J 
Yudkin, V Mohamed-Ali, A Holmes. Marseille: I Juhan-Vague, MF Aillaud, PE 
Morange, MC Alessi, P Ambrosi, I Canavy, F Paganelli, R Didelot, J Ansaldi, M 
Billerey. San Giovanni Rotondo: G Di Minno, M Margaglione, D Cimino, N Dello 
Iacono, A Cimino, G Gaeta, C Blasich, G Pucciarelli. London: SE Humphries, E Hawe, 
L Ahn Luong Leiden: V van Hinsbergh, T Kooistra. Milan: E Tremoli, C Banfi, L 
Mussoni. 
CABG study sample. The CABG patients were drawn from the coronary artery 
surgery inflammation study (CASIS) and are described in detail in the study of Brull et 
al. (Brull et al. 2001). All patients undergoing elective first time CABG at the 
Middlesex Hospital, London, UK, between October 1999 and September 2000 were 
invited to participate. Subjects undergoing additional surgical procedures (such as 
valvar surgery or aneurysmectomy), subjects with evidence of a preexisting 
inflammatory state or unstable coronary artery disease, and subjects who suffered 
potentially confounding infective postoperative complications or circulatory failure 
requiring inotropic support were excluded. Aspirin was omitted routinely 10 days 
before surgery. Blood samples were drawn preoperatively. These were centrifuged 
immediately (3500g, 10 minutes), and plasma and cells were separated and frozen at -
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20°C. In the end this CABG group included in total 439 individuals (20 % women) 
having different ethnic origin (83% Caucasians, 8% Asians, 2% Afro-Caribbean, 2% of 
other ethnicity and 5% of unknown origin). The CASIS principle investigators include: 
HE Montgomery, J Sanders, and SE Humphries. 
FH study samples. Two independent groups of FH patients were recruited from 
London hospitals. The first FH sample included 410 definite FH adult patients (47.7% 
women) recruited by one of the six outpatient hospital lipid clinics participating in the 
Simon Broome Familial Hyperlipidaemia Register Group and Scientific Steering 
Committee (FH-SB group). The second group of 94 FH patients was recruited from the 
Royal Free Hospital, London (FH-RF group).  
The diagnostic criteria for familial hypercholesterolaemia were defined as a total 
cholesterol concentration above 7.5 mmol/l (treated or untreated), or LDL cholesterol 
above 4.9 mmol/l, together with the presence of tendon xanthomas either in the patient 
or in a parent, child, grandparent, sibling, uncle, or aunt (Scientific Steering Committee 
1991). Patients with known diabetes, renal, or thyroid disorders were excluded. Clinical 
CHD was defined as patients with a definite MI (new Q waves and/or ST elevation 
and/or new T wave inversion persisting in more than two leads together with creatine 
kinase > 400 iu/l or other equivalent enzyme changes) or having undergone coronary 
artery bypass grafting, percutaneous transluminal coronary angioplasty, having angina 
with an ischaemic resting ECG, or an abnormal angiogram CHD. Using these criteria, 
CHD was documented in 104 of the 211 men and in 55 of the 199 women with mean 
ages of onset of 43.1 and 46.5 years, respectively (Neil et al. 2004) among the FH-SB 
patients. The mean age of the FH-RF patients was 57.7 years (SD=14.6) and 17 of them 
suffered from CHD.  
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All studies had been designed and carried out according to the Helsinki 
declaration and received approval from the ethics committee of the respective 
recruitment centers/hospitals. All patients gave written informed consent. The principle 
investigators of the FH-SB study group, which is part of the Simon Broome Familial 
Hyperlipidaemia Register Group FH patient sample, include: A Neil and SE Humphries. 
The principle investigators of the FH-RF study group include: & D Nair and SE 
Humphries. 
1.2.2 Phenotypic variables 
Details on lifestyle factors (i.e. smoking, alcohol consumption, and physical 
activity), personal and family medical history, medication and physiological 
measurements [i.e., height, weight, BP] were acquired using standardised questionnaires 
and protocols (Brull et al. 2001; Neil et al. 2004) by each study‘s principle 
investigators.  
1.2.3 Measurement of leukocyte telomere length  
Leukocyte DNA was extracted by the salting-out method, as described in the 
―General methods‖ paragraph 2.1 (pages 109-112). Telomere length was measured in 
these DNA samples using the validated qPCR-based method, which is thoroughly 
described in the ―First result chapter‖, pargraphs 1, 2 and 3 (pages 149-174). The 
coefficient of variation in repeated measurements was 5.6%. The corresponding 
telomere length in bp was calculated from the T/S ratio measured in each sample using 
the linear regression line between measures obtained by both the qPCR-based method 
and the conventional TRF analysis for the same set of 32 samples, as described in the 
―First result chapter‖, paragraph 3.3 (page 173). 
216 
 
To assess the validity of the method, variability in telomere and SCG PCR 
amplification efficiency was compared between the three studies. Values were 
comparable, and the standard deviations overlapped, rendering the T/S ratios obtained 
in different runs comparable. To ascertain that inter-assay variability did not interfere 
with the results, T/S ratio measurements were repeated for 32 randomly selected 
samples from the FH group without CHD and 32 region-matched controls from the 
HIFMECH study in two runs including samples from both studies. LTL was longer in 
the FH group (9.41 kb, SD=6.20) compared to the UK controls (8.49, SD=5.10; 
p=0.059) for this sub-set of samples, as reported for the total group.  
1.2.4 Statistical analysis 
Statistical analysis was performed using Stata (version 10, StataCorp Texas). 
Analysis was restricted to Caucasians in order to maintain ethnic homogeneity in the 
sample. LTL, BMI, triglycerides, insulin, homocysteine, C-reactive protein and systolic 
blood pressure were not normally distributed, and thus log-transformed data were used 
for the analysis. For all transformed variables, geometric means with approximate 
standard deviation (SD) are presented in tables. Results on telomere lengths are 
presented as geometric means with 95% confidence intervals (CIs). The comparison 
between cases and controls for the variables presented in table 1 was performed with 
conditional logistic regression models in HIFMECH matching for age and centre. For 
the FH study, mean values were compared by t test. For the association of telomere 
length with lifestyle parameters, p values were obtained from analysis of covariance 
models, and the regression estimates were used to obtain adjusted mean values. 
Adjustment was made for age, centre and exercise in HIFMECH, age in CABG and age 
and gender in FH.  
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The comparison between CHD cases and controls is also presented as odds 
ratios obtained from conditional logistic regression models using telomere length as a 
categorical variable, after dividing into tertiles. The tertiles of telomere length were 
constructed using the combined case-control group with the age-adjustment made 
within the separate groups. In the end a random effects meta-analysis of the odds ratios 
in each study was performed. Statistical significance was taken as p<0.05. 
 
1.3 RESULTS 
1.3.1 General characteristics of study subjects 
Mean LTL was successfully determined in 559 cases and 520 controls of the 
HIFMECH study, 413 cases of the CABG study and 461 FH patients in total (367 FH-
SB and 94 FH-RF patients). The characteristics of these subjects are shown in Table 1, 
and they did not differ significantly from that of the whole group for any of the 
parameters. In both the HIFMECH and the FH studies, there were the expected 
significant differences between CHD cases and controls in risk factors such as BMI, 
diastolic blood pressure, cholesterol, triglyceride levels and where available 
inflammatory [i.e. CRP and interleukin 6 (IL6)] factors. 
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Table IV-1. Characteristics of study subjects. 
 HIFMECH CABG FH - SB FH - RF 
 Controls Cases p   - CHD + CHD p - CHD + CHD p 
Number 
%women 
559 
(0) 
520 
(0) 
- 
413 
(20.8) 
222 
(56.8) 
145 
(33.8) 
<0.001 
77 
(61.3) 
17 
(47.1) 
0.28 
Age (yrs) 51.5 (5.5) 51.9 (5.4) - 64.9 (92.2) 44.3 (13.4) 56.1 (10.3) <0.001 51.9 (14.3) 58.7 (14.0) 0.08 
BMI* 26.1 (3.2) 27.1 (3.3) 0.001 28.2 (4.5) 23.8 (4.0) 25.1 (3.4) 0.005    
SBP* 127.8 (14.4) 127.7 (16.9) 0.75  123.7 (15.6) 130.6 (19.7) <0.001    
DBP 84.0 (8.4) 81.7 (10.2) <0.001  77.3 (9.1) 79.3 (11.3) 0.06    
TC 5.52 (0.97) 5.40 (1.18) 0.06 4.71 (1.03) 6.91 (1.30) 6.35 (1.31) <0.001 8.76 (1.50) 10.11 (2.77) 0.02 
TG* 1.44 (0.61) 1.88 (0.77) <0.001  1.24 (0.56) 1.46 (0.69) 0.001 1.52 (0.68) 2.16 (1.24) 0.03 
LDL    2.53 (0.88) 4.80 (1.28) 4.21 (1.23) <0.001 6.34 (1.48) 7.65 (2.68) 0.05 
HDL    1.23 (0.35) 1.38 (0.35) 1.28 (0.36) 0.01 1.47 (0.40) 1.10 (0.29) 0.005 
GLU    6.19 (2.05) 4.82 (0.59) 5.07 (0.59) <0.001    
Insulin* 37.8 (24.3) 49.3 (34.5) <0.001        
HC* 8.27 (2.59) 8.55 (3.36) 0.03  10.54 (3.45) 11.57 (3.20) 0.005    
CRP* 1.23 (1.40) 2.22 (2.55) <0.001 2.29 (2.77) 1.16 (1.34) 1.42 (1.59) 0.10    
IL-6  1.24 (0.78) 1.97 (1.33) <0.001 4.55 (3.12) 1.58 (1.14) 2.18 (1.34) <0.001    
Unadjuste
d LTL‡ 
8.04 
(7.88-8.20) 
7.90 
(7.77-8.03) 
0.34 
6.85 
(6.69-7.01) 
9.82 
(9.51-10.13) 
9.04 
(8.68-9.40) 
0.001 
9.82 
(9.30-10.34) 
9.04 
(7.99-10.09) 
0.001 
 
Means with standard deviation are presented for each variable unless otherwise stated. 
*data were log-transformed and geometric means (approx SD) are presented, ‡ Data were log-transformed and the geometric means with 
95% confidence intervals (95%CI) was then used to calculate the corresponding telomere length in kb.  
BMI: Body mass index in kg/m
2
, SBP: systolic blood pressure in mmHg, DBP: diastolic blood pressure in mmHg, TC: total cholesterol in 
mmol/l, TG: triglycerides in mmol/l, HDL: high density lipoprotein in mmol/l, GLU: Glucose in mmol/l, INS: insulin in (mU/l), HC 
Homocysteine in mmol/l CRP: C reactive protein in (mg/l), IL-6: interleukin 6 in pg/ml, LTL: leukocyte telomere length in kb. 
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1.3.2 Age and gender differences in telomere length 
As shown in figure 1, LTL correlated negatively with age in all three study samples, 
HIFMECH (r=−0.07, p=0.03), CABG (r=−0.18, p=0.0003), FH-SB (r= −0.16, p<0.0002) 
and FH-RF (r= −0.35, p=0.0002). No significant gender difference was found in the CABG 
group (0.95 kb in men vs. 0.93 kb in women, p=0.74), whereas among FH patients, men 
had significantly shorter telomeres than women (9.23 kb in men vs. 9.82 kb in women, 
p=0.01 for the FH-SB group and 6.93 kb in men vs. 7.57 kb in women, p=0.02 for the FH-
RF patients). Therefore, telomere length was adjusted for age in all further analysis and for 
age and gender in analysis concerning the FH groups. 
 
Figure IV-1. Decrease of telomere length with age in each study sample.  
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1.3.3 Lifestyle-related differences in telomere length  
Smoking and alcohol intake did not have a significant effect on telomere length 
(p>0.4). However, it appeared that the less active subjects had longer telomeres in the 
combined HIFMECH cohort after adjustment for case–control status (sedentary: 7.90 (7.75-
8.05) n=399, moderate active: 7.99 (7.81-8.17) n=399, active: 7.53 (7.29-7.77) n=183 and 
fit: 7.58 (7.26-7.89) n=93, p=0.005). When cases and controls were examined separately, 
no significant association between LTL and level of exercise was found. Nevertheless, in 
order to avoid any possible confounding effect in the rest of the analysis in HIFMECH, 
telomere length was also adjusted for exercise level.  
1.3.4 Geographical differences in telomere length 
Age, exercise and case–control status adjusted telomeres were significantly longer 
in subjects from the South compared to the North of Europe in HIFMECH [7.99 kb (7.81-
8.17) vs. 8.27 kb (8.14-8.40), p=0.02] (Figure 2); a difference corresponding to 
approximately 280 bp. All further analysis in HIFMECH was also adjusted for 
geographical region.  
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Figure IV-2. Comparison of mean leukocyte telomere length (kb) between North and 
South of Europe in HIFMECH study. 
 
Geometric mean of age, exercise and status adjusted leukocyte telomere length (LTL) in kb 
and 95% confidence intervals are presented. 
 
1.3.5 The effect of CHD risk factors on telomere length 
As shown in table 2, in the FH-SB subjects, BMI and triglyceride and glucose 
correlated positively with telomere length (r=0.26, p<0.0001, r=0.11, p=0.03 and r=0.14, 
p=0.006respectively) but these effects were not consistent across studies. Insulin levels 
displayed a negative correlation with telomere length in HIFMECH cases (r=-0.15, 
p=0.005) only but not the controls. Homocysteine has been previously shown to increase 
the amount of telomere length loss per population doubling in endothelial cells through a 
redox-dependent pathway (Xu et al. 2000). Thus its correlation with LTL was also tested, 
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but no significant effect was observed. No association was found between telomere length 
and diabetes, hypertension or hyperlipidaemia in the HIFMECH and the CABG cohorts.  
 
Table IV-2. Partial Pearson correlation coefficients of telomere length with classical 
risk factors. 
 
 HIFMECH CABG FH 
 Controls Cases   
 r p  r p  r p r p 
BMI (kg/m
2
) -0.07 0.09 -0.07 0.13 0.03 0.63 0.26 <0.0001 
SBP (mmHg) -0.01 0.76 0.04 0.35   -0.06 0.29 
DBP (mmHg) -0.02 0.60 -0.02 0.73   -0.08 0.13 
TC (mmol/l) -0.02 0.61 -0.03 0.56 -0.01 0.86 -0.03 0.54 
TG (mmol/l) -0.004 0.93 -0.07 0.15   0.11 0.03 
HDL (mmol/l)     -0.02 0.8 -0.03 0.54 
Glucose (mmol/l)     -0.06 0.38 0.14 0.006 
Insulin (mU/l) -0.008 0.87 -0.15 0.005     
Homocysteine 
(mmol/l) 
-0.03 0.53 -0.06 0.16   0.02 0.77 
 
Partial Pearson correlation coefficients r was adjusted for age, center and exercise in 
HIFMECH, age in CABG and age and gender in FH and further adjusted for case–control 
status when cases and controls are pooled. 
BMI: Body mass index, SBP: systolic blood pressure, DBP: diastolic blood pressure, TC: 
total cholesterol, TG: triglycerides HDL: high density lipoprotein. 
BMI, triglyceride, insulin, homocysteine, CRP, SBP and homocysteine were log-
transformed for tests. 
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1.3.6 Polygenic CHD case–control differences in telomere length 
i) HIFMECH 
Age, exercise and region adjusted LTL was significantly shorter in premature MI 
cases [7.85 kb (7.72-7.98)] compared to controls [8.04 kb (7.88-8.20), p=0.04] (Figure 3). 
The difference corresponded to approximately 190 bp.  
ii) CABG 
The CABG cases were compared to region-matched controls from the HIFMECH 
study. Due to the geographical differences observed in LTL between South and North of 
Europe, the North Europe controls from the HIFMECH study were used in order to match 
the UK recruited CABG cases. LTL, adjusted to the age of 65 years, was significantly 
shorter in CABG cases [6.89 kb, (6.74-7.04)] compared to the North region HIFMECH 
controls [7.99 kb (7.39-8.59), p=0.003] (Figure 3), but also compared to all HIFMECH 
controls [7.72 kb (7.62-7.82), p<0.0001].  
After 6 years follow-up of the CABG patient sample, 40 deaths were recorded. 
Interestingly, subjects who died in these 6 years had shorter telomeres [6.66 kb (6.20-7.12)] 
compared to those who survived [6.94 kb (6.78-7.10), p=0.28], but this difference was not 
significant. 
1.3.7 Monogenic CHD case–control differences in telomere length 
Since both FH patient samples were recruited from UK according to the same 
diagnostic criteria, they were combined for the comparison of LTL between those with and 
without CHD in order to increase statistical power. In the combined FH cohort, age, gender 
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and study adjusted LTL was shorter in those with CHD [8.68 kb (8.36-9.0)] compared to 
those patients without CHD [9.23 kb (8.97-9.49), p=0.01) (Figure 3). The difference 
between those with and without CHD was also examined in each FH patient sample 
separately. The same trend towards shorter telomeres in those with CHD was observed 
[FH-SB: 9 kb (8.64-9.36) vs. 9.46 kb (9.17-9.75), p=0.09 and FH-RF: 6.84 kb (6.43-7.25) 
vs. 7.53 kb (7.20-7.86), p=0.15].  
In addition, telomere length was compared between the combined FH patients 
without CHD and region-matched controls from HIFMECH. LTL, adjusted to males at the 
age of 51.6 years, was longer in FH patients compared to the region-matched controls [8.81 
kb (8.49-9.14) vs. 7.85 kb (7.58-8.13), p<0.0001].  
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Figure IV-3. Comparison of telomere length between CHD cases and controls. 
 
 
 
Geometric mean of LTL in kb and 95% confidence intervals are presented. In HIFMECH, telomere length is adjusted for age, 
region and exercise, in CABG for age and in FH study, for age and gender. 
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1.3.8 Overall association of CHD with telomere length / meta-analysis 
 To better illustrate the association of CHD with short telomeres, the present study 
samples were divided in tertiles of LTL. In each of the three case-control designs the 
subjects with LTL in the lowest tertile, i.e. shorter telomeres, displayed higher odds ratio 
for CHD when compared to subjects in the middle and the highest tertile of LTL 
[HIFMECH: 1.24 (95%CI: 0.95-1.62), CABG: 1.74 (95%CI: 1.07-2.81), FH: 1.49 (95%CI: 
0.95-2.36)]. A meta-analysis of the three case-control studies showed that being in the 
lowest tertile of LTL is significantly associated with 37% higher odds ratio for CHD 
compared to those in the middle and highest tertiles of LTL [1.37 (95%CI: 1.11-1.69), 
p=0.003] (Figure 4).  
 
Figure IV-4. Odds ratio (OR) for CHD when having LTL in the lowest tertile / meta-
analysis.  
 
P=0.003
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1.4 Discussion 
The results of this chapter showed that premature MI male patients, CHD patients 
undergoing CABG and FH patients with CHD have shorter age-adjusted LTL compared to 
subjects without CHD. These observations confirm that shortened telomeres are linked to 
CHD and extend this association to those with monogenic and polygenic forms of CHD. 
Using the correlation between telomere length and age, the decline in telomere length can 
be approximately estimated at 14 bp per year in HIFMECH and 34 bp per year in the FH 
studies. From these values, the difference in mean LTL between CHD cases and controls 
(190 bp in HIFMECH and 550 bp in FH) corresponds to a biological age equivalent to 14 
older for the polygenic CHD cases and 16 years older for the monogenic CHD cases 
compared to controls. This is in accordance with Brouilette et al. (Brouilette et al. 2003) 
who found that premature MI cases had 300 bp shorter LTL than controls, which 
corresponded in average to a biological age gap of 11 years.  
These data, coupled with those of others (Brouilette et al. 2003; Brouilette et al. 
2007; Fitzpatrick et al. 2007; Farzaneh-Far et al. 2008; Mukherjee et al. 2009), suggest that 
shorter LTL, is a marker for CHD and MI. Since LTL has been shown to strongly correlate 
with vascular wall telomere length (Wilson et al. 2008), it can be concluded the association 
of CHD with shorter LTL, reflects the common underlying abnormality of excessive 
vascular wall ageing in patients developing CHD. This raises the possibility for telomere 
length to prove useful in identifying individuals at particularly high risk of CHD, who may 
benefit from earlier or more intensive treatment (Spyridopoulos et al. 2004). However, 
because telomere length is highly variable between subjects of different ethnicity (Salpea et 
al. 2009) and ages (Aviv 2008), and, so far, the data on the rate of shortening are scarce, it 
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is not yet possible to establish a cut-off value in order to distinguish patients who may 
benefit from early use of medication.  
In the present study samples, there were a few significant correlations between 
classical risk factors and LTL. The inverse correlation with insulin in HIFMECH cases 
could possibly reflect the inverse association of LTL with insulin resistance, although it 
was not significant in HIFMECH controls. Unfortunately, data on insulin levels were not 
available in the other studies. In the FH patients, unexpected positive correlations with 
BMI, triglycerides and glucose were observed; however these findings were not replicated 
in the other three study samples. The fact that no consistent correlation with risk factors, 
such as HDL levels, BMI and smoking, were observed throughout the four studies is in 
contrast to other published reports (Valdes et al. 2005; Chen et al. 2009; Lee et al. 2011). 
In each particular study presented here, the absence of a significant correlation can be due 
to lack of power resulting from a relatively small sample size. Given these data, we cannot 
confirm the correlations observed nor refute those reported in other studies.  
Worthy of remark are the geographical differences observed in the multicenter 
European study employed here (HIFMECH), with telomeres being approximately 280 bp 
longer in the South (San Giovanni Rotondo, Italy and Marseille, France) compared to the 
North of Europe (Stockholm, Sweden and London, UK) At the same time, the regions 
having longer telomeres have also been repeatedly shown to have lower CHD risk 
(Iacoviello et al. 2001) and CVD-related mortality rates (Muller-Nordhorn et al. 2008) 
compared to the North, where mean telomere length was found to be shorter.  
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Figure IV-5. Color-illustrated age-standardised mortality from CVD among men of 
the age group 45–74 years in Europe (Muller-Nordhorn et al. 2008) and age-adjusted 
mean LTL (kb) in each of the four recruitment centers (Stockholm, Sweden; London, 
UK; Marseille, France; San Giovanni Rotondo, Italy) in HIFMECH. 
 
 
  
~8.17kb
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As illustrated in figure 5, there appears to be an agreement between the region-
specific mortality from CVD across Europe with the differences seen in telomere length, 
supporting the association of telomere length with the development and possibly the 
prognosis of CVD. However, more data on telomere length in the different European 
countries is needed to confirm this.  
In the present study LTL was, for the first time, evaluated in FH patients. The 
patients suffering from CHD had roughly 550 bp shorter telomeres than FH patients 
without CHD, broadening the association of short telomeres with CHD to also monogenic 
forms. This finding is important as it shows that short telomeres reflect an essential feature 
of CHD pathogenesis, common in both polygenic and monogenic forms, which probably is 
the accelerated vascular wall ageing. Interestingly, the differences observed with the CHD 
cases of monogenic aetiology, in this case FH, are greater than the difference in telomere 
length observed with cases of polygenic CHD aetiology in the present study and that of 
Brouilette et al.  
Of particular interest is the observation that FH patients, which have not developed 
CHD, had an estimated 960 bp longer telomeres than healthy controls after adjustment for 
age and gender. A possible explanation could be that the FH patients without CHD, being 
recruited in this study, are the ―survivors‖, and the FH patients with shorter telomere length 
had died earlier, most likely from CHD. Another possibility is that the prolonged statin 
treatment, prescribed to FH patients early in life, is responsible for the longer telomere 
length observed in these subjects. Evidence supporting this hypothesis comes from studies 
showing that statin administration attenuates telomere shortening. Satoh et al. showed that 
in a culture of endothelial progenitor cells subject to oxidative stress (by inhibiting the 
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cellular detoxification of peroxides), intensive lipid lowering treatment with atorvastatin led 
to the prevention of endothelial progenitor cells telomere shortening (Satoh et al. 2009). 
Moreover, Mahmoudi et al. showed that atorvastatin treatment reduced telomere shortening 
in vascular smooth muscle cells cultured with a free radical-generating agent (Mahmoudi et 
al. 2008). Regarding the possible mechanism of this effect, Mahmoudi et al. (Mahmoudi et 
al. 2008) showed that statin treatment reduced telomere shortening in their experiments by 
markedly enhancing DNA repair. Also, Spyridopoulos et al. showed in vitro that statins 
induce an increase in expression of the important telomere capping protein TRF2, 
(Spyridopoulos et al. 2004), which potentially stabilises the structure of telomeres 
preventing their shortening. The direct relevance of this to patients has yet to be confirmed.  
Considering the protective effect of statins against telomere shortening as shown in 
the above studies, it is possible that the longer telomere length in the FH patients free of 
CHD compared to healthy subjects could be a consequence of the prolonged statin 
treatment that these patients have received. While a proof of this hypothesis would require 
the availability of follow-up measurements of telomere length in subjects on statins or not, 
the observed significant negative correlation between telomere length and duration of statin 
use in the FH-SB group renders this explanation less likely (Figure 6). 
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Figure IV-6. Correlation between telomere length and duration of statin use in FH 
patients.  
 
 
 
Nonetheless, it will be of great interest to evaluate telomere length and rate of 
attrition in larger samples of FH patients, in order to examine whether the observed longer 
telomeres is a chance finding or not and investigate the underlying mechanism. 
In conclusion, it is now strongly confirmed that short telomeres length is a marker 
of CHD along with its complications, such as MI. The present data in three different case– 
control studies support this concept and provide the first data on the association of short 
telomeres with CHD among FH patients.  
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2. LEUKOCYTE TELOMERE LENGTH IN TYPE 2 DIABETES PATIENTS  
 
2.1 INTRODUCTION 
 The first aim of the present thesis included the comparison of telomere 
length between diabetes patients and controls. T2D is also an age-related disease, where 
cell senescence plays a major role in its pathogenesis, and at the same time consists a major 
feature of its complications (Sampson et al. 2006).  
Conditions preceding T2D (like prediabetes and metabolic syndrome) (Hansel et al. 
2004; Su et al. 2008), and the disease itself (Sampson et al. 2006), are characterised by 
increased oxidative stress, and consequent high oxidative DNA damage. The high levels of 
ROS in the above mentioned conditions may be a result of hyperglycaemia which leads to 
an increased input of reducing equivalents into the mitochondrial electron transport chain 
and a consequent higher production of reactive oxygen species (ROS) as byproducts 
(Nishikawa et al. 2000; Brownlee 2001). Moreover, it is likely that in these hyperglycaemic 
conditions the catabolism of glucose is increased leading to an increased production of 
reducing equivalents and thus to a high NADPH-to-NADP ratio which in turn enhances the 
NADPH oxidases activity and the consequent ROS formation (Raddatz et al. 2011). 
Finally, either of the above scenarios in combination with a less effective antioxidant cell 
defence (decreased superoxide dismutase and/or glutathione peroxidase activity) may 
underlie the observed increase in ROS levels in prediabtes, metabolic syndrome or diabetes 
itself. With telomeric DNA being particularly prone to oxidative DNA damage, the high 
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ROS levels in the above conditions presumably lead to accelerated telomere erosion 
(Petersen et al. 1998; Serra et al. 2000).  
Therefore, it is hypothesised that accelerated telomere erosion in conditions 
predisposing to diabetes, eventually leads to extensive and premature senescent phenotypes 
in multiple cell types, including beta cells, the consequent apoptosis of which hastens the 
onset of diabetes.  
The data on T2D and telomere length are scarce, with only a few small studies 
published with up to 80 subjects, showing that T2D patients have shorter telomeres than 
controls (Adaikalakoteswari et al. 2005; Sampson et al. 2006; Uziel et al. 2007). Therefore, 
the aim of this work was to examine the association of telomere length with the presence of 
T2D in a large cohort. 
 
2.2 METHODS 
2.2.1 Subjects 
 University College London Diabetes and Cardiovascular disease Study 
(UDACS): The UDACS is a cross-sectional sample of diabetes patients designed to study 
the association between common genetic variants and biochemical risk factors implicated 
in coronary heart disease (CHD) in patients with diabetes. One thousand and eleven 
subjects were consecutively recruited from the diabetes clinic at University College London 
Hospitals NHS Trust (UCLH) between the years 2001–2. Diabetes was diagnosed 
according to the World Health Organization criteria (Alberti & Zimmet 1998). No subjects 
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requiring renal dialysis were recruited. In the end, the study comprised of 742 T2D and 164 
T1D eligible patients. The sample of T2D included three ethnic groups: Caucasians 
(n=569), South Asians (n=103) and Afro-Caribbeans (n=70), while of the 164 T1D patients 
the 158 were Caucasians. Ethical approval was obtained from UCL /UCL Hospitals ethics 
committee and all subjects gave informed consent. Characteristics of patients were 
originally described by Stephens et al. (Stephens et al. 2004). The principal investigator of 
the UDACS study is Prof Jeffrey Stephens and patients‘ characteristics have been described 
in more detail in the study by Stephens et al. (Stephens et al. 2004). 
 European Atherosclerosis Research Study II (EARS II): The EARSII was 
carried out in 1993. Male students between the ages of 18 and 28 years whose fathers had 
proven MI before the age of 55 (cases, n=407) and age-matched male controls (n=415) 
were recruited from 14 university student populations of 11 European countries and were 
designated in to four regions: Baltic, UK, Middle and South Europe. Only the controls of 
this study were considered in the present chapter. The study has been approved by ethics 
committees of collaborating centres and the subjects have given informed consent. Details 
of the study are described in the ―Third result chapter‖, paragraphs 1.2.1 (page 257).  
Hypercoagulability and Impaired Fibrinolytic function MECHanisms 
predisposing to myocardial infarction (HIFMECH): The HIFMECH study consists of 
598 male survivors of a first myocardial infarction aged <60 years (excluding patients with 
FH and insulin-dependent diabetes mellitus) and 653 population-based control subjects of 
the same age and region recruited from four centers in Europe, designated in to two 
regions: North Europe and South Europe. Only the controls of this study were considered in 
the present chapter. The study has been approved by ethics committees of collaborating 
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centres and the subjects have given informed consent. The study is described in more detail 
in the paragraph ―2.1.2 Methods‖ of the present chapter.  
2.2.3 Measurement of leukocyte telomere length  
Described in paragraph 1.2.3 of the present chapter (page 215) and in detail in the 
―First result chapter‖, paragraphs 1, 2 and 3 (pages 149-174).  
2.2.4 Statistical analysis  
Statistical analysis was performed with SPSS statistical software (version 15.0 for 
Windows). Baseline characteristics were transformed to a normal distribution where 
appropriate. To compare telomere length in T2D and controls, mean values were adjusted 
to an age of 68 years (the mean age in the T2D cases) for all studies. Odds ratios were 
calculated from logistic regression models using telomere length both as a continuous 
variable and after dividing into tertiles. The tertiles of telomere length were constructed 
using the combined case-control group with the age-adjustment made within the separate 
groups. Partial Pearson correlation coefficients were used to examine the association 
between telomere length and continuous classical risk factors after adjustment for age 
(when testing the correlation with age, telomere length was not age-adjusted). Differences 
in telomere length between ethnic groups and categorical characteristics were tested using 
analysis of covariance. All models used to test the difference in telomere length were 
adjusted for age. Results were presented as the geometric mean telomere length (95% CI). 
Statistical significance was taken as p<0.05. 
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2.3 RESULTS 
2.3.1 Study cohorts – Ethnic/geographical diversity 
 UDACS T2D cases: Mean LTL was successfully determined in 742 T2D patients. 
Significant differences were found among the three ethnicities, after adjusting for age 
(p<0.0001). Afro-Carribeans had 510 bp longer mean length compared to Caucasians [7.46 
(95%CI:7.21-7.71) and 6.94 (95%CI:6.80-7.03), p<0.0001, respectively] and 500 bp longer 
than South Asians (6.96 (95%CI: 6.78-7.09), p=0.004), while Caucasians‘ and South 
Asians‘ length did not differ significantly (p=1.00) (Figure 7). Due to these ethnic 
differences, and in order to allow the comparison with the Caucasian controls, only the 569 
Caucasian T2D cases were examined in further analysis. The characteristics of T2D 
patients are typical (Table 3), with a mean age of 68 [24-92] years, a mean age of diabetes 
onset of 55 (13) years and the majority of them (59.4%) being males. The duration of T2D 
diabetes was 9 [4-16] years and their BMI 29.3 (5.5) kg/m
2
. 
EARSII controls: The control subjects from two different studies were employed 
in an effort to cover the large age range of the cases (24-92 years for T2D and 21-80 years 
for T1D patients). LTL was measured in 396 controls from the EARSII study aged between 
18 and 28 years recruited from 4 different European regions. In EARSII (Salpea et al. 
2008) significant differences in telomere length were observed among the geographical 
regions of Europe, as described in the ―Third result chapter‖, paragraph 1.3.2 (page 260). 
Therefore, for the analysis only the 81 UK region controls were used to match the UDACS 
Caucasian patients which have been recruited in the UK (Table 3).   
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HIFMECH controls: LTL was also measured in 520 HIFMECH controls with an 
age range of 40-61 years recruited from the North and the South part of Europe. Again, due 
to the differences in telomere length found between the South and the North [8.27(4.14) kb 
vs. 7.99(4.51) kb, p=0.02) only the analysis of the 367 controls from the North of Europe 
was used, matching to the UK Caucasian cases of UDACS (Table 3). 
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Figure IV-7. Ethnic differences in mean age-adjusted leukocyte telomere length (LTL) of the type 2 diabetes patients. 
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Table IV-3. Characteristics of the Caucasian type 2 diabetes (T2D) cases and controls. 
 
 
UDACS T2D 
cases 
N=569 
EARSII 
controls 
N=81 
HIFMECH 
controls 
N=367 
Age (yrs), median [range]
+
 68 [24-92] 21 [18-28] 53 [40-61] 
T2D onset age(years)** 55 (13)   
Duration of T2D (years)
+
 9 [4-16]   
% Females (N) 40.6 (231) 0 (0) 0 (0) 
% Females >50 yrs (N) 94.4 (218)   
BMI (kg/m
2
)* 29.3 (5.5) 23.0 (2.4) 25.6 (3.1) 
SBP (mmHg)* 140.5 (20.9) 112.6 (9.8) 127.1 (15.3) 
DBP (mmHg)* 79.3 (11.4) 66.0 (7.6) 82.8 (8.0) 
TC (mmol/l)* 4.96 (1.09) 4.06 (0.70) 5.50 (0.96) 
TG (mmol/l)* 1.92 (1.08) 0.93 (0.35) 1.40 (0.60) 
HDL (mmol/l)* 1.28 (0.37) 1.17 (0.20)  
Glucose (mmol/l)* 9.8 (4.3) 5.20 (0.37)  
HBA1c (%)* 7.65 (1.61)   
%Hypertension (N) 83.4 (472) 0 (0) 4.2 (15) 
%Ex/Current smokers (N) 52.3 (291) 38.3 (31) 60.8 (223) 
Hypoglycaemics 
% None (N) 
% Insulin (N) 
% Oral (N) 
% Both (N) 
 
11.2 (63) 
13.1 (74) 
62.6 (353) 
13.1 (74) 
0 (0) 0 (0) 
% Statin use (N) 31.6 (177) 0 (0) 0 (0) 
Unadjusted LTL (kb) ‡ 6.94 (6.80-7.03) 
9.27 (8.86-
9.73) 
7.85 (7.67-8.04) 
 
*data were log-transformed and geometric means [(approximate standard deviation (SD)] 
are presented, ** mean with SD is presented, 
+median [IQR] is presented, ‡ Data were log-
transformed and the geometric means with 95% confidence intervals (95%CI) was then 
used to calculate the corresponding telomere length in kb.  
TC: total cholesterol, BMI: body mass index, SBP: systolic blood pressure, DBP: diastolic 
blood pressure, TG: triglycerides, HDL: high density lipoprotein, LDL: density lipoprotein, 
CRP: C-reactive protein, LTL: leukocyte telomere length. 
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2.3.2 The effect of T2D risk factors on telomere length  
As expected, overall mean telomere length in the T2D diabetes patients showed a 
significant negative correlation with age (r=-0.18, p<0.0001, figure 8). Telomere length 
was therefore age-adjusted in all further analyses.  
 
Figure IV-8. The correlation of telomere length (T/S ratio) with age in Caucasian type 
2 diabetes patients. 
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However, no other classical T2D risk factor was significantly correlated with LTL, 
including BMI, glucose, triglycerides and BMI (Table 4). Moreover, there was no 
significant difference in age-adjusted telomere length between males and females, between 
patients with different smoking history, or between hypertensive and normotensive subjects 
(Table 5). Interestingly, as also shown in Table 5, there was no significant association with 
the age of onset or the duration of diabetes, the use of hypoglycaemic drugs or statins 
(Table 5).  
 
Table IV-4. Partial Pearson correlation coefficients of age-adjusted telomere length 
with classical risk factors in Caucasian type 2 diabetes patients. 
 
 
r p N 
BMI (kg/m
2
) 0.02 0.64 563 
SBP (mmHg) 0.05 0.27 566 
DBP (mmHg) −0.03 0.51 566 
TC (mmol/l) 0.03 0.41 566 
TG (mmol/l) −0.03 0.44 566 
HDL (mmol/l) 0.04 0.40 566 
Glucose (mmol/l) −0.02 0.59 566 
HBA1c (%) 0.01 0.77 563 
 
BMI: body mass index, SBP: systolic blood pressure, DBP: diastolic blood pressure, TC: 
total cholesterol, TG: triglycerides, HDL: high density lipoprotein, LDL: density 
lipoprotein. 
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Table IV-5. Age-adjusted telomere length by sex, smoking, hypertension status, age of 
diabetes onset, duration of diabetes and medication use in Caucasian type 2 diabetes 
patients. 
 
  Telomere length (kb) * P  N 
Sex 
 
Males 
Females 
6.90 (6.8-7.01) 
6.96 (6.84-7.08) 
0.48 
338 
231 
Smokers 
 
Never 
Ex/Current 
6.96 (6.86-7.06) 
6.88 (6.76-7.01) 
0.33 
341 
205 
Hypertension 
 
No 
Yes 
6.88 (6.69-7.07) 
6.94 (6.85-7.02) 
0.58 
96 
470 
Age of onset 
 
<55 
>=55 
6.87 (6.74-7.00) 
6.97 (6.86-7.1) 
0.28 
259 
310 
Duration of diabetes 
 
0-5 
5-10 
10-15 
>15 
6.86 (6.71-7.01) 
6.97 (6.83-7.12) 
6.95 (6.77-7.13) 
6.93 (6.79-7.08) 
0.74 
150 
159 
100 
160 
Hypoglycaemic 
treatment 
 
None 
Insulin 
Oral 
both 
6.88 (6.66-7.12) 
6.86 (6.66-7.08) 
6.93 (6.83-7.03) 
7.01 (6.79-7.23) 
0.79 
63 
74 
353 
74 
Statin use 
 
No 
yes 
6.89 (6.8-6.99) 
7.01 (6.88-7.16) 
0.15 
384 
177 
 
* Data were log-transformed and the geometric mean (95%CI) was then used to calculate 
the corresponding telomere length in kb.  
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2.3.3 Case-Control differences 
The T2D cases [6.94(6.80-7.03)] displayed shorter age-adjusted LTL compared to 
the EARSII [8.27(7.62-9.00), p<0.001] and the HIFMECH controls [7.58(7.39-7.81), 
p<0.001] as well as the two control samples combined [7.72(7.53-7.90), p<0.001] (Figure 
9).  
Decreasing age-adjusted telomere length was associated with a higher odds ratio for 
T2D when comparing the cases to the EARSII controls [2.96(2.16-4.06), p<0.001], the 
HIFMECH controls [1.88(1.58-2.24), p<0.001] and the combined controls [2.38(1.45-
3.89), p<0.001] (Figure 10A). To better illustrate this effect the age-adjusted telomere 
length was divided in tertiles. Subjects in the middle and the lowest tertile of length had 
significantly higher odds ratio for T2D compared to the highest tertile [1.50(1.08-2.07) and 
5.04(3.63-6.99) respectively, p<0.0001], with the effect being more pronounced between 
lowest and highest tertiles (Figure 10B). 
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Figure IV-9. Type 2 diabetes case-control differences in mean age-adjusted leukocyte telomere length (LTL). 
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Figure IV-10. A) The odds ratio of type 2 diabetes for one standard deviation decrease 
in age-adjusted telomere length when comparing the cases with i) the HIFMECH 
controls, ii) the EARSII controls and iii) the combined controls. B) The odds ratio of 
type 2 diabetes for each tertile of age-adjusted telomere length when comparing the 
cases with the combined controls.  
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2.4 DISCUSSION 
 The present study is the largest to date to demonstrate that LTL is significantly 
shorter in T2D compared to controls over a wide age range. T2D patients had on average 
780 bp shorter telomeres than healthy individuals, a difference which represents a 
biological age gap of approximately 24 years. This difference in LTL between T2D cases 
and controls is greater than the previously reported 500bp difference in Caucasians 
(Sampson et al. 2006) but smaller compared to the 3.1 kb difference found in an Asian 
Indian cohort (Adaikalakoteswari et al. 2005). The discrepancy of the effect size on 
telomeres might be due to the small sample size of these other studies but also, in the 
second case, might point to the increased tendency for diabetes in South Asians compared 
to Caucasians (Adaikalakoteswari et al. 2005). Nevertheless, the differences in telomere 
length of diabetes patients and controls, including the one observed here, are much greater 
than the ~300 bp difference reported in other studies between coronary heart disease (CHD) 
patients and controls (Samani et al. 2001; Brouilette et al. 2003; Brouilette et al. 2007; 
Mukherjee et al. 2009). Moreover, in this study decreasing telomere length was associated 
with more than two fold higher risk for T2D. Having telomeres in the middle tertile of 
length was associated with 50% higher odds ratio for T2D, while having telomeres in the 
lowest tertile of length was associated with a fivefold higher odds ratio for T2D. These data 
suggest an important role of biological ageing in diabetes.  
Men have been reported to have shorter telomeres than women of the same age 
(Bekaert et al. 2007). In the present sample, women had longer age-adjusted telomeres than 
men but this difference was not significant, possibly due to the fact that most of these 
women were postmenopausal. An oestrogen-responsive element exists in telomerase, the 
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enzyme that replaces telomeric loss in progenitor cells (Kyo et al. 1999); thus hormonal 
changes may influence telomerase to maintain telomere length in the progenitor cells after 
menopause. 
LTL has been shown to be representative of telomere length in vascular wall cells 
(Wilson et al. 2008) and thus inter-individual differences in LTL probably apply to those of 
other cell types including pancreatic beta cells. Oxidative DNA damage and up-regulated 
DNA repair mechanisms have been observed in beta cell in T2D (Tyrberg et al. 2002), and 
an inverse relationship between beta cell volume density and levels of DNA oxidation 
products has been reported (Sakuraba et al. 2002). My data, coupled with these 
experiments, support the theory that diabetes-related oxidative stress may accelerate local 
and systemic senescence process, as reflected by telomere dynamics.  
A plausible mechanism of the situation in subjects who developed T2D may be that 
hyperglycaemia in the prediabetic state induces high oxidative stress, which in turn causes 
oxidative telomeric DNA damage and consequent shortened telomeres, which eventually 
lead to premature senescence. Evidence supporting the plausibility of this mechanism come 
from the study of Tarry-Adkins et al. who observed short telomeres together with increased 
markers of oxidative stress and cell senescence in beta cells of low birth weight rats (Tarry-
Adkins et al. 2009). This theory is also compatible with the beta cell failure in T2D, and 
also the vascular endothelial and smooth muscle cell senescence which promotes 
atherogenesis in T2D patients.  
Nevertheless, T2D patients‘ LTL was not associated with any classical risk factors, 
including glucose and triglycerides. Possibly the oxidative stress conferred by all risk 
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factors collectively, rather the individual risk factor‘s effect, is responsible for the short 
telomeres found in T2D. On the other hand the short telomeres in T2D subjects could be 
the result of chronic inflammatory responses involved in diabetes development and 
progression (Bekaert et al. 2007). These hypotheses will be investigated in the following 
result chapter (Result Chapter 3). 
Interestingly, measures of diabetes severity such as the age of onset and the duration 
of the disease were not associated with differences in length. However, T2D in most cases 
has a silent onset; therefore the age of onset cannot be defined with precision in contrast to 
other diseases as CHD where specific overt symptoms as stable or unstable angina pectoris 
or myocardial infarction indicate the disease onset. In addition, I believe that duration of 
diabetes is not representative of the severity of diabetes in the present cohort, since it was 
not possible to evaluate whether and for how long glycaemia was effectively controlled 
with treatment. Uziel et al. evaluated arterial and blood mononuclear cell telomere length in 
diabetic patients and found that glycaemic control attenuated the shortening, but in the 
present study it was not possible to examine this (Uziel et al. 2007). A better indicator of 
diabetes severity and worsening is probably the complications of the disease as kidney 
failure, blindness, and cardiovascular disease or the increasing need for hypoglycaemic 
treatment. Indeed, shorter telomeres were significantly associated with higher odds ratio for 
coronary heart disease in the studied patients (see data in next paragraph 2.3). Records on 
other T2D complications were not available.  
Another very interesting finding of the present study is the ethnical diversity in 
telomere length among T2D patients. These data confirm the recent observation of Hunt et 
al. (Hunt et al. 2008) that Africans have longer telomeres than Caucasians, but also show 
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that South Asians have similar telomere length to Caucasians. Hunt et al. showed in their 
study (Hunt et al. 2008) that the rate of age-dependent telomere shortening was faster in 
Africans than in Caucasians. Such evidence supports the theory that Africans are more 
likely to be born with longer telomeres and is in accordance with previously reported 
evidence of a high degree of genetic determination in telomeric length (Graakjaer et al. 
2004). The ethnic differences seen in telomere length though imply an important genetic 
component in its determination. The role of genetic predisposition to shorter telomeres in 
subjects prone to develop diabetes with regard to environmental factors needs further 
investigation.  
 Limitations of this study need to be considered. The absence of data on T2D 
complications other than CHD and increasing need for hypoglycaemic treatment did not 
allow the association of the disease severity and telomere length to be examined. Moreover, 
this study does not include any data on telomere loss over time, as all measurements were 
taken at a certain time point and therefore the rate of telomere attrition in diabetes patients 
could not be addressed. Finally, no definite conclusions can be made on whether the 
observed shorter telomeres in patients are a cause or a consequence of diabetes since this is 
a case-control study.  
 In conclusion, this study showed that T2D is associated with shorter telomeres in 
Caucasians. Thus, telomere length might be of use as a marker of biological age, providing 
a valuable tool in the management of T2D. A prospective evaluation of T2D risk in relation 
to LTL could shed light on the question of whether telomere shortening is a cause or a 
consequence of diabetes, and provide an insight to the potential of using telomere length for 
the risk assessment of T2D development.  
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3. LEUKOCYTE TELOMERE LENGTH IN TYPE 1 DIABTES PATIENTS 
Although, the aetiology of T1D is different to that of T2D, and T1D is not an age-
related disease, in both types beta cell failure is the final trigger. Therefore, if the 
hypothesis that critically short telomeres contribute to the onset of diabetes by eliciting 
senescent phenotypes in beta cells is true, then in T1D patients mean LTL should also be 
shorter compared to healthy subjects. In order to test this hypothesis, LTL was measured in 
the 158 Caucasian T1D cases included in UDACS. The characteristics of the T1D cases are 
shown in table 6. 
For the T1D case-control comparison, both the control samples (EARSII and 
HIFMECH) which were used for the comparison with the T2D cases were also employed in 
order to cover their age range of 21 to 80 years. Also, since the T1D subjects were also 
recruited in London hospitals, the geographical region-matched subjects from EARSII and 
HIFMECH were only used. Thus, age-adjusted LTL was significantly shorter in T1D cases 
[7.12 (6.85-7.35)] compared to the EARSII UK controls [8.27(7.62-9.00), p<0.001] and the 
North region HIFMECH controls [7.58(7.39-7.81), p<0.001], as well as compared to the 
combined control samples [7.72(7.53-7.90), p<0.001] (Figure 11).  
As shown in Figure 10, T1D patients had approximately 500 bp shorter telomeres 
than healthy subjects, a difference which is smaller compared to the difference between 
T2D patients and controls, but in agreement with the difference observed in previous 
smaller studies with T1D (Jeanclos et al. 1998; Uziel et al. 2007). Thus, it can be 
speculated that critically short telomeres may contribute to the onset of both types of 
diabetes by eliciting senescent phenotypes in beta cells. 
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Table IV-6. Characteristics of the Caucasian type 1 diabetes (T1D) cases. 
UDACS T1D cases 
N=158 
Age (years), median [range] 48.9 [21-80] 
Age of T1D onset (years) 23.3 (12.8) 
Duration of T2D (years)
+
 24 [16-33] 
% Females (N) 36.7 (58) 
% Females >50 years (N) 0 
BMI (kg/m
2
)* 26.0 (4.4) 
SBP (mmHg)* 132.9 (16.7) 
DBP (mmHg)* 78.2 (10.6) 
TC (mmol/l)* 5.17 (0.94) 
TG (mmol/l)* 1.05 (0.56) 
HDL (mmol/l)* 1.70 (0.56) 
LDL (mmol/l)
x
 2.85 (0.83) 
CRP (mg/l)* 1.09 (0.89) 
Glucose (mmol/l)* 8.9 (5.8) 
HBA1c (%)* 8.08 (1.33) 
% Hypertension (N) 51.6 (81) 
% Ex/Current smokers (N) 17.8 (28) 
% Insulin use (N) 95.6 (151) 
% Statin use (N) 25.3 (40) 
 
*data were log-transformed and geometric means [(approximate standard deviation (SD)] 
are presented, ** mean with SD is presented, 
X
 data were square root transformed and 
square of mean (approx SD) is presented, 
+
median [IQR] is presented. 
TC: total cholesterol, BMI: body mass index, SBP: systolic blood pressure, DBP: diastolic 
blood pressure, TG: triglycerides, HDL: high density lipoprotein, LDL: density lipoprotein, 
CRP: C-reactive protein, LTL: leukocyte telomere length. 
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Figure IV-11. Type 1 and type 2 diabetes case-control differences in mean age-adjusted leukocyte telomere length (LTL). 
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4 LEUKOCYTE TELOMERE LENGTH IN CO-EXISTENCE OF 
CARDIOVASCULAR DISEASE AND TYPE 2 DIABETES 
Based on the ―common soil‖ hypothesis for CVD and T2D, it is relevant to examine 
whether telomere length partly represents the speculated common abnormalities underlying 
the pathogenesis of these diseases.  
Nevertheless, a very interesting finding, supported by independent studies, is that 
patients with diabetes or prediabetes exhibiting atherosclerotic manifestations have the 
shortest telomeres compared to patients with diabetes or CVD alone. Adaikalakoteswari et 
al. found that among T2D patients those with atherosclerotic plaques had shorter telomeres 
(Adaikalakoteswari et al. 2007). The study of Olivieri et al. showed that T2D patients with 
MI had shorter telomeres than T2D subjects free of MI (Olivieri et al. 2009). 
Among the present T2D patients, there was a trend to higher odds ratio for CHD 
with decreasing telomere length. Compared to subjects in the highest tertile of telomere 
length, those in the lowest tertile of telomere length had an odds ratio for CHD of 1.67 
(1.04-2.69), and those subjects in the middle tertile of telomere length had an odds ratio for 
CHD of 1.33 (0.82-2.16), p=0.03 (Figure 12).  
When the association of telomere length with the presence of diabetes was 
examined among subjects with already developed CHD (i.e. HIFMECH and CABG 
patients), no significant differences were detected. This might be due to a greater tissue 
ageing manifestation in patients with CVD which does not allow the discrimination 
between T2D and non-T2D patients. Nonetheless, Satoh et al. showed that CHD patients 
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with metabolic syndrome had shorter telomeres than CHD patients without metabolic 
syndrome (Satoh et al. 2008).  
 
Figure IV-12. The odds ratio of coronary heart disease for each tertile of age-adjusted 
telomere length among patients with type 2 diabetes. 
 
 
 
In conclusion the above observations, collectively, suggest that substantially 
decreased telomere length, either caused by the common risk factors between CVD and 
diabetes and/or genetic predisposition to short telomeres, possibly reflects greater tissue 
ageing and greater prevalence of senescent phenotypes in various tissues, including the 
vascular wall and pancreatic islets.  
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V. THIRD RESULT CHAPTER: “DETERMINANTS OF SHORT 
TELOMERES IN CARDIOVASCULAR DISEASE AND DIABETES”. 
 
The results of the previous chapter showed that short telomeres characterise CVD 
and T2D. Thus, the aim of this chapter was to examine how these short telomeres arise in 
those predisposed to or already with CVD and/or T2D. Shorter telomeres can be attributed 
to short length inherited at birth and/or high rate of shortening during life. The rate of 
shortening may be determined by the balance between oxidative stress and antioxidant 
defence and the level of consequent telomeric DNA damage. In addition, the rate of 
shortening may be also influenced by sustained inflammatory response possibly through 
enhanced cell turnover. It is important to shed light on the mechanisms leading to short 
telomeres, since they may contribute to the development of age-related diseases such as 
CVD and T2D through their effect on telomeres.  
 
1 ASSOCIATION OF FAMILY HISTORY WITH TELOMERE LENGTH  
1.1 INTRODUCTION 
As described in the ―Introduction‖, paragraph 6.2 (page 94), telomere length is 
documented to have a strong hereditary component (Graakjaer et al. 2004). This may imply 
that the observed short telomeres in CVD and T2D patients can at least be partly attributed 
to inherited short telomeres in those predisposed to premature onset of these diseases. Since 
family history of premature CVD and T2D is a well-established independent risk factor for 
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their development (Barrett-Connor & Khaw 1984; Morris et al. 1989; Myers et al. 1990; 
Evans et al.), this leads to the hypothesis that family history of these diseases may be due to 
a familial predisposition to short telomeres in the offspring, and through this is leading to 
premature development of age-related diseases.  
In order to examine this hypothesis, it was investigated whether family history of 
CHD is associated with shorter LTL in healthy subjects compared to controls of the same 
age and whether this effect is independent of classical risk factors, across Europe. 
Employing the EARS II, LTL was compared between healthy young men with or without 
paternal history of premature MI.   
 
1.2 METHODS 
1.2.1 Subjects 
EARSII: The EARS II was carried out in 1993. Male students between the ages of 18 and 
28 years whose fathers had proven MI before the age of 55 (cases, n=407) and age-matched 
male controls (n=415) were recruited from 14 university student populations from 11 
European countries: Tallinn in Estonia (cases/controls, 32/36), Helsinki (32/33) and Oulu 
(23/23) in Finland were designated Baltic; Glasgow (31/31), Belfast (33/33) and Bristol 
(22/23) were designated United Kingdom (UK); Aarhus in Denmark (30/30), Hamburg in 
Germany (32/32), Ghent in Belgium (32/32), and Zurich in Switzerland (36/36) were 
designated Middle Europe; Lisbon in Portugal (18/18), Reus in Spain (30/33), Naples in 
Italy (30/30), and Athens in Greece (26/25) were designated South Europe. The subjects 
were presumed to have been born in the country where they were studying. Details of 
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lifestyle i.e. smoking, alcohol consumption, medication and physical activity, personal and 
family medical history, and physiological measurements [i.e. height, weight, BP, waist and 
hip circumferences] were established using standardised questionnaires and protocols. BMI 
was calculated as weight/height
2
. The study has been approved by ethics committees of 
collaborating centres and the subjects have given informed consent. The principle 
investigators of this study are listed in Appendix I (page 368).  
1.2.2 Biochemical measurements  
Blood samples were handled according to specified instructions and were sent to 
Nancy (France) for storage. They were then dispatched to the different laboratories for 
specific analyses. The shipment of blood aliquots was done in dry ice. All fasting lipids, 
glucose and insulin were measured after 12-h overnight fasting. Plasma total cholesterol, 
HDL cholesterol and triglycerides were measured in Glasgow, UK according to the Lipid 
Research Clinics Manual of Laboratory Operations standardised to the Centres for Disease 
Control, Atlanta, GA, USA. Blood glucose was measured after protein removal by glucose 
dehydrogenase method and insulin level by radioimmunoassay (RIA). The reliability of 
laboratory performance was assessed by undertaking a repeat blinded analysis of one blood 
sample in every 20. The correlation between the repeated measurements was r>0.95. More 
details on the design of EARS I and II studies are described in the article published by ―The 
EARS Group‖ (Group 1994).  
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1.2.3 Measurement of leukocyte telomere length 
The method is described in paragraph 1.2.3 of the ―Second result chapter‖ (page 
215) and in detail in the ―First result chapter‖, paragraphs 1, 2 and 3 (pages 149-174).  
1.2.4 Statistical analysis 
 Statistical analysis was performed using the SAS statistical software (version 9.1). 
The differences in the clinical characteristics between cases and controls were tested by a 
Chi
2
 test, for lifestyle factors which were categorical, and by a general linear model 
adjusted for age and region, for continuous phenotypes. The mean LTL (T/S ratios), 
triglycerides and homocysteine were not normally distributed (positive skewness), and thus 
log transformed data were used for tests and correlations, while geometric means (95% CI) 
are presented in the tables. Differences in LTL between European regions were tested by a 
general linear model adjusted for age and case-control status. Differences between cases 
and controls in LTL were calculated by a general linear model adjusted for age and region. 
Homogeneity of the case-control difference across regions was tested by introducing the 
corresponding interaction term in the general linear model. Partial Pearson‘s correlation 
coefficients between LTL and continuous classical CHD risk factors, calculated separately 
in cases and controls, were adjusted for age and region. For this purpose, region was 
introduced as 3 dummy variables. Homogeneity of the associations in cases and controls 
was tested by use of a general linear model where the interaction term: ―status X telomere 
length‖, was introduced. Since all interactions were non-significant, cases and controls 
were pooled to calculate partial Pearson‘s correlation coefficients further adjusted for case-
control status. The association between LTL and categorical lifestyle factors (physical 
activity, alcohol and tobacco consumption) were calculated separately in cases and controls 
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by a general linear model adjusted for age and region. After having verified that there was 
no interaction between status and categorical factors, cases and controls were pooled to 
calculate the overall associations further adjusted for case-control status. 
 
1.3 RESULTS 
1.3.1 Study cohort 
 Mean LTL was successfully determined in 369 cases and 396 controls. The cases 
and the controls did not differ significantly in any physiological or lifestyle characteristics. 
Total cholesterol was higher in cases than in controls. No significant differences were 
found in the other biochemical measurements (Table 1).  
1.3.2 Geographical differences 
There was a significant difference in mean LTL across the geographical regions of 
Europe after adjustment for age and paternal history of MI (p<0.0001). Shorter mean length 
was found in the Baltic [7.94 (7.49-8.49)] and South [7.62 (7.21-8.08)] regions and the 
longest in the Middle of Europe [10.28 (9.68-10.97)] (Figure 1, Table 2).  
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Table V-1. Characteristics at recruitment in EARSII cases and controls. 
 
Cases 
(n=369) 
Controls 
(n=396) 
P 
Age (years) 22.7 (0.1) 22.7 (0.1) 0.92 
BMI (kg/m
2
) 23.4 (0.1) 23.3 (0.1) 0.64 
Waist/hip ratio 0.852 (0.002) 0.852 (0.002) 0.99 
SBP (mmHg) 117.4 (0.5) 117.4 (0.5) 0.95 
DBP (mmHg) 73.3 (0.5) 73.1 (0.5) 0.75 
TC (mmol/l) 4.53 (0.04) 4.30 (0.04) <0.001 
HDL (mmol/l) 1.19 (0.01) 1.19 (0.01) 0.98 
TG(mmol/l)
a
 0.91 (0.88 - 0.95) 0.91 (0.87 - 0.94)) 0.72 
Glucose (mmol/l) 5.16 (0.02) 5.17 (0.02) 0.53 
Insulin (mU/l) 10.1 (0.2) 10.6 (0.2) 0.15 
Homocysteine (mol/l)a 10.15 (9.82 - 10.49) 10.31 (9.98 - 10.64) 0.50 
Alcohol consumption 
>median (>8g/day) (%) 
46.9% 42.2% 0.19 
Smokers (%) 26.4% 25.6% 0.80 
Physical activity (%)    
Low 9.9% 8.4%  
Moderate 72.3% 76.3% 0.78 
Heavy 14.8% 15.3%  
 
Means (standard error) after adjustment for age and region are presented.  
a
TG and homocysteine were log-transformed for tests and geometric means (95% CI) are 
presented. 
BMI: body mass index, SBP: systolic blood pressure, DBP: diastolic blood pressure, TC: 
total cholesterol, HDL: high density lipoprotein, TG: triglycerides. 
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Figure V-1. Distribution of leukocyte telomere length in each European region for the combined cohort. 
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Table V-2. Geometric mean (95% CI) of telomere length (T/S ratio) in cases and control across the Europe. 
 
 
Telomere length 
in combined 
cases and control 
Telomere length 
in cases 
Telomere length 
in controls 
P value 
for the case-control 
difference 
Overall 
(369 cases/396 controls) 
8.86 (8.54-9.14) 8.49 (8.13-8.91) 9.04 (8.68-9.50) 0.05 
Baltic 
(85 cases / 88 controls) 
7.94 (7.49-8.49) 6.94 (6.39-7.53) 9.18 (8.36-10.10) <0.0001 
UK 
(69 cases / 81 controls) 
9.64 (8.91-10.42) 10.05 (9.00-11.29) 9.32 (8.45-10.37) 0.27 
Middle 
(121 cases / 122 controls) 
10.28 (9.68-10.97) 10.23 (9.36-11.15) 10.37 (9.55-11.33) 0.82 
South 
(94 cases / 105 controls) 
7.62 (7.21-8.08) 7.58 (6.98-8.22) 7.72 (7.12-8.36) 0.78 
 
Mean T/S ratio for the combined cohort in each region was adjusted for age and paternal history. Mean T/S ratio in cases and 
controls were adjusted for age in each region, and further adjusted for region for the overall results. The geometric means with 
95% confidence intervals (95%CI) of T/S ratios were then used to calculate the corresponding telomere length in kb.  
Tests of homogeneity for the case-control differences among regions: p<0.001. 
P-value for the difference in mean telomere length across regions: p<0.0001. 
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1.3.3 Case-control differences 
Overall, cases had borderline significantly shorter mean length than controls after 
adjusting for age and region [8.49 (8.13-8.91) vs. 9.04 (8.68-9.50)], p=0.05, Table 2). This 
difference corresponds to 550 bp approximately. When each geographical region was 
considered separately, only in Baltic was mean LTL significantly shorter (~2.24 kb) in 
cases compared to controls [6.94 (6.39-7.53) vs. 9.18 (8.36-10.10)], p<0.0001, Table 2).  
The length was cateforised in region-specific quintiles, in order to illustrate the 
length‘s distribution and minimise misclassification. It appeared that the greater difference 
between the percentages of cases and controls was seen in the lowest quintile of length in 
the Baltic region (Figure 2). 
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Figure V-2. Distribution of telomere length in each European region for the cases and the controls. 
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1.3.4 Association of mean telomere length with classical risk factors and paternal age 
at birth. 
LTL was not significantly correlated with age (r=0.01, p=0.79) and this was 
probably due to the very narrow age range (18-28 yrs) of the present young cohort. The 
correlation of LTL with classical risk factors and homocycteine levels was tested here, as in 
all the other study samples used in the present thesis. There was a weak but significant 
positive correlation of LTL with HDL cholesterol (r=0.10, p=0.005) and glucose (r=0.21, 
p=0.0001) levels and also weak but significant negative correlation with waist/hip ratio (r=-
0.09, p=0 .02), and homocysteine concentration (r=-0.10, p=0.01), after adjustment for age, 
region and case-control status (Table 3). These correlations, apart from the one with 
glucose, were not consistent in cases and controls, although for all of them the test of 
homogeneity for the effect in cases and controls was not significant. When adjusted for 
HDL, glucose, waist/hip ratio, and homocysteine levels the association between length and 
case-control status remained highly significant in the Baltic and non-significant in the other 
regions. The significance in the geographical differences did not change after these 
adjustments. No significant association of LTL with smoking, alcohol consumption or 
physical activity was found in cases, controls or the combined cohort (data not shown).  
According to previous studies (De Meyer et al. 2007), paternal age at birth may 
have an effect on the child‘s telomere length. The paternal age at birth was calculated from 
the age of the offspring and the fathers‘ age at recruitment in the control group. There was 
no significant correlation between father‘s age at birth and child‘s LTL (r=0.02, p=0.08, 
Table 3). Such data were insufficient for the cases, since one third of their fathers had 
already died at the time of recruitment.  
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Table V-3. Partial Pearson correlation coefficients of telomere length with classical 
risk factors. 
Risk factors 
r 
in cases 
P 
in cases 
r 
in controls 
P 
in controls 
r 
in cases 
and 
controls 
pooled 
P 
in cases 
and 
controls 
pooled 
Age 0.10 0.06 -0.07 0.14 0.01 0.79 
BMI -0.12 0.02 -0.02 0.69 -0.07 0.05 
Waist/hip ratio -0.08 0.12 -0.11 0.04 -0.09 0.02 
SBP 0.09 0.11 0.04 0.45 0.06 0.12 
DBP -0.03 0.60 -0.03 0.59 -0.04 0.30 
TC -0.07 0.17 -0.04 0.48 -0.05 0.19 
HDL 0.16 0.003 0.05 0.30 0.10 0.005 
TG -0.08 0.16 -0.03 0.62 -0.05 0.19 
Glucose 0.26 <0.001 0.18 0.0004 0.21 <0.001 
Insulin -0.07 0.17 0.06 0.29 -0.02 0.66 
Homocysteine -0.15 0.007 -0.04 0.40 -0.10 0.01 
 
Pearson partial correlation coefficient r was adjusted for age and region and further 
adjusted for case-control status when cases and controls are pooled.  
Tests of homogeneity of the association of telomere length with waist/hip ratio, HDL 
cholesterol, glucose and homocysteine between cases and controls were non-significant. 
BMI: body mass index, SBP: systolic blood pressure, DBP: diastolic blood pressure, TC: 
Total cholesterol HDL: high density lipoprotein, TG: Triglycerides. 
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1.4 DISCUSSION 
 This study demonstrated a borderline significant association of shorter LTL and 
paternal history of premature MI in a large multicentre European study and a highly 
significant association in the Baltic region. Specifically, overall the offspring of premature 
CHD patients had on average ~550 bp shorter telomeres than individuals of the same age 
free of paternal history. This difference is greater than the ~300 bp difference between 
coronary artery disease patients and controls of 42-72 years of age, reported by Samani et 
al. (Samani et al. 2001), or the ~300 bp difference between MI patients and controls of 40-
53 years of age, reported by Brouillete et al. (Brouilette et al. 2003). Although, the effect is 
of modest statistical significance, it is likely that the true size of the effect is larger when 
taking into account that the present cohort consists of young healthy men of a very narrow 
age range (18 to 28 years) having just paternal history as discriminator between cases and 
controls. Moreover, the effect observed here is diluted since only half the genetic 
information of an offspring is inherited from the CHD prone father, with the mother‘s non-
risk telomeres contributing to 50% of the measured length.  
 The present data composed the first documentation of a geographical diversity in 
LTL across Europe. Students from the Baltic countries and the South of Europe had shorter 
telomeres (~7.94 kb and ~7.62 kb respectively) while students from the Middle of Europe 
had the longest (~10.28 kb). A geographical diversity in LTL across Europe was also 
observed in the HIFMECH study. Comparison between the HIFMECH and the EARSII 
sample is difficult considering the broad definition of the geographical regions in these two 
studies. In HIFMECH the South region displayed longer telomeres compared to the North 
region of Europe (see ―Second result chapter‖, paragraph 1.3.4, page 220). Nevertheless, 
269 
 
the region considered as South in HIFMECH lies between the geographical regions 
considered as Middle and South in EARSII, and thus the data appear broadly consistent. 
The association of the length with paternal MI history also displayed a geographical 
diversity. Young men from the Baltic countries whose fathers suffered an early MI had 
~2.24 kb shorter telomeres than men of the same age free of paternal history. This 
difference was highly significant, while this was not the case for the other regions. The 
strong association seen in the Baltic cannot be attributed to particularly short mean length 
in that region, since the length was as short in the South, but rather to greater differences 
between cases and controls. A possible explanation of this discrepancy could be that the 
Baltic population differs genetically from the rest of Europeans. In support of this, the 
frequency of various genetic polymorphisms (e.g. PPARγ Pro12Ala, MTHFR C677T, LPL 
HindIII, LPL S447X) is also different in the Baltic compared to the rest of Europe 
(Gudnason et al. 1998; Humphries et al. 1998; Poirier et al. 2000). The strong association 
of short length with paternal history of MI in the Baltic compared to the rest of Europe may 
also be attributed to the effect of an adverse environment on the LTL of fathers in this 
region.  
 Of the clinical, biochemical and lifestyle risk factors measured, HDL cholesterol 
and glucose were positively correlated with the LTL, while waist/hip ratio and 
homocysteine displayed a negative correlation. Although the correlations with HDL, 
waist/hip ratio and homocysteine were as expected, the correlation with glucose was 
unexpectedly positive. This positive correlation with glucose was consistent in EARSII 
cases and controls and was also observed in the FH subjects examined in the previous 
chapter. The FH and EARSII subjects are younger and with low glucose levels compare to 
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the other study samples, where no correlation between LTL and glucose was detected. Thus 
the observed correlation might reflect a difference in the metabolism of younger subjects 
with normal glucose tolerance. This finding deserves further investigation in additional 
patient and population samples, as well as in vitro experiments. Nevertheless, the 
association of short telomeres and paternal history did not change appreciably after 
adjusting for waist/hip ratio, HDL, glucose and homocysteine levels, indicating that it is not 
mediated by them. Another factor which was shown in previous studies (De Meyer et al. 
2007) to have an effect on the offspring telomere length is paternal age at birth. However, 
no such association was observed in this study, even though the range of paternal age at 
birth was relatively wide (31±12 yrs).  
 So far, the influence of CHD paternal history in the EARS I and II studies was 
mainly expressed in terms of differences in the lipid profile (e.g. cholesterol and 
triglyceride levels) (De Backer et al. 1999; Tiret et al. 2000). The present study 
demonstrates a potential biomarker attributing to the family history-related risk 
independently of biochemical or lifestyle factors. In addition, most candidate gene studies 
with the EARS II sample, apart from the HindIII and S447X variants in the lipoprotein 
lipase gene (LPL), found no differences in genotype frequencies between cases and controls 
(Gudnason et al. 1998; Humphries et al. 1998; De Backer et al. 1999; Poirier et al. 2000). 
Thus, telomere length offers a novel insight into the genetic basis of family history, 
constituting a possible inherited and early expressed risk factor for CHD. 
 Limitations of this study need to be considered. Although other studies have used 
leukocyte DNA to examine the relationship of telomere length with CHD risk (Samani et 
al. 2001; Brouilette et al. 2003; Brouilette et al. 2007), telomeres display tissue-specific 
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lengths and rates of loss, so it is not firmly established whether inter-individual differences 
seen in LTL apply to other cell types and especially the vascular tissue. However it is clear 
that, in comparison to other persons, these who exhibit relatively short or long length in one 
type of a proliferative somatic cell, respectively express relatively short or long telomeres 
in other somatic cells (Martens et al. 1998). A possibility of a certain degree of degradation 
due to storage of the leukocyte DNA for a long period of time should be considered, 
although telomeres are rather stable complexes of GC-rich double stranded DNA and 
should maintain their structure when diluted DNA is frozen. The evaluation of telomere 
length in leukocyte DNA samples stored for as long as the EARSII samples (~14 years) has 
been previously performed in the West of Scotland Primary Prevention Study (WOSCOP) 
study (Group 1992; Brouilette et al. 2007). The estimates of LTL reported in WOSCOP 
were lower in average than those in EARS II, as it would be expected due to the different 
mean age of the two study cohorts. 
 To summarise, the data suggest that, in young men, the biological expression of a 
paternal history of premature CHD, primarily in the Baltic, is at least in part mediated 
through inherited short telomeres, independently of the CHD classical risk factors 
examined. The outcome of the present study, coupled with that of twin studies showing that 
epigenetic/environmental effects on length are relatively minor during life (Graakjaer et al. 
2004), support the theory that in individuals born with relatively short telomeres, vascular 
cells will reach senescence faster and thus they are predisposed to develop atherosclerosis 
prematurely. 
  
272 
 
2 ASSOCIATION OF SYSTEMIC OXIDATIVE STRESS WITH TELOMERE 
LENGTH  
 
2.1 INTRODUCTION 
 The rate of shortening after birth is in part genetically determined, but 
environmental factors, or gene-environment interactions, also exert their effect during life 
(Huda et al. 2007). The factors determining the rate of telomere shortening and the 
underlying mechanisms are not fully elucidated. There is evidence from in vitro studies 
supporting a role of oxidative stress (Petersen et al. 1998; Serra et al. 2000; von Zglinicki 
2000). The high levels of oxidative stress in vivo probably arise from metabolic disorders, 
like obesity, linked to increased nutrient concentration. Increased nutrient availability (e.g. 
glucose and free fatty acids) potentially leads to a higher rate of oxidative phosphorylation 
in the mitochondria and a consequent higher production of reactive oxygen species (ROS) 
as byproducts, and/or to an enhancement of NADPH oxidase-dependent production of 
superoxide. Exposure to free radicals or oxidants causes DNA damage and telomere 
erosion as shown with in vitro experiments (Petersen et al. 1998; Serra et al. 2000; 
Matthews et al. 2006). 
In metabolic disorders, such as insulin resistance and obesity, conditions preceding 
or co-existing with CVD and T2D may result in shorter telomeres in those who develop 
these age-related diseases. In support of this, shorter telomeres have been observed in 
circulating epithelial progenitor cells in patients with metabolic syndrome (Satoh et al. 
2008) and in other conditions of high oxidative stress, such as smoking and obesity (Valdes 
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et al. 2005). The short telomeres could be the molecular mechanism linking the metabolic 
disorders to atherosclerosis, diabetes and premature ageing.  
In order to examine the role of systemic oxidative stress on LTL, I examined 
employed T2D patients, since they are considered to be at high oxidative stress and 
therefore any possible association is more likely to be detected.  
 
2.2 METHODS 
2.2.1 Subjects 
 University College London Diabetes and Cardiovascular disease Study 
(UDACS). For the purpose of this chapter only the T2D Caucasian subjects were 
employed. Due to the ethnic differences in LTL observed in result chapter 2, only the 569 
Caucasian T2D cases were considered in the present analysis. The UDACS sample of 
patients has been described in paragraph 2.2.1 of the ―Second result chapter (page 234).  
2.2.2 Determination of plasma total antioxidant status (TAOS) 
Various methods for measuring total antioxidant status (TAOS) exist and all include 
the generation of a free radical, and the estimation of the antioxidant activity of the test 
sample against this free radical (Erel 2004). In this study, a modification by Sampson of 
Laight‘s photometric microassay (Sampson et al. 2002) was used to measure plasma 
TAOS.  
Plasma TAOS was determined by its capacity to inhibit the peroxidase-mediated 
formation of the 2,2-azino-bis-3-ethylbensthiazoline-6-sulfonic acid radical (ABTS
+
). The 
274 
 
relative inhibition of ABTS
+
 formation in the presence of plasma was proportional to the 
antioxidant capacity of the sample. In each sample, the increase in absorbance at 405nm 
due to the accumulation of ABTS
+
 was measured with the Labsystems Multiscan Ex 
microplate reader. The relative inhibition of ABTS
+
 formation in each patient‘s plasma 
sample was determined according to a control included in all assays. The control consisted 
of PBS instead of plasma. Each assay was performed in a 96 well ELISA plate using 2.5l 
of plasma. Plasma was specifically used instead of serum in these assays, because serum is 
obtained after the clotting of blood at room temperature, and ROS may be released by the 
aggregation of platelets during this process (Leo et al. 1997). The UDACS plasma samples 
were collected within a 12-month period and stored immediately at –80 °C. 
The inter-assay coefficient of variation was 10.5% and the intra-assay 4.3%. These 
figures were derived from repeating the measurement of a single sample 30 times in the 
same assay for the intra-assay coefficient of variation and in 15 different assays for the 
inter-assay coefficient of variation. In order to test whether TAOS is a valid measure of 
oxidative stress, the correlation between plasma TAOS and esterified F2-isoprostane was 
previously examined and found to be significant (r=-0.65; p=0.003) (Stephens et al. 2006). 
Since the measures obtain by the two methods correlate, the inter-individual differences in 
TAOS and/or the correlation to other variables is feasible by using either method.  
In general terms, using this method, increased oxidative stress within a sample is 
negatively correlated with consumption of antioxidants and diminished antioxidant status 
within that sample. 
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2.2.3 Leukocyte telomere length measurement 
The method is described in paragraph 1.2.3 of the ―Second result chapter‖ (page 
215) and in detail in the ―First result chapter‖, paragraphs 1, 2 and 3 (pages 149-174).  
2.2.4 Statistical analysis  
Statistical analysis was performed with SPSS statistical software (version 15.0 for 
Windows). Baseline characteristics were transformed to a normal distribution where 
appropriate. To examine the associations of age-adjusted LTL and glucose with TAOS, the 
Spearman‘s rho correlation coefficient was calculated. Differences in LTL between tertiles 
of TAOS were tested using analysis of covariance. All models used to test the difference in 
LTL were adjusted for age. Partial correlation coefficients were used to examine the 
association of TAOS with continuous classical risk factors. 
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2.3 RESULTS 
There was a significant positive correlation of the mean length with continuous 
TAOS measurements overall (r=0.12, p=0.01, Figure 3) i.e. reduced oxidative stress, as 
reflected by increased TAOS, correlates significantly with longer LTL. To further examine 
the effect on telomeres, TAOS measures were categorised in tertiles. Overall, individuals in 
the low tertile had significantly shorter telomeres compared to those in the middle and the 
high tertile of TAOS (p=0.04) (Table 4 and Figure 4].  
 
Figure V-3. The correlation of age-adjusted telomere length (T/S ratio) with plasma 
total antioxidant status (TAOS) in Caucasian type 2 diabetes patients. 
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Table V-4. Mean leukocyte telomere length (LTL) in tertiles of plasma total 
antioxidant status (TAOS) in Caucasian type 2 diabetes patients. 
 
Tertiles of TAOS 
Number of 
patients(N) 
Age-adjusted 
mean LTL (kb) 
95%CI 
P 
 
Low 186 6.81 6.68-6.94  
Middle 188 6.99 6.9-7.08  
High 187 6.99 6.88-7.1  
Middle & High 375 6.99 6.89-7.09 0.04 
 
 
 
Figure V-4. The mean age-adjusted telomere length in tertiles of plasma total 
antioxidant status (TAOS) measures in Caucasian type 2 diabetes patients. (The error 
bars represent 95% confidence intervals). 
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As already shown previously, low levels of TAOS reflect the burden of metabolic 
disturbances such as low HDL and high TG, glucose and HBA1c (Stephens et al. 2006), 
which are related to prediabetes (or the metabolic syndrome) and diabetes. Specifically, 
TAOS in UDACS patients correlates positively with plasma HDL-cholesterol and 
negatively
 
with TG, glucose, and HbA1c concentrations [r= 0.12, –0.15, –0.11 and –0.10, 
respectively; all
 
p<0.05]. Stepwise backward regression showed that glucose and TG 
concentrations were the strongest independent predictors
 
of plasma TAOS (glucose: p= 
0.004 and TG: p= 0.005). No
 
significant correlations were observed with other risk factors, 
such as BP, smoking status, other lipid measures, CRP, or BMI. 
 
2.4 DISCUSSION 
 The results of this chapter demonstrated that high systemic oxidative stress is 
accompanied by short mean telomere length, at least in peripheral blood cells, suggesting 
that the shorter telomeres in patients can be partially attributed to high oxidative stress.  
 Prediabetes (Su et al. 2008) and diabetes (Orie et al. 2000) are characterised by 
increased oxidative stress, and in the present patient cohort higher glucose and triglyceride 
levels were strongly correlated with lower TAOS, which corresponds to higher plasma 
oxidative status. Plasma TAOS measures the anti-oxidant consumption, which is 
proportional to oxidative stress generation and represents the net effect of many different 
compounds and systemic interactions. A typical example of synergism between 
antioxidants is the ability of glutathione to regenerate ascorbate (Packer et al. 1979), and 
subsequently for ascorbate to regenerate alpha-tocopherol (Stocker et al. 1986). Therefore 
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it is possible that plasma TAOS gives more biologically relevant information than that 
obtained from measuring plasma concentrations of individual antioxidants (e.g. alpha-
tocopherol or ascorbate). Within the described sample no subject was known to take any 
form of vitamin supplements.  
As initially hypothesised, there was a significant correlation between LTL and 
measures of oxidative stress, with higher levels of systemic oxidative stress –measured as 
low TAOS- being associated with shorter telomeres in leukocytes. Thus, the burden of 
oxidative stress conferred by the metabolic disorders related to diabetes seems to partly 
determine telomere length in patients, while the risk factors related to these disorders, such 
as glucose, triglyceride and HBA1c levels did not display individually a significant 
association with LTL (―Second result chapter‖, paragraph 2.3.2, page 241). This 
observation in plasma is likely to be representative of the processes involved in the 
development and progress of T2D in other tissues, such as the pancreatic islets and the 
vascular wall. LTL has been shown to be representative of that in vascular wall cells 
(Wilson et al. 2008), and thus inter-individual differences in LTL probably apply to those 
of other cell types including beta cells. Oxidative DNA damage and up-regulated DNA 
repair mechanisms have been observed in beta cells of T2D subjects (Tyrberg et al. 2002), 
and an inverse relationship between beta cell volume density and levels of DNA oxidation 
products has been reported (Sakuraba et al. 2002). The present data, coupled with these 
experiments, support the theory that hyperglycaemia-induced oxidative stress may 
accelerate local and systemic senescence process, as reflected by telomere dynamics. 
A plausible mechanism of the situation in subjects who developed T2D may be that 
hyperglycaemia induces high oxidative stress, which in turn causes oxidative telomeric 
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DNA damage and consequent shortened telomeres, which eventually lead to premature 
senescence in these cells e.g. pancreatic and vascular wall cells (Figure 5). This theory is 
compatible with the beta cell failure in T2D and also the vascular endothelial and smooth 
muscle cell senescence, which promotes atherogenesis in hyperglycaemic patients.  
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Figure V-5. Proposed mechanism in cardiovascular disease and type 2 diabetes. 
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3. ASSOCIATION OF VARIATION IN GENES REGULATING REACTIVE 
OXYGEN SPECIES WITH TELOMERE LENGTH 
 
3.1 INTRODUCTION 
 In order to further enlighten the effect of ROS on telomere shortening, I also studied 
the effect of functional variants in genes regulating ROS, as well as gene variants 
associated with oxidative-induced DNA repair, in determining LTL.  
Uncoupling protein 2 (UCP2): This ubiquitously expressed protein is a plausible 
negative regulator of ROS production, since it dissipates the inner mitochondrial membrane 
electrochemical gradient that drives ATP synthesis and uncouples respiration from 
oxidative phosphorylation (Casteilla et al. 2001). Decreased UCP2 expression results in 
increased mitochondrial ROS production, in vitro (Duval et al. 2002), while animal studies 
have shown that absence of UCP2 causes higher oxidative stress (Blanc et al. 2003). To 
maintain homeostasis, UCP2 expression is induced by elevated oxygen species 
concentration (Echtay et al. 2002). UCP2 genotype has been associated with T2D and CVD 
development (Dhamrait et al. 2004; Wang et al. 2004). 
A common functional variant exists in the promoter of human UCP2 gene (-
866G>A, rs659366), with the A allele being associated with lower mRNA levels in adipose 
tissue, while a non-synonymous SNP leading to an alanine to valine substitution has been 
indentified in exon 4 of the gene (p.A55V, rs660339) (Wang et al. 2004). A previous study 
from our laboratory, demonstrated that the UCP2-866G>A variant interacts with smoking 
to increase oxidative stress in T2D patients (Stephens et al. 2008). Given this finding and 
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the established function of UCP2, I hypothesised that these functional variants in the UCP2 
gene will be associated with the stress-induced telomeric DNA damage and therefore with 
the telomere length of T2D patients, in whom oxidative stress is elevated.  
Cytochrome b-245 alpha subunit (CYBA): The CYBA gene encodes the alpha 
subunit of cytochrome b-245, which is an essential component of the superoxide-generating 
vascular NADH/NADPH oxidase (Ushio-Fukai et al. 1996). The NADPH oxidase 
(nicotinamide adenine dinucleotide phosphate-oxidase) is a membrane-bound enzyme 
complex, which generates superoxide by transferring electrons from NADPH inside the cell 
across the membrane and coupling these to molecular oxygen to produce the superoxide. 
Antisense CYBA cDNA transfection into rat VSMCs results in decreased cytochrome-b 
content and superoxide production (Ushio-Fukai et al. 1996). With NADPH being a key 
enzyme of superoxide production in the vasculature, the CYBA gene has been implicated in 
the pathogenesis of atherosclerosis (Alexander 1995). There are two important 
polymorphsims in the CYBA gene, one located in the potential heme-binding sites which 
changes histidine at position 72 to tyrosine (c.242C>T or p.H72Y, rs4673) and, another 
located in the 3΄ untranslated region (UTR), the c.24A>G polymorphism (rs1049254). 
There are data suggesting that the T allele of the c.242C>T SNP has a protective effect on 
coronary risk (Inoue et al. 1998), whereas the 3΄ UTR c.24A>G SNP has been associated 
with reduced ROS generation (Bedard et al. 2009).  
Angiotensin I-converting enzyme (ACE): ACE hydrolyses angiotensin I into 
angiotensin II (Ang II), which is a potent vasopressor and also inactivates bradykinin, a 
potent vasodilator. Thus, ACE is widely known for its key role in electrolyte balance and 
blood pressure regulation. Nonetheless, Ang II is a pleiotropic peptide with other important 
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biological roles; it may induce mitochondrial dysfunction, while ACE inhibitors can 
attenuate it (de Cavanagh et al. 2003; Monteiro et al. 2005; Doughan et al. 2008). More 
specifically, the AngII-induced mitochondrial dysfunction was found to be mediated by 
endothelial cell NADPH oxidase activation and consequent production of superoxide and 
peroxynitrite production (Doughan et al. 2008). The ACE gene insertion/deletion (I/D, 
rs4340) polymorphism is a well-known risk factor of CVD and progression of diabetic 
nephropathy. In carriers of allele D, the serum level of Ang II is higher, which is associated 
with increased oxidative stress and subsequent endothelial damage (Molnar et al. 2004). 
Thus, this variant may also affect LTL, through its effect on Ang II levels and in turn on 
mitochondrial ROS production.  
Manganese superoxide dismutase (MNSOD):  Variation in genes encoding 
proteins protecting against ROS could also be expected to influence telomere length. The 
MNSOD enzyme has a primary role in antioxidant defence, since it catalyses the 
dismutation of the superoxide anion (O2−) to hydrogen peroxide (H2O2) (Soerensen et al. 
2009), and is localised in the mitochondria (Slot et al. 1986). The MNSOD gene has a 
c.47T>C SNP (rs4880), which results in a valine to alanine substitution at position 16 
(p.V16A) and is located within the mitochondrial targeting sequence (Rosenblum et al. 
1996). The C allele, which results in the coding of alanine, has been associated with 
decreased mortality (Soerensen et al. 2009). Thus, it is possible that this SNP has also an 
effect on LTL. 
Glutathione peroxidase 1 (GPX1): GPX1 encodes an enzyme which also has a 
major role in antioxidant defence. It catalyses the reduction of H2O2 to H2O and is localised 
both in the mitochondria and the cytoplasm (Esworthy et al. 1997). The c.599C>T 
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(rs1050450), which leads to a proline to leucine substitution at position 200 (p.P200L), has 
been associated with decreased mortality, most likely by affecting the enzyme‘s activity 
(Soerensen et al. 2009). Thus, it is possible that this SNP also affects telomere length, 
through its effect on antioxidant defence, and this way on human survival. 
X-ray repair, complementing defective in Chinese hamster 1 (XRCC1): XRCC1 
repairs single-strand breaks, typical of those induced by ROS and ionizing radiation. This 
enzyme stimulates the DNA kinase and DNA phosphatase activities of human 
polynucleotide kinase at damaged DNA ends, and thereby it accelerates the overall repair 
reaction (Whitehouse et al. 2001). Since telomere loss during replication is also attributed 
to accumulation of oxidative-induced single-strand breaks (as described in the 
―Introduction‖, page 100), enzymes repairing such breaks are likely to have an effect on the 
determination of telomere length. The common functional variant in XRCC1, p.R399Q 
(rs25487), will be investigated here for its effect on LTL.  
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3.2 METHODS 
3.2.1 Study sample 
 The UDACS Caucasian T2D patients (N=569) were genotyped for the eight SNPs 
described above. The Caucasian patients were only employed, due to the significant ethnic 
differences observed in LTL, and in order to use a homogenous population for the gene 
association approach.  
3.2.2 Genotyping  
SNP genotyping is described in detail in the ―General methods‖, paragraph 4.3.2 
(page 127). Briefly, genotyping was carried-out using TaqMan Assay-by-Design platform 
(Applied Biosciences, ABI, Warrington UK). Only in the case of the CYBA A640G SNP 
Assay, which failed the Assay-by-Design By Design  quality control, the manual design by 
Source BioScience LifeSciences was employed. Five µL reactions were performed on 384-
well microplates and analysed using ABI TaqMan 7900HT software.  
3.2.3 Statistical analysis  
Statistical analysis was performed with SPSS statistical software (version 15.0 for 
Windows). Differences in mean LTL between the SNP genotypes were tested using 
analysis of covariance. All models used to test the difference in LTL were adjusted for age. 
In each case of SNP all three possible models (additive, dominant, recessive) were tested 
and the best fitted one was chosen by the higher R
2
 of the test. The differences in TAOS 
among the SNP genotypes were tested with Kruskall-Wallis or Mann-Whitney U tests. A 
nonparametric test for trend was also used to examine these differences. Haplotypes were 
inferred after excluding individuals with missing values using THESIAS 
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(http://www.genecanvas.org). Haplotypes with frequency of less than 2% were excluded 
from the analysis. Results were presented as the geometric mean LTL (95% CI) for two 
copies of each haplotype assuming a multiplicative effect and the mean TAOS (95% CI) 
assuming an additive effect. Statistical significance was taken as p<0.05. 
In the present study specific a priori hypothesis was tested. Therefore I believe 
adjustment for multiple comparisons is not necessary. As described in the article by 
Rothman (Rothman 1990) correction for multiple comparisons is too conservative in 
hypothesis-deriving analysis such as this and has also been suggested to lead to errors in 
interpretation (Perneger 1999). 
 
3.3 RESULTS 
 Among the 569 Caucasian T2D patients, genotype was obtained in 566 (99.5%) for 
the -866 UCP2 G>A SNP, in 544 (95.6%) for the UCP2 p.A55V SNP, in 414 (73%) for the 
CYBA A640G SNP, in 565 (99.3%) for the CYBA p.H72Y SNP, in 561 (98.6%) for the 
ACE I/D variant, in 569 (100%) for the MNSOD p.V16A SNP, 568 (99.8%) for the GPX1 
p.P200L SNP and 555 (97.5%) for the XRCC1 p.R399Q SNP (Table 5). Only in the case of 
CYBA A640G SNP the genotype call rate was low, probably due to the lower quality of a 
manually designed Taqman assay compared to the Assay-by-Design platform used for the 
other SNPs. The genotype distribution for all variants was as expected from Hardy–
Weinberg equilibrium (p>0.05).  
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Table V-5. Age-adjusted leukocyte telomere length and plasma total antioxidant status (TAOS) measures by the different 
SNP genotypes in 569 Caucasian type 2 diabetes patients.  
SNP/haplotype %Genotype/haplotype (N) Telomere length (kb)* P TAOS (%)
+
 P 
UCP2 -866G>A 
(rs659366) 
GG 
GA 
AA 
GA/AA 
 
 
40.8 (231) 
46.5 (263) 
12.7 (72) 
59.2 (335) 
 
 
7.03 (6.91-7.15) 
6.86 (6.75-6.98) 
6.84 (6.63-7.06) 
6.86 (6.76-6.96) 
 
 
0.11 
 
 
0.04 
 
 
45.6 [35.4-54.2] 
44.3 [35.7-51.7] 
42.1 [34.1-48.7] 
43.9 [35.4-50.7] 
 
 
0.20 (0.08 
for trend) 
 
0.17 
UCP2 p.A55V 
(rs660339) 
AA 
AV 
VV 
AV/VV 
 
 
35.5 (193) 
48.4 (263) 
16.2 (88) 
64.5 (351) 
 
 
7.00 (6.86-7.14) 
6.9 (6.79-7.02) 
6.8 (6.62-6.99) 
6.87 (6.78-6.97) 
 
 
0.24 
 
 
0.15 
 
 
45.8 [35.3-54.6] 
44.7 [365.-52.8] 
41.8 [32.1-48.5] 
44 [35.4-50.9] 
 
 
0.05 (0.03 
for trend) 
 
0.20 
UCP2 haplotype: 
-866G>A/p.A55V‡ 
G/A 
G/V 
A/V 
 
 
63.0 
4.0 
33.0 
 
 
6.98 (6.83-7.14) 
6.89 (6.06-7.91) 
6.79 (6.56-7.04) 
 
 
 
0.85 
0.25 
 
 
44.8 [42.4-47.2] 
42.0 [30.1-53.9] 
39.4 [35.6-43.1] 
 
 
 
0.03 
0.65 
CYBA c.640A>G 
(rs1049254) 
AA 
AG 
GG 
 
 
28.0 (116) 
53.4 (221) 
18.6 (77) 
 
 
6.80 (6.66-6.98) 
6.85 (6.71-6.94) 
6.94 (6.71-7.12) 
 
 
0.61 
 
 
 
 
42.2 [34.6-50.2] 
42.8 [33.3-51.6] 
44.5 [37.3-52.8] 
 
 
0.39 
 
 
CYBA p.H72Y 
(rs4673) 
HH 
HY 
YY 
 
 
41.4 (234) 
46.5 (263) 
11.2 (68) 
 
 
6.98 (6.85-7.12) 
6.85 (6.75-6.98) 
6.98 (6.75-7.21) 
 
 
0.28 
 
 
 
 
44.9 [35.9-54.2) 
43.4 [35.1-50.5] 
44.9 [38.6-51.0] 
 
 
0.37 
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CYBA haplotype: 
A640G/H72Y ‡ 
A/H 
A/Y 
G/H 
G/Y 
 
 
40.1 
14.7 
24.5 
20.8 
 
 
6.91 (6.73-7.11) 
6.47 (6.11-6.86) 
6.93 (6.68-7.19) 
6.86 (6.53-7.22) 
 
 
 
0.07 
0.91 
0.81 
 
 
40.5 [37.9-43.1] 
40.6 [35.0-46.2] 
43.6 [39.7-47.5] 
42.6 [37.3-47.9] 
 
 
- 
0.96 
0.26 
0.49 
ACE I/D 
(rs4340) 
II 
ID 
DD 
IΙ/ΙD 
 
 
18.2 (102) 
49.9 (280) 
31.9 (179) 
68.1 (382) 
 
 
7.00 (6.82-7.18) 
6.98 (6.87-7.09) 
6.79 (6.66-6.93) 
6.98 (6.89-7.08) 
 
 
0.07 
 
 
0.02 
 
 
44 [35.9-50.3] 
45.9 [35.4-53.3] 
44 [35.6-51.7] 
45.0 [35.4-53.2] 
 
 
0.58 
 
 
0.41 
MNSOD p.V16A 
(rs4880) 
VV 
VA 
AA 
VV/VA 
 
 
25.5 (145) 
51.0 (290) 
23.5 (134) 
74.5 (424) 
 
 
6.91 (6.76-7.07) 
6.90 (6.79-7.01) 
6.99 (6.84-7.16) 
6.93 (6.84-7.02) 
 
 
0.64 
 
 
0.83 
 
 
42.7 [35.3-51] 
45 [35.4-53.3] 
44.8 [36.2-53] 
44.9 [35.6-53.2] 
 
 
0.63 
 
 
0.35 
GPX1 p.P200L 
(rs1050450) 
PP 
PL 
LL 
PL/LL 
 
 
43.5 (247) 
45.4 (258) 
11.1 (63) 
56.5 (321) 
 
 
6.83 (6.72-6.94) 
7.06 (6.95-7.18) 
6.81 (6.59-7.04) 
7.01 (6.91-7.12) 
 
 
0.01 
 
 
0.02 
 
 
43.5 [33-51.1] 
44.8 [36.2-52.1] 
46.6 [38.6-54.2] 
44.9 [36.6-53] 
 
 
0.17 
 
 
0.17 
XRCC1 p.R399Q 
(rs25487) 
RR 
RQ 
QQ 
RQ/QQ 
 
 
44.1 (245) 
43.6 (242) 
12.3 (68) 
55.9 (310) 
 
 
6.95 (6.84-7.07) 
6.88 (6.77-7.00) 
6.86 (6.65-7.09) 
6.87 (6.78-6.98) 
 
 
 
0.63 
 
0.34 
 
 
44.8 [34.1-53.3] 
43.9 [36.5-51.3] 
45.6 [37.3-53.3] 
44.3 [36.5-51.8] 
 
 
 
0.49 
 
0.59 
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*Data were log-transformed and the geometric mean (95%CI) was then used to calculate the corresponding telomere length in 
kb. 
+median [IQR] is presented. ‡Data is presented for 2 copies of each haplotype. All haplotypes with frequency <2% are 
excluded from the analysis. 
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As shown in table 5 and figure 6, carriers of the UCP2 -866A allele had ~170 bp 
(2.4%) shorter mean length than the GG subjects and there was a trend to lower TAOS 
towards the UCP2 -866A allele carriers. The effect of the UCP2 -866A allele on TAOS 
was statistically significant among smokers of the present cohort, as previously shown by 
Stephens et al. (Stephens et al. 2008). The UCP2 p.A55V amino acid change was 
associated with lower TAOS measures, but the effect on LTL was not significant (Table 5). 
Haplotype analysis using these SNPs in combination failed to detect a statistically 
significant effect on LTL (Table 5). Significant differences were observed with the ACE 
I/D variant; the homozygotes for the D allele had significantly shorter mean LTL compared 
to heterozygotes and wild-type subjects (p=0.02, Table 5). Moreover, significant 
differences in LTL were also detected among the different genotypes of the GPX1 p.P200L 
variant, with carriers of the minor L allele having significantly longer mean LTL compared 
to the wild-type subjects (p=0.02, Table 5). Nonetheless, this association is not considered 
robust, since the rare homozygotes had similar LTL to the wild type homozygotes and the 
heterozygotes had the longest mean LTL. The effect of the GPX1 p.P200L and ACE I/D 
variants on TAOS was not significant (Table 5). Finally, the XRCC1 p.R399Q variant did 
not display any significant effect on LTL. 
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Figure V-6. The mean age-adjusted telomere length in Caucasian type 2 diabetes 
patients carrying or not the UCP2 -866 G>A variant (The error bars represent 95% 
confidence intervals). 
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3.4 DISCUSSION 
In order to examine in more depth the association of telomere length with oxidative 
stress, I evaluated the effect of functional variants in genes involved in ROS generation 
(UCP2, CYBA, ACE) or detoxification (MNSOD, GPX1) and in a gene involved in the 
repair of oxidative DNA damage (XRCC1). This investigation was carried out in T2D 
patients, who are under high oxidative stress, and thus the possible effect of gene variants 
on LTL would be more pronounced. 
Among the genes playing a role in ROS generation, functional variants in UCP2, an 
established negative regulator of mitochondrial ROS overproduction (Casteilla et al. 2001), 
and in ACE, a gene implicated with mitochondrial dysfunction and consequent ROS 
production (de Cavanagh et al. 2010), displayed association with shorter LTL. The data 
showed that those carrying the functional promoter variant -866A of UCP2 have shorter 
telomeres. The minor allele -866A has been previously shown to interact with smoking to 
increase oxidative stress (Stephens et al. 2008). Considering this, and that in the present 
diabetes patients plasma oxidative stress was correlated with shorter LTL, it is likely that 
the observed effect of the A allele on telomeres is due to its association with greater 
mitochondrial ROS production. On the other hand, it is believed that the association of 
UCP2 with T2D is caused by a pancreatic effect of UCP2 on insulin secretion. UCP2 is 
involved in the glucose-induced insulin secretion, through the uncoupling of ATP 
production from glucose metabolism. The uncoupling of the ATP production from glucose 
catabolism reduces the ATP production which in turn results in lower ATP/ADP ratio in 
the pancreatic cell and therefore decreased insulin secretion (Gable et al. 2006). This 
explains the higher risk for diabetes conferred by UCP2 -866A allele (O'Rahilly 2001), 
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while this allele has been associated with higher gene expression in the pancreatic β cells 
(Krempler et al. 2002). Thus, the possibility of UCP2 -866G>A being involved in cell 
senescence in T2D as reflected by the telomere dynamics here, through a pathway triggered 
by disturbed insulin secretion, in addition or not to disturbed regulation of ROS, cannot be 
excluded.  
Similarly to the UCP2 variant, the DD genotype of the ACE gene was also 
associated with shorter LTL. In the case of the ACE gene, since the D allele leads to higher 
Ang II levels and Ang II in turn has been shown to cause mitochondrial dysfunction and 
high oxidative stress (Molnar et al. 2004), it can be inferred that this variant‘s effect on 
telomere length is also mediated through an increased mitochondrial ROS generation. By 
contrast, functional variants in CYBA, the gene encoding a key component of the 
cytoplasmic NADPH-oxidase, did not show any association. Overall, the associations 
observed of UCP2 and ACE variation but not of CYBA variation with LTL or TAOS, 
suggest that the ROS related to telomere damage and shortening are predominantly of 
mitochondrial origin. 
Regarding the genes involved in the antioxidant defence, variation in the GPX1, 
which encodes the enzyme forming water from the potent oxidant H2O2, demonstrated an 
association with LTL, with carriers of the rare allele having longer telomeres compared to 
wild type. This association also supports the hypothesis that genetic predisposition to 
higher oxidative stress is linked with shorter telomeres. The leucine variant of the GPX1 
p.P200L was associated with lower enzyme activity in two previous studies (Bastaki et al. 
2006; Ravn-Haren et al. 2006) and with no difference in activity in another one (Forsberg 
et al. 2000). Hence, the leucine variant possibly holds a slightly lower activity, which 
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seems contradictory to the hypothesis that efficient antioxidant enzyme activity contributes 
to reduced oxidative stress and thus to longer telomeres. However, there is a possibility that 
moderate levels of ROS have beneficial effects on cellular homeostasis (Droge 2002; 
Radak et al. 2008); or that a more active GPX1 enzyme leads to increased OH− levels due 
to decreased levels of reduced glutathione. A delicate balance between the advantageous 
and disadvantageous effects of ROS might exist, and therefore justify the association of the 
low antioxidant activity variant (leucine variant) with longer telomeres observed here and 
with lower mortality observed by Sorensen et al. (Soerensen et al. 2009). It can be 
speculated that the leucine variant‘s beneficial effect on survival (Soerensen et al. 2009) is 
partly mediated by its effect on telomere length. On the other hand, variation in the other 
antioxidant gene, MNSOD, which was also associated with mortality in the study of 
Soerensen et al. (Soerensen et al. 2009), did not show any association with LTL. Thus more 
thorough investigation is needed before any conclusions can be made. 
Apart from a trend, there was not any significant association between the functional 
variants in genes involved in ROS regulation and the plasma antioxidant capacity (TAOS), 
as measured in the present study. Yet again this may be due to the fact that the loss of the 
delicate balance in the levels of various ROS and antioxidant molecules is causing 
telomeric damage, rather than the high levels of any ROS or the low antioxidant defence, as 
estimated by TAOS. Nevertheless, this may also be attributed to the fact that the single, 
cross-sectional evaluation of oxidative stress with TAOS is not representative of the 
accumulated burden of oxidative stress which T2D patients, carrying the respective 
polymorphisms, experience. Therefore, the genetic variants may be more useful in 
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providing a better indicator of the oxidative/antioxidant balance on telomeres, especially 
since genetic variants exert their effect throughout life.  
Finally, oxidative damage at telomeric sequences and consequent telomere 
shortening involves single strand breaks of the telomeric 3‘ overhang. Oxidative DNA 
damage and up-regulated DNA repair mechanisms have been observed in the beta cell in 
T2D (Tyrberg et al. 2002).Therefore, it was reasonable to expect genes, which are involved 
in the repair of oxidative-induced single strand breaks, such as the XRCC1 (Whitehouse et 
al. 2001), to have an effect on telomere length of individuals with high levels of oxidative 
stress, such as T2D patients. However, in the present sample of T2D patients, the functional 
variant in XRCC1 did not have an effect on LTL.  
 The present data overall suggest that shorter telomeres in T2D patients can be partly 
attributed to deregulation of the mitochondrial ROS production and to impaired antioxidant 
defence. In vitro investigation of UCP2, ACE and GPX1 regulation will establish the role of 
these genes in determining the intra-cellular oxygen species levels, the oxidative-induced 
telomere loss and its consequent effect on cell senescence.  
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Figure V-7. Proposed mechanism. 
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4. ASSOCIATION OF SYSTEMIC INFLAMMATION WITH TELOMERE 
LENGTH  
 
4.1 INTRODUCTION 
 Regarding the factors which determine the telomere length and the underlying 
mechanisms of shortening, the evidence presented in the previous chapter coupled with 
those from in vitro studies, support a role of oxidative stress. Nevertheless, chronic 
inflammatory response might also be responsible for the short telomeres in those with 
CVD and T2D. Metabolic disorders, like obesity and insulin resistance, subclinical 
atherosclerosis, as well as overt CVD and T2D, are linked not only to high oxidative 
stress, but also to an underlying chronic inflammatory response and increased secretion 
of pro-inflammatory molecules (Pillarisetti & Saxena 2004; Hulsmans & Holvoet 
2010). These pro-inflammatory cytokines may lead to a higher rate of telomeric loss, 
through the stimulation of a sustained cell turnover (Serrano & Andres 2004), or by 
enhancing the consumption of substrates by the respiratory chain, which in turn leads to 
higher production of ROS as byproducts (Busik et al. 2008).  
The aim of the present chapter was to study the association of circulating 
markers of inflammation with LTL in CVD and T2D patients. The inflammatory 
markers evaluated here are CRP, a non-specific marker of systemic inflammation, 
which has been associated with sub-clinical measure of atherosclerosis and a high risk 
for CHD (Kivimaki et al. 2008) and interleukin-6 (IL6), a circulating pro-inflammatory 
cytokine IL6, which has been associated with higher mortality in epidemiological 
studies (Gouin et al. 2008). 
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4.2 METHODS 
4.2.1 Subjects 
 For this chapter all the study samples used in previous chapters were employed: 
1)  CHD cases and controls from the HIFMECH study (described in the ―Second result 
chapter‖, paragraph 1.2.1, page 212). 
2)  CHD patients from the CABG (described in the ―Second result chapter‖, paragraph 
1.2.1, page 212). 
3)  CHD and non-CHD patients from the FH group (described in the ―Second result 
chapter‖, paragraph 1.2.1, page 212). 
4)  T2D patients from the UDACS study (described in the ―Second result chapter‖, 
paragraph 2.2.1, page 234). 
Analysis in all study samples was restricted to Caucasians in order to maintain ethnic 
homogeneity in the sample. 
4.2.2 Measurement of inflammatory markers 
HIFMECH: Core laboratories performed the biochemical determinations on all 
samples from the entire HIFMECH cohort. CRP was determined with an in-house 
enzyme immunoassay using rabbit antihuman antibodies (X0293) from Dako 
Diagnostics (Ely, Cambs, UK), validated against the International Reference 
Preparation, with an assay range of 0.15 to 48mg/l and with intra-assay and inter-assay 
coefficient of variation (CV) of <10%. IL-6 was measured by 2-site high sensitivity 
enzyme-linked immunosorbent assay (ELISA) (R & D Systems, Oxon, UK) with a 
detection limit of 0.09 pg/ml and intra-assay and inter-assay CVs of 5.3% and 9.2% 
(Yudkin et al. 2004). 
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CABG: Citrated 4.5-mL blood samples were drawn before and after surgery and 
immediately centrifuged (3500g, 10 minutes) in order to separate the plasma and freeze 
it at -20°C until analysis. C-reactive protein was measured on a BN Prospec (Dade 
Behring). Inter-assay and intra-assay coefficients of variation were <4% and <2%, 
respectively, with a detection limit of 0.20 mg/l. IL-6 concentration was measured using 
a commercial assay (R&D Systems) by staff blind to all subject data. Inter-assay and 
intra-assay coefficients of variation were 5% and 3%, respectively, with a detection 
limit of 0.70 pg/ml (Brull et al. 2003). 
FH Simon Broome (SB): A fasting venous blood specimen was taken at the 
registration visit and CRP and IL6 were measured by the laboratories routinely used by 
the participating clinics (Neil et al. 2003).  
UDACS: Blood samples were taken at recruitment and CRP and IL6 was measured at 
the laboratory routinely used by the diabetes clinics at UCL hospital (UCLH). 
4.2.3 Measurement of leukocyte telomere length 
The method is described in paragraph 1.2.3 of the ―Second result chapter‖ (page 
215) and in detail in the ―First result chapter‖, paragraphs 1, 2 and 3 (pages 149-175).  
4.2.4 Statistical analysis  
Statistical analysis was performed using Stata (version 10, StataCorp Texas). 
LTL and CRP and were not normally distributed, thus log-transformed data were used 
for the analysis, and geometric means (approx SD) are presented in the tables. In table 
6, p values comparing cases and controls for different parameters are from conditional 
logistic regression models in HIFMECH taking account of matching on age and centre. 
For the FH study mean values are compared by t-test. Correlations were assessed using 
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Pearson partial correlations to allow adjustment for age and other covariates. 
Adjustment was made for age, centre and exercise in HIFMECH, age in CABG and age 
and gender in FH. 
 
4.3 RESULTS 
Table 6 shows the mean values of the two inflammatory markers in each study 
sample. As expected, the CHD cases have significantly higher levels in both markers 
compared to controls, apart from CRP levels in FH patients with and without CHD. The 
values of both markers are also high in the T2D cases. For the CABG sample, only the 
pre-operative values are presented.  
 
Table V-6. Inflammatory markers in the study samples. 
Study 
sample 
 
Number 
(% 
women) 
Age (years ) CRP (mg/l) 
IL6 
(pg/ml) 
HIFMECH 
CHD controls 559 (0) 51.5 (5.5) 1.23 (1.40) 1.24 (0.78) 
CHD Cases 520 (0) 51.9 (5.4) 2.22 (2.55) 1.97 (1.33) 
p value   <0.0001 <0.0001 
CABG CHD cases 341 (20.8) 64.9 (92.2) 2.29 (2.77) 4.55 (3.12) 
FH - SB 
FH without 
CHD 
222 (56.8) 44.3 (13.4) 1.16 (1.34) 1.58 (1.14) 
FH with 
CHD 
145 (33.8) 56.1 (10.3) 1.42 (1.59) 2.18 (1.34) 
p value <0.0001 <0.0001 0.10 <0.0001 
UDACS T2D cases 569 (40.6) 68 (12.3) 1.72 (1.49) 3.50 (2.50) 
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Table V-7. Partial Pearson correlation coefficients of age-adjusted telomere length 
with inflammatory markers.  
Study sample  
CRP (mg/l) 
(r) 
P 
IL-6 (pg/ml) 
(r) 
P 
HIFMECH 
Controls -0.01 0.77 0.02 0.75 
CHD Cases 0.003 0.95 -0.06 0.25 
CABG CHD cases 0.12 0.03 0.23 <0.001 
FH - SB 
FH without CHD -0.01 0.90 -0.03 0.62 
FH with CHD 0.05 0.34 0.07 0.16 
UDACS T2D cases -0.05 0.21 0.03 0.43 
 
 As shown in table 7, a significant correlation of LTL with pre-operative 
IL6 and CRP levels was observed in CABG patients alone (r=0.23, p<0.0001 and 
r=0.12, p=0.03, respectively). In all other study samples there was no significant 
correlation of LTL with either of the inflammatory markers and LTL. 
 
4.4 DISCUSSION 
In the four studies presented here, no consistent correlation was found between 
LTL and inflammatory markers, such as CRP and IL6, although in the CABG patients, 
a positive correlation of pre-operative IL6 and CRP levels with LTL was found. These 
findings in CABG patients differ from previous studies showing a negative correlation 
of LTL with IL6 levels in a community-based population (Fitzpatrick et al. 2007) and 
multiple myeloma subjects (Wu et al. 2003), and with CRP in haemodialysis patients 
(Carrero et al. 2008) in another community-based sample (Bekaert et al. 2007). 
However, these associations in CABG patients did not persist postoperatively (data not 
shown), and also were not replicated in the other CHD cases examined (HIFMECH and 
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FH). A number of previous studies have also failed to detect a significant correlation of 
LTL with inflammatory markers, such as CRP, in postmenopausal women (Lee et al. 
2005; Aviv et al. 2006), in individuals with diabetes or impaired glucose tolerance 
(Sampson et al. 2006; Adaikalakoteswari et al. 2007; Olivieri et al. 2009), as well as in 
chronic pulmonary disease subjects (Houben et al. 2009).  
One possible explanation of the unexpected positive association of IL6 with 
LTL is that in the preclinical phase of disease, systemic inflammation promotes both 
atherosclerosis and LTL attrition. However, once CHD is established other genetic and 
environmental factors, possibly influencing the activity of telomerase, have greater 
influence in determining the rate of telomere shortening.  
On the other hand, in any particular study, the absence of a significant 
correlation can be due to lack of power resulting from the relatively small sample size. 
Thus, I cannot confirm or refute the reported associations with inflammatory markers, 
although in general, they appear to be relatively weak. Since no robust association of 
inflammatory markers and LTL was observed, further investigation on the effect of 
genes involved in chronic inflammatory response was not performed.  
Whether LTL shortening contributes directly to the progression of CHD or T2D 
at the cellular level cannot be determined from the present results. In vitro work with 
cell cultures being treated with pro-inflammatory molecules may be of help in 
understanding this phenomenon. 
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5. FACTORS DETERMING THE TELOMERE LENGTH CHANGE OVER 
FOLLOW UP 
 
5.1 INTRODUCTION  
The cross-sectional data presented so far in this thesis support an association of 
short LTL with CVD and T2D; also, apart from the genetically determined telomere 
length at birth, the data suggest an age- and oxidative stress-related telomere attrition 
during life time.  
However, a single telomere length assessment leaves unclear whether the 
observed associations are due to shorter length at birth or rather a mere reflection of 
accelerated telomere attrition during lifetime, or else, a combination of both. As 
previously mentioned twin and family studies show that telomere length‘s heritability 
ranges from 44% to 80% (Slagboom et al. 1994; Vasa-Nicotera et al. 2005; Njajou et 
al. 2007). On the other hand, data from studies focusing in older twin pairs indicate that 
non-genetic factors can have significant effects on telomere length during life. The 
lengths between identical twins were found to be almost as similar as between fraternal 
male twins over 70 years old (Huda et al. 2007). Another study has shown that identical 
twins who exercised had longer LTL than the identical twin who did not (Cherkas et al. 
2008), which also suggests a large non-genetic influence.  
Thus, longitudinal studies are required to accurately assess telomere attrition, its 
presumed link with accelerated ageing and its association with oxidative stress and 
inflammation. For this purpose, it was considered of great importance to examine the 
change of LTL over time and the factors determining it. Follow up blood samples were 
obtained for a subset of the UDACS patients and the study of LTL change over time 
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was performed. Identifying modifiable risk factors which influence telomere length over 
time, may lead to novel insights into mechanisms which can delay biological ageing.  
 
5.2 METHODS 
5.2.1 Study sample 
Subjects were a subset of participants in the UDACS study, recruited from the 
diabetes clinic at UCL Hospitals in 2001–2 (described in the ―Second result chapter‖, 
paragraph 2.2.1, page 234). Among these T2D patients, 80 individuals re-attended the 
diabetes clinic at UCL Hospitals in 2008 and therefore participated in the UDACS 
follow up. During the follow up, the patients went through physical examination and 
blood samples were drawn for biochemical analysis and DNA extraction. The collection 
of data and samples from the 80 UDACS individuals in 2008 was performed by Dr 
Nikos Gkranias.  
5.2.2 Leukocyte telomere length measurement 
In this prospective sample of 80 individuals with T2D, mean LTL was measured 
at baseline, and after the seven years of follow up, using the MMQPCR. LTL was 
measured in leukocyte DNA samples from these patients extracted from whole blood 
using the salting out method (Bolla et al. 1995). The TL at baseline and follow up of 
each patient was measured in the same plate to avoid confounding of the LTL change 
(ΔLTL) assessment due to inter-assay variability. Briefly, the new version of the qPCR-
based method, the MMQPCR, differs compared to the original q-PCR in the following 
points: a) Both the SCG and the telomere PCR are concurrently performed in the same 
tube, in order to increase accuracy of the estimation of the copies of the genome and the 
number of telomere repeats in the same sample, b) the SCG employed for this method is 
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the HBB and c) the cycling profile is adapted accordingly for a multiplex qPCR. This 
version of the qPCR method was also validated with samples measured also with TRF. 
The coefficient of inter-assay variation of the method was estimated at 5.22%. The 
method is described in detail in the ―First result chapter‖, paragraph 5, pages 187-210.  
5.2.3 Statistical analysis  
Statistical analysis was performed using Stata (version 10, StataCorp Texas). 
Baseline risk factors were transformed to a normal distribution where appropriate. 
Partial correlation coefficients were used to examine the association of the percentage % 
of change in LTL (% ΔLTL) with selected continuous risk factors. All models for 
baseline LTL included baseline age. Models for change were adjusted for the change in 
age from baseline to follow-up. Adjusted mean changes were obtained from analysis of 
covariance models. ΔLTL was determined as the change in LN transformed values 
which allowed the % ΔLTL to be calculated. Stepwise regression models with change in 
LN (LTL) as the dependent variable were used in order to identify the independent 
predictors of the % ΔLTL over the seven-year follow up. The model was validated 
using 1000 bootstrap samples with the bootstrap inclusion fraction set at 60%. 
Statistical significance was taken as p<0.05. 
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5.3 RESULTS 
5.3.1 Characteristics of T2D patients with follow up  
This subset of UDACS included subjects aged from 35 to 87 years and their 
characteristics were typical for T2D patients (Table 8). The age-adjusted mean LTL of 
this subset of patients at baseline was similar to the mean LTL of the whole UDACS 
(p=0.85).  
 
Table V-8. Characteristics of the total of T2D cases and of the subset participating 
in follow up. 
 
UDACS T2D cases 
 
N=569 
UDACS T2D cases 
with follow-up 
N=81 
P 
Age (yrs)
+
 68 [24-92] 63 [29-82] <0.001 
Age of T2D onset (yrs)** 55 (13) 50 (13) <0.001 
Duration of T2D (years)
+
 9 [4-16] 9 (5-15) 0.99 
% Females (N) 40.6 (231) 37.0 (30) 0.52 
% Females >50 years (N) 94.4 (218) 83.3 (25) 0.01 
BMI (kg/m
2
)* 29.3 (5.5) 29.3 (4.3) 0.98 
SBP (mmHg)* 140.5 (20.9) 138.8 (17.7) 0.30 
DBP (mmHg)* 79.3 (11.4) 80.0 (8.3) 0.36 
TC (mmol/l)* 4.96 (1.09) 4.91 (1.02) 0.62 
TG (mmol/l)* 1.92 (1.08) 1.88 (0.97) 0.77 
HDL (mmol/l)* 1.28 (0.37) 1.27 (0.36) 0.92 
CRP (mg/l)* 1.72 (1.49) 1.81 (1.68) 0.57 
Glucose (mmol/l)* 9.8 (4.3) 10.2 (4.3) 0.61 
HBA1c (%)* 7.65 (1.61) 8.13 (1.54) 0.006 
 
*data were log-transformed and geometric means [(approximate standard deviation 
(SD)] are presented, ** mean with SD is presented, 
+
median [IQR] is presented,  
TC: total cholesterol, BMI: body mass index, SBP: systolic blood pressure, DBP: 
diastolic blood pressure, TG: triglycerides, HDL: high density lipoprotein, LDL: density 
lipoprotein, CRP: C-reactive protein, LTL: leukocyte telomere length. 
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5.3.2 Seven-year change in LTL 
The patients were categorised in three groups according to their % ΔLTL during 
the seven-year follow up. A cut-off of 10% ΔLTL was chosen for the grouping of 
patients, which fell outside the ~5% range of variability expected from the assay (i.e. 
the 5.22% coefficient variation of the MMQPCR method), and also corresponded to 
substantial and, thus more meaningful, changes in LTL. A similar approach has been 
used by other studies assessing the longitudinal change of LTL (Epel et al. 2009; 
Farzaneh-Far et al. 2010). Thus the patients were categorised in the following groups of 
LTL change:  
A) ―Shortened LTL‖ group: Included subjects with % ΔLTL <-10% i.e. greater 
than 10% decrease in LTL. The percentage of subjects in this group was 2.5% (N=2) 
and they displayed a reduction in LTL of 21.59% and 11.78%.  
B) ―Maintained LTL‖ group: Included subjects with % ΔLTL <-10% and <10% 
i.e. a decrease in LTL smaller than 10% or an increase in LTL smaller than 10%. The 
percentage of subjects in this group was 8.8% (N=7). The mean change in LTL was a 
1.42% decrease (Median: -1.42, Inter-quartile range: -3.74 to 2.70). 
C) ―Lengthened LTL‖ group: Included subjects with % ΔLTL >10% i.e. greater 
than 10% increase in LTL. The percentage of subjects in this group was 88.8% (N=71). 
The mean increase in LTL was 54.7% (Median: 54.70, Inter-quartile range: 36.72 to 
81.11). 
5.3.3 Determinants of longitudinal change in LTL 
The % ΔLTL was found to significantly correlate with baseline LTL (r=-0.22 
p=0.05, Table 9 and Figure 8).  
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The association of % ΔLTL with TAOS, CRP, IL6, HBA1c and the change in 
HBA1c and BMI over the follow up was examined by including the change in age from 
baseline to follow-up as a covariate. Baseline LTL was not included, since baseline 
adjustment has been suggested to induce spurious statistical associations between the 
different exposures and the resulting change (Glymour et al. 2005). Among these 
variables, low baseline CRP was significantly correlated with a greater increase in LTL 
(r=-0.32 p=0.005, Table 9 and Figure 9).  
 
Table V-9. Partial correlation coefficients of baseline LTL and % ΔLTL with 
selected risk factors. 
 
 Baseline LTL* % ΔLTL** N 
Baseline LTL 
Baseline IL6 
Baseline CRP 
TAOS 
Change in HBA1c 
Change in BMI 
Duration of diabetes 
 
r=-0.21,  p=0.06 
r=0.04,  p=0.73 
r=-0.08,  p=0.46 
r=0.07,  p=0.55 
r=-0.02,  p=0.86 
r=-0.03,  p=0.80 
r=-0.22,  p=0.05 
r=-0.09,  p=0.41 
r=-0.32,  p=0.005 
r=-0.07,  p=0.53 
r=-0.19,  p=0.11 
r=-0.01,  p=0.94 
r=-0.19,  p=0.10 
80 
78 
78 
80 
77 
80 
80 
 
* The model for baseline LTL includes baseline age.  
**In the model for % ΔLTL the dependent variable is change and includes as a 
covariate the change in age from baseline to follow-up. 
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Figure V-8. Correlation graph of baseline LTL with % ΔLTL (LN change). 
 
 
Figure V-9. Correlation graph of CRP with % ΔLTL (LN change). 
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Then, using a stepwise regression model which also looked at the change in LTL 
only, without adjusting for baseline, we sought to identify any independent predictor/s 
of % ΔLTL. Basleine CRP was found to eb an inpependent predictor of % ΔLTL with 
one SD lower baseline CRP being associated with a 9.8% increase in LTL (p=0.005). 
 
Table V-10. Differences in baseline LTL and % ΔLTL by medication and T2D 
complications. 
 
  Baseline LTL % ΔLTL 
Medication 
Anti-inflammatory 
No (N=13) 
Yes (N=66) 
P value 
 
6.73 (6.45-7.01) 
7.02 (6.88-7.15) 
0.08 
 
81.8 (51.8-117.8) 
50.3 (39.0-62.6) 
0.06 
Anti-cholesterolaemic 
No (N=18) 
Yes (N=62) 
P value 
 
6.9 (6.64-7.17) 
7.0 (6.85-7.14) 
0.56 
 
56.7 (34.3-82.7) 
54.6 (42.4-67.9) 
0.88 
Hypoglycaemic 
No (N=2) 
Yes (N=78) 
P value 
 
6.96 (6.18-7.74) 
6.97 (6.85-7.1) 
0.97 
 
51.5 (-4.0-139.3) 
55.2 (44.2-66.9) 
0.92 
T2D complications 
(i.e. cardiovascular 
event, systemic 
event, nephropathy 
or retinopathy) 
Any T2D complication 
No (N=15) 
Yes (N=65) 
P value 
 
7.32 (6.99-7.64) 
6.9 (6.77-7.03) 
0.02 
 
53.9 (30.2-81.8) 
55.4 (43.4-88.3) 
0.92 
 
For the %ΔLTL, means with 95% confidence intervals (CI) are presented. 
For the baseline LTL, means with 95% confidence intervals are used to calculate the 
corresponding values in kb based on the regression line between measures obtained by 
both the MMQPCR-based method and the conventional TRF analysis for the same set 
of 32 samples, as described in te ―First result chapter‖, paragraph 5.3.3 (page 206).  
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Interestingly, a borderline significant association of the change in LTL over 
follow up with medication was observed, with those under anti-inflammatory drug 
therapy displaying a greater change in LTL compared to those who did not receive any 
ani-inflammatory treatment. The treatment with other groups of medication did not have 
an effect on the follow up change in LTL (Table 10). Nevertheless, information on 
specific drugs was not available. Also, it was considered possible that the change in 
LTL might reflect the worsening of the disease, thus the association with T2D 
complications was tested but no significant differences were found. However, the 
baseline LTL was shorter in the patients who went on to develop T2D complications 
during the follow up period (p=0.02) (Table 10).  
 
5.4 DISCUSSION 
This is the first evaluation of temporal change in LTL, and the factors 
determining it, in individuals with established T2D. The majority of patients, in the 
present longitudinal study, displayed a lengthening of their LTL over the seven-year 
time period. Moreover, short baseline LTL and a low grade of inflammation at baseline 
were found to be independent predictors of LTL lengthening. 
Previous longitudinal studies have also observed lengthening of LTL. In young 
adults of the ―Bogalusa Heart Study‖, a biracial population-based cohort, LTL was 
lengthened in 12% of Caucasians and 14% of African-Americans over the five-year 
follow up (Aviv et al. 2009). In a study of healthy elderly men, telomere lengthening 
was observed in 24% of subjects over 2.5 years (Epel et al. 2009). The ―Heart and Soul 
Study‖ showed that in 23% of individuals with stable CHD participating in the study, 
LTL was lengthened over the five-year follow up (Farzaneh-Far et al. 2010). In the 
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present sample of diabetes patients, a greater percentage (89%) displayed an increase in 
mean LTL. Worthy of remark is that older or diseased study samples display greater 
percentages of LTL lengthening. It is likely that the study samples displaying highest 
percentages of LTL lengthening are those with the shorter LTLs at baseline. This is 
further supported by the consistent association of baseline LTL with its change over 
time in all relevant studies (Aviv et al. 2009; Epel et al. 2009; Farzaneh-Far et al. 
2010).  
The purpose of this chapter was also to reveal the determinants of this temporal 
change in LTL of diabetes patients. Based on the hypothesis that inflammation and 
oxidative stress are the forces driving the rate of telomere change over time, the effect 
of TAOS, an estimate of antioxidant defence, and the effect of the inflammatory 
markers CRP and IL6 was examined. It was also investigated whether duration of 
diabetes, disease worsening or improvement, as reflected by good or not glycaemic 
control, and gain or loss of weight play a role. Glycaemic control in diabetes patients 
has been previously associated with telomere length (Uziel et al. 2007), and is widely 
monitored by the changes in HBA1c (Colman et al. 1997). Finally, the effect of baseline 
LTL was tested, since previous studies have suggested a significant role in predicting 
telomere length trajectory (Aviv et al. 2009; Epel et al. 2009; Farzaneh-Far et al. 2010). 
Among the factors examined, short baseline LTL and low baseline levels of CRP 
showed a significant correlation with the increase in LTL. The low level of 
inflammation at basleine, as reflected by CRP, was found to be the only independent 
predictor of LTL lengthening.  
First, the present data suggest that LTL may increase in patients with T2D, as a 
result of a negative feedback mechanism for the regulation of LTL in humans. This 
mechanism is probably activated in very short telomeres, such as the leukocyte 
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telomeres of T2D patients. The enzyme telomerase, which is active in hematopoietic 
stem and progenitor cells, as well as in peripheral blood leukocytes at low levels 
(Ornish et al. 2008), is a good candidate for mediating this mechanism. The change in 
LTL over time is proportional to the baseline both in individuals who display shortening 
and lengthening. Regarding the proportional shortening of long telomeres, Aviv et al. 
propose that oxidative stress might be the driving force, since longer telomeres contain 
more G triplets, which are the targets of free radicals (Aviv et al. 2009). However, the 
proportional lengthening, observed mainly in the present study, cannot be explained by 
the same mechanism. It can be attributed either to telomerase activation at a very short 
telomere length, or to the regeneration of blood cells from haematopoietic cells. The 
addition of new blood cells generated from the stem cell pools, which preserve their 
mean LTL through an active telomerase, could be the reason for the increase in mean 
telomere length of blood cells during the follow up period (Aviv et al. 2009).  
Second, in the present study, the low grade of inflammation was the independent 
predictor of the lengthening of telomeres in diabetes patients, implying that 
inflammatory molecules are detrimental to the telomere length regulation. Alternatively, 
it can be speculated that high levels of inflammation at baseline have already caused 
exhaustion of stem cell reserves.  
Whereas CRP was observed to have an influence on the change of LTL did not 
also display significant correlation with the cross-sectional measurement of LTL at 
baseline. This finding suggest that epidemiology of the longitudinal telomere dynamics 
is different to epidemiology of cross-sectional telomere length estimations (Farzaneh-
Far et al. 2010). Presumably, the single time point measurements reflect the lifelong 
effect of environmental factors in combination with the genetic effect, while telomere 
length trajectory is mainly driven by a negative feedback mechanism for protection of 
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very short telomeres, or the rate of stem cell turnover during that certain period of time. 
In support of this is also the association of short baseline LTL, and not of the relative 
change in LTL, with the development of T2D complications during the follow up.  
Finally, the use of anti-cholesterolaemic or hypoglycaemic was not associated 
with the LTL increase observed in the present T2D patients, while anti-inflammatory 
treatment was marginally associated with those under treatment showing a smaller 
increase in LTL. Possibly the patients prescribed anti-inflammatory drugs were those 
more severly diseased and/or with higher CRP levels at baseline. However, This 
association should be interpreted with caution, since no information was available on 
the specific drugs or their effectiveness. Moreover, the possibility that a class of drugs 
has a beneficial effect on LTL change, as previously suggested for statins 
(Spyridopoulos et al. 2004; Mahmoudi et al. 2008; Satoh et al. 2009), cannot be 
excluded based on the present data, since only groups of drugs were examined and may 
any drug-sepcfic effect may have been diluted.  
Limitations of this study need to be considered. The small sample size of 80 
subjects, the lack of comparison with longitudinal data in controls or patients free of 
medication question the reliability of the findings of the present study, especially 
regarding the factors determining the change in LTL,. Unfortunately, data on several 
key factors, such as oxidative stress measures, inflammatory markers and drug use, 
were missing at follow up and this limited the ability to identify all the possible factors 
determining the longitudinal LTL change. On the other hand the fact that the majority of 
patients displayed a considerable lengthening of LTL and that both the baseline and the 
follow up samples were measured in the same assays, avoiding bias due to inter-assay 
variability, offer robustness to the observation of LTL lengthening in T2D patients 
under treatment.  
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In conclusion, the present observations suggest a bidirectional regulation of 
telomere length, and raise the possibility to reverse telomere-dependent ageing. Also, 
this study raises the potential for LTL to prove useful as a marker for disease 
improvement. Thus the factors governing telomere dynamics during lifetime deserve 
further study. 
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VI. FOURTH RESULT CHAPTER: “IN VITRO INVESTIGATION OF THE 
DETERMINANTS OF TELOMERE LENGTH DURING AGING” 
 
1. THE EFFECT OF PRO-INFLAMMATORY CONDITIONING AND/OR 
HIGH GLUCOSE ON TELOMERE SHORTENING OF AGING FIBROBLASTS 
 
1.1 INTRODUCTION 
The studies included in the previous chapter aimed at elucidating the 
determinants of short telomeres in patients with CVD and T2D. It was shown that 
shorter telomeres, at least in T2D patients, can be partly attributed to mitochondrial 
production of ROS and impaired antioxidant defence. However, glucose displayed an 
unexpected positive correlation with LTL in the EARSII and FH subjects, which is in 
contrast to the hypothesis that hyperglycaemia elicits the high levels of ROS that may 
cause telomere shortening. Moreover, whether inflammation contributes to the shorter 
telomeres in CHD or T2D patients was not determined by the cross-sectional data of the 
previous chapter. Whereas, follow up analysis suggested that low grade of inflammation 
may favor the lengthening of telomeres, in diabetes patients, implying that 
inflammatory molecules are unfavorable to telomere length maintenance. In order to 
shed more light on these mechanisms, I decided to carry out in vitro experiments 
investigating what CVD/T2D risk factors determine telomere shortening during aging at 
the cellular level.  
My hypothesis was that factors having an effect on telomeres may be arising 
from metabolic disorders, linked to increased nutrient concentration, or chronic 
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inflammation. Increased nutrient availability (e.g. glucose) potentially leads to a higher 
rate of oxidative phosphorylation in the mitochondria and/or a consequent higher 
production of reactive oxygen species (ROS) as byproducts. Also, an increased 
catabolism of these nutrients is likely to lead to an increase of the NADPH-to-NADP 
ratio and a consequent enhancement of NADPH oxidase-dependent production of 
superoxide. The high levels of ROS are known to cause oxidative DNA damage, and 
therefore to result in greater loss of telomeric sequences during replication as shown in 
vitro (Petersen et al. 1998; Serra et al. 2000; von Zglinicki 2000). Nevertheless, the data 
on whether hyperglycaemia elicits an increase in intracellular ROS production are 
conflicting, with other studies supporting the gucose-induced increase in ROS 
generation  (Nishikawa et al. 2000; Piconi et al. 2006; Morgan et al. 2007) and others 
which argue that this is true under all circumstances (Martens et al. 2005; Busik et al. 
2008).  
Pro-inflammatory cytokines may lead to a higher rate of telomeric loss through 
the stimulation of a sustained cell turnover, or through an enhancement of substrate 
consumption by the respiratory chain, which in turn leads to higher production of ROS 
as byproducts. Interestingly, Busik et al. have shown that high glucose alone may not 
result an augmentation of ROS production, whereas the pro-inflammatory cytokine 
IL1B may trigger higher glucose consumption by the respiratory chain, and thus to an 
enhancement of ROS production (Busik et al. 2008).  
 Therefore, my aim was to examine whether high concentration of a basic 
mitochondrial substrate, such as glucose, and/or pro-inflammatory conditioning with 
IL1B, cause greater telomere erosion in a well described in vitro model of replicative 
senescence (i.e. telomerase is not expressed), the human skin fibroblast (Goldstein 
1990). Interleukin 1 beta (IL1B) was chosen based on its regulatory role in the 
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atherosclerotic process (Galea et al. 1996) and its implication in the failure of β-cells 
during diabetes development (Maedler et al. 2009) but also on the experiment of Busik 
et al. (Busik et al. 2008) which showed that IL1B may enhance ROS production. For 
the in vitro modelling of oxidative stress, an inhibitor of γ-glutamyl cysteine synthase, 
buthionine sulphoximine (BSO), was employed (Kurz et al. 2004); γ-glutamyl cysteine 
synthase is a key enzyme of the glutathione redox-cycle, which is part of the  
intracellular machinery for peroxide detoxification (Griffith & Meister 1979). The 
number of copies of mitochondrial DNA per cell was investigated in parallel, since it 
has been suggested to increase with oxidative stress (Lee et al. 2000) and respiratory-
function decline during aging (Ames et al. 1995). 
 
1.2 METHODS 
1.2.1 Cell culture 
 Materials: Normal Human Dermal Fibroblasts (NHDF) from juvenile foreskin, 
fibroblast growth medium lacking ascorbic acid (FGM –AA) and fibroblast detach kit 
were purchased from PromoCell GmbH (Heidelberg, Germany). L-buthionine-[S,R]-
sulphoximine (BSO) and L-glucose were from Sigma-Aldrich (Steinheim, Germany). 
IL1B was purchased from Peprotech (London, UK) and D-glucose from Peprotech 
(London, UK). 
 Procedure: First passage cryopreserved NHDF from four genetically distinct 
donors were grown in FGM –AA for 13 days (up to passage 4). The growth medium 
was especially made without ascorbic acid, in order to exclude the antioxidant effect of 
ascorbic acid on the pro-oxidant effect of the treatments applied subsequently in the 
present experiment. The donors were 3, 14, 2 and 2 years old. For each donor six 
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independent cultures were initiated and serially passaged under different conditions for 
90 days. The six different conditions were: 1) FGM –AA only (control), 2) FGM –AA + 
10 μM BSO (pro-oxidant treatment), 3) FGM –AA + 25mM D-glucose (high glucose 
treatment), 4) FGM –AA + 1ng/ml IL1B (pro-inflammatory conditioning), 5) FGM –
AA + 25mM D-glucose + 1ng/ml IL1B (combination). In addition a culture from each 
donor was treated with FGM –AA + 25mM L-glucose in order to control for any 
osmotic effect caused to cells by the high concentration in medium. The medium 
containing each treatment was changed every three days. The number of population 
doubling (PD) was calculated using the formula PD = [ln(number of cells harvested) – 
ln(number of cells seeded)] / ln2 and the cumulative PD (CPD) by progressively adding 
the PD in each passage.  
1.2.2 Telomere length measurement 
 At each passage a sample of the cells harvested from each culture was used for total 
DNA extraction with the PUREGENE DNA kit (Qiagen, West Sussex, UK). The 
extracted DNA samples were frozen at −20° C until measurement, without repeated 
freeze–thawing cycles. Mean telomere length was measured in these DNA samples 
using the validated quantitative PCR-based method as described in the ―First result 
chapter‖, paragraph 1, 2 and 3 (pages 149-175).  
1.2.3 Mitochondrial DNA (mtDNA) copy number measurement 
 The DNA samples extracted, as described above from each culture at each passage, 
were also used for the estimation of the copy number of mtDNA per nucleus, which is 
representative of the mitochondria number per cell. For this purpose, I set up a 
quantitative PCR-based method previously described by Xing et al. (Xing et al. 2008) 
for the first time in our lab. The method was validated before applied in the present 
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experiment. The relative number of mtDNA copies per genomic DNA copies (M/G 
ratio) was calculated as the ratio of the mitochondrial subunit 1 (MTND1) gene copies 
to the genomic 36B4 (now called RLP0) gene copies. These genes are single copy genes 
for the mtDNA and the genomic DNA respectively. The number of mtDNA copies and 
genomic DNA copies in each sample was determined in comparison to a reference 
sample in a MTND1 and a 36B4 quantitative PCR, respectively. All PCRs were 
performed on the Rotor-Gene 6000 (Corbett Research Ltd, Cambridge UK). The 
relative concentrations of PCR products were estimated using the comparative 
quantification analysis (Rotor-Gene 6000 software, Corbett Research Ltd, Cambridge, 
UK). The second derivative of the amplification curve was considered in order to 
identify the peak of the exponential amplification and determine the Take-Off of the 
reaction. The Take-Off was estimated by finding the first point to be 80% below the 
peak level. Based on the Take-Off point and the amplification, the software calculated 
the relative quantity of MTND1 and 36B4 copies in each sample compared to the 
reference sample. The same reference DNA was used in all runs to allow comparison of 
the results in different runs. The MTND1 and the 36B4 PCRs for each sample were 
performed in duplicate in the same run in order to increase accuracy. The specificity of 
all amplifications was determined by melting curve analysis. 
 The primers, used for the MTND1 amplification, were: MTND1 forward: 5′-
TGGGTACAATGAGGAGTAGG-3′, MTND1 reverse: 5′-
GGAGTAATCCAGGTCGGT-3′ at a 215nM concentration and for the 36B4 these 
were: 36B4 forward: 5΄-CCCTAAAACCCGCCACATCT-3΄, 36B4 reverse: 5΄-
GAGCGATGGTGAGAGCTAAGGT-3΄ at a 300/500nM (forward/reverse) 
concentration. For both PCRs the cycling profile was 95
o
C incubation for 10min, 
followed by 34 cycles of 95
o
C for 15sec and 58
o
C for 60sec and the final reaction 
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consisted of 1xqPCR mix (2x SensiMix NoRef DNA kit, Quantace, London, UK), 30ng 
of template and the respective primer concentrations at a 25μl total volume.  
 A dilution series (1.25 ng/μl - 80 ng/μl, two-fold dilution, seven points) was run 
after optimization for both the MTND1 and 36B4 PCRs. For both assays, linearity 
(R
2
>0.99) over this range of input DNA and 100% efficiency was observed (Figure 1 A 
and B). 
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Figure VI-1. A) Mitochondrial single copy gene (MTND1) PCR standard curve. B) Genomic single copy gene (36B4) PCR standard 
curve. 
 
A) 
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B) 
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 In order to test the reproducibility of the method, 16 randomly chosen samples were 
run in duplicate on two consecutive days. There was significant linearity between the 
measurements obtained on the two different days in linear regression analysis (R
2
=0.52, 
p=0.002, Figure 2). Moreover, the reproducibility was also assessed with Spearman‘s 
non-parametric test of pair-wise correlation that looks at the ranking of each sample. 
The correlation of the mtDNA copy number ranking as measured on the two different 
days was significant (Spearman rho coefficient= 0.69, p=0.003). The coefficient of 
inter-assay variation in repeated measurements was 7.4%.  
 
Figure VI-2. Linear regression between messurements of mtDNA copy number 
measurement with the quantitative PCR in 16 samples acquired on two 
consecutive days (R
2
=0.52, p=0.002). 
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1.2.4 Quantification of apoptosis 
 The Annexin-V-FLUOS Staining Kit (Roche Diagnostics GmbH, Penzberg, 
Germany) was employed for the quantification of apoptosis, and differentiation from 
necrosis, as described in the ―General Methods‖, paragraph 6.3 (page 138). NHDF cells 
from donors 1 and 2 were treated for seven days under the conditions indicated above. 
A sample from the cells harvested from each culture was stained with Annexin V-
Fluorescein and/or PI. The samples were then analysed on the FACSCalibur (Becton-
Dickinson).  
1.2.5 Measurement of intracellular ROS content  
 The ROS detection reagent, H2DCFDA (Molecular Probes, Invitrogen, Oregon, 
USA), was applied for the measurement of intracellular ROS content, as described in 
the ―General Methods‖, paragraph 6.4 (page 142). NHDF cells were treated for seven 
days under the conditions indicated above. A sample from the cells harvested from each 
clture was stained with H2DCFDA. The samples were then analysed on the 
FACSCalibur (Becton-Dickinson). Apoptotic and/or necrotic cells, as detected with 
Annexin-V/PI staining, were excluded from the estimation of ROS content.  
 
1.2.6 Gene expression assays 
 Total RNA was extracted using the RNeasy Mini Kit 250 (Qiagen, West Sussex, 
UK), as described in the ―General Methods‖, paragraph 3 (page 115), from samples of 
each culture before treatment and at two time points during treatment (after six and 45 
days of treatment). cDNA was synthesised using the Superscript III Reverse 
Transcriptase (Invitrogen, Paisley, UK), as described in General Methods (page 116). 
The level of expression of the telomere reverse transcriptase (TERT) and the 
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mitochondrial transcription factor A (TFAM) genes were estimated using TaqMan 
technology, described in the ―General Mehtods‖, paragraph 4.3.1 (page 126), using the 
respective probes:: TERT (Hs01082775_m1) and TFAM (Hs00162669_m1), Applied 
Biosystems, Cheshire, UK. The qPCR reactions were performed on the ABI prism 
7900HT sequences detection system (Applied Biosystems, Cheshire, UK), in triplicate, 
and the results were analysed with the S.D.S.2.1 Applied Biosystems software for 
relative quantification. The BestKeeper software (Pfaffl et al. 2004) was used to test the 
suitability of the three housekeeping genes. The relative expression ratio of the target 
genes was estimated after standardisation with the three house-keeping, using the REST 
software as previously described (Pfaffl et al. 2002) (Web appendix 2). 
1.2.7 Statistical analysis 
 Statistical analysis was performed with SPSS statistical software (version 17.0 for 
Windows). Telomere length and mtDNA copy number were log-transformed (natural 
log) to a normal distribution. The differences in CPD, telomere length and mtDNA copy 
number among the cultures generated from the four different donors were tested with 
univariate analysis of variance using the pooled data and adjusting for treatment. The 
data from the four independent experiments, generated from the four donors, were 
analysed pooled after adjusting for donor as well as on a per donor basis. The 
association of the days of treatment with telomere length and mtDNA copy number as 
well as the association of CPD with telomere length and mtDNA copy number were 
evaluated using partial correlation coefficients controlling for donor. To assess the 
effect of each treatment on the telomere length change over time, I used a linear 
regression model with telomere length as the dependent variable and the days of 
treatment, the donors and the different treatments as the independent variables. The 
treatments were introduced in the model as dummy variables by leaving out of the 
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model the dummy variable corresponding to the control. This was done in order to force 
the comparison of each treatment to the control, since this was my hypothesis. The same 
model with the CPD or the mtDNA as independent variables was used to test the effect 
of the treatments on the growth rate (i.e. the CPD change over time) or the change of the 
mtDNA copy number over time, respectively. In order to examine the effect on 
telomere length or the mtDNA copy number of each treatment compared to the control 
adjusting for the CPD, I used the respective linear regression models as described 
above, by replacing the days of treatment with the CPD in the list of independent 
variables. The p values from the comparison of each treatment with the control were 
obtained from the multivariable regression models described above. The percentages of 
change in telomere length and mtDNA per day or PD, as well as the PD per day 
presented, were obtained from separate analysis for each treatment regression model 
adjusted for donor. Statistical significance was taken as p<0.05. Regarding the 
comparisons between the percentages of apoptotic and necrotic cells, as well as the 
intracellular ROS content of each treatment with the control, non parametric tests were 
used due to the small number of measurements. The Kruskal-Wallis test was used for 
comparisons among all treatments and the Mann-Whitney test for the comparison of 
each treatment with the control. The relevant data are presented as median with inter-
quartile range (IQR) of the measurements from different donors in each of the two 
independent experiments performed. 
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1.3 RESULTS 
1.3.1 General characteristics of cultures 
 Fibroblasts were serially passaged for approximately 90 days. The general 
morphology of fibroblasts in cultures was that of elongated spindle-shaped cells having 
a branched cytoplasm, which is a normal morphology for skin fibroblasts. This normal 
morphology was retained in all cultures for the time course of 90 days. Also, no osmotic 
effect was observed in cultures treated with L-glucose compared to the control cultures.  
Figure 3 shows pictures of the fibroblast cultures, after 62 days of treatment in each of 
the experimental conditions, taken with a ―Zeiss Axioshop 2‖ microscope. One of the 
cultures generated from donor 4, which was treated with the combination of high 
glucose and IL1B, was contaminated at day 25 of the culture period, thus the 
measurements from this culture were discarded from all analyses.  
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Figure VI-3. Microscope pictures of cultures, after 62 days of treatment in each of the experimental conditions. 
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1.3.2 Growth rate 
 The cultures from the four different donors displayed significantly different growth rate, 
as reflected by the number of cumulative population doublings (CPD) (p=0.04) occurring 
during the course of the experiment. The rate of growth was also significantly different 
among cultures with different treatments (p=0.001), after adjusting for donor. A lower growth 
rate was observed in cultures treated with high glucose and BSO compared to the control 
[Glucose: 0.14 PD/day, p<0.001 and BSO: 0.11 PD/day, p=0.006 vs. Control: 0.16 PD/day], 
whereas, cultures treated with IL1B displayed a marginally higher cell turnover compared to 
the control [IL1B: 0.19 PD/day, p=0.093 vs. Control: 0.16 PD/day] (Figure 4A and Table 1). 
 Similar results were observed when growth curves were plotted separately and the effect 
of the treatments was compared on a donor per donor basis, as shown in Figure 4B. More 
specifically, the growth rate under IL1B treatment was significantly higher compared to 
control in two out of four donors (donor 1: p=0.03 and donor 4: p=0.09). BSO treatment 
caused a significantly lower growth rate compared to the control in three out of four donors 
(donor 1: p<0.001, donor 2: p<0.001 and donor 3 p=0.03) and high glucose in one out of four 
donors (donor 1: p=0.05). The relatively low rates of growth measured (5 to 10 days were 
needed for a whole PD to occur) is probably due to the fact that the flasks used for the 
cultures had a very large surface and thus longer time was needed for them to become 
confluent. Whereas, typically, cultures are grown in 75 cm
2
 or 150 cm
2
 flasks, the largest 
commercially available flasks of 225 cm
2 
were used in this experiment
 
due to the need to 
harvest a large number of cells in each passage for the various measurements carried out. 
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Figure VI-4. The cumulative population doublings (CPD) over the time of culture in each treatment (growth rate). A) In pooled 
data from all four donors, B) In each of the four donors separately. 
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1.3.3 Telomere length 
 As expected, mean telomere length displayed a strong negative correlation with the 
number of days of culture (r= -0.65, p< 0.001) and the CPD (r= -0.59, p< 0.001) when 
the data from all treatments were pooled. Mean telomere length differed significantly 
between the cell cultures from the four different donors (p= 0.008). After adjusting for 
donor, the rate of telomere shortening over the time of treatment was significantly 
higher in cells treated with IL1B compared to the control [IL1B: -0.8%/day (95%CI:-
1.1, -0.5) vs. Control: -0.6%/day (95%CI:-0.8, -0.3), p=0.012] (Figure 5 and Table 1). 
No significant differences were found with the other treatments compared to control. 
 The effect of the treatments on telomere length was also compared on a donor per 
donor basis, and the observed results were similar to the pooled data analysis. A 
significanlty higher rate of telomere shortening was observed in cultures treated with 
IL1B in two out of the four donors (donor 1: p=0.05, donor 3: p=0.01). Nevertheless, as 
shown in Figure 5B where the curves of telomere shortening are plotted separately for 
each donor, the cultures treated with IL1B displayed an accelerated telomere shortening 
in all donors. Also the combination of treatment with high glucose and IL1B caused a 
higher rate of telomere shortening compared to the control in donors 1, 3 and 4, which 
reached the level of significance only in donor 1 (p=0.06). 
 In order to examine whether the effect of each treatment on telomere shortening 
was caused by their effect on cell turnover, I tested the differences in the decline of 
telomere length with each treatment, adjusting for CPD. The effect of IL1B on telomere 
shortening was attenuated only to some extent and retained borderline significance 
[IL1B: -4.1%/PD (95%CI:-5.7, -2.4) vs. Control: -2.5%/PD (95%CI:-4.4, -0.7), 
p=0.067] (Figure 6 and Table 1). The respective regression models in each donor 
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separately also showed that the adjustement for CPD did not change the effect of IL1B 
on telomere shortening. This effect of IL1B compared to the control remained 
significant in donors 1 and 3 (p=0.03 and p=0.05, respectively) as before the 
adjustment. In addition, the effect of the combination of high glucose and IL1B on 
telomere shortening remained borderline significant in donor 3 after the adjustment for 
CPD (p=0.06).  
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Figure VI-5. The shortening of mean telomere length over time of culture in each treatment. A) In pooled data from all four 
donors, B) In each of the four donors separately. 
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Figure VI-6. The shortening of mean telomere length over the number of cell divisions occurring during the experiment, as 
reflected by the cumulative population doublings (CPD), in each treatment. 
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1.3.4 MtDNA copy number per nucleus 
 In all treatments, a statistically significant increase in the number of mtDNA copies per 
nucleus over time was observed (r= 0.19, p= 0.019). A modest increase in the number of 
mtDNA copies per nucleus was also observed with the number of cell divisions (r= 0.16, 
p= 0.056). The cultures from the four donors displayed significant differences in the 
number of mtDNA copies per nucleus (p= 0.041). After adjusting for donor, treatment with 
BSO resulted in a greater increase in the number of mtDNA copies per nucleus over the 
time of culture compared to the control [BSO: 0.2%/day (95%CI:-0.2, 0.6) vs. Control: 
0.1%/day (95%CI:-0.1, 0.4), p=0.047] (Figure 7 and Table 1). The effect of the treatments 
on telomere length was also compared on a donor per donor basis. Treatment with BSO 
resulted in a significantly higher increase in the number of mtDNA copies per nucleus over 
the time of culture compared to the control in donor 2 (p=0.02). This effect was only 
observed in cultures generated from donor 2, whereas the regression models testing the 
change in mtDNA copies over the time of culture in the three other donors were not 
significant. As shown in Figure 7B, where the curves of mtDNA copies change over time 
are plotted separately for each donor, there is no specific pattern of the treatments effect in 
all four donors. 
 The effect of BSO was not altered when adjusting for CPD in both the pooled data 
analysis [BSO: 2.3%/PD (95%CI:-0.8, 5.6) vs. Control: 1.5%/PD (95%CI:0.0, 3.1), 
p=0.042] (Figure 8 and Table 1) and the the donor per donor analysis (Donor 2: BSO vs 
control, p= 0.01). No other treatment had a statistically significant effect on the number of 
mtDNA copies per nucleus compared to the control.  
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Figure VI-7. The change in the number of mitochondria per cell, as reflected by the copy number of mtDNA per nucleus, 
over time in each of the treatments. A) In pooled data from all four donors, B) In each of the four donors separately. 
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Figure VI-8. The change in the number of mitochondria per cell, as reflected by the copy number of mtDNA per nucleus, 
over the number of cell divisions occurred during the experiment [cumulative population doublings (CPD)] in each 
treatment. 
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Table VI-1. Percentage changes in mean telomere length and mtDNA copies per nucleus over the time of culture (days) or 
cell divisions occurred during the experiment (CPD). The primary experimental data on these parameters are presented 
in Appendix II (page 370).  
 
 
Telomere Length mtDNA CPD 
 
%/day 
(95%CI) 
P 
%/CPD 
(95%CI) 
P 
%/day 
(95%CI) 
P 
%/CPD 
(95%CI) 
P 
CPD/day 
(95%CI) 
P 
CONTROL 
-0.6 
(-0.8- -0.3)  
-2.5 
(-4.4- -0.7)  
0.1  
(-0.1- 0.4)  
1.5  
(0.0- 3.1)  
0.16  
(0.14- 0.18) 
 
BSO 
-0.2 
(-0.6- 0.2) 
0.112 
-0.9 
(-4- 2.2) 
0.843 
0.2  
(-0.2- 0.6) 
0.047 
2.3  
(-0.8- 5.6) 
0.042 
0.11  
(0.09- 0.13) 
0.006 
GLUCOSE 
-0.4 
(-0.7- 0.0) 
0.685 
-2.3 
(-4.7- 0.0) 
0.341 
0.1  
(-0.4- 0.5) 
0.436 
0.1  
(-2.9- 2.8) 
0.442 
0.14  
(0.13- 0.16) 
<0.001 
IL1B 
-0.8 
(-1.1- -0.5) 
0.012 
-4.1 
(-5.7- -2.4) 
0.067 
0.1  
(-0.1- 0.3) 
0.210 
0.3  
(-0.7- 1.4) 
0.461 
0.19  
(0.18- 0.2) 
0.093 
GLUCOSE+
IL1B 
-0.8 
(-1.2- -0.4) 
0.156 
-4.3 
(-6.3- -2.4) 
0.169 
0.3  
(0.0- 0.6) 
0.136 
1.2  
(-0.4- 2.9) 
0.230 
0.18  
(0.17- 2.0) 
0.926 
 
Percentage changes (%) in telomere length or mtDNA with days or CPD were obtained from separate regression models for each 
treatment adjusted for donor and are presented with 95% confidence intervals (CI). CPD per days were also obtained from 
separate regression models for each treatment adjusted for donor and are presented with 95% confidence intervals (CI). P values 
for the percentage changes (%) over days or CPD were obtained from regression models including all treatments as dummy 
variables compared to the control, adjusting for donor.  
%: percentage change, CPD: cumulative population doublings, mtDNA: mitochondrial DNA, IL1B: interleukin 1B, BSO: 
buthionine sulphoximine. 
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1.3.5 Apoptosis and necrosis 
 The percentage of apoptotic and necrotic cells was evaluated in duplicate, in cultures of 
each of the five treatments generated from two of the donors, after a period of seven days. 
Measurements were obtained from two independent experiments. In both experiments, all 
treatments displayed higher percentages of apoptotic and necrotic cells compared to the 
control. The results from one of the independent experiments are presented in figure 9. The 
difference between the control and each treatment was not statistically significant 
(p=0.121). However, overall there was a borderline significant difference in the percentages 
of apoptosis and necrosis (p=0.081), which appeared to be driven by the effect of the 
combination of high glucose and IL1B. The pattern was similar in the other independent 
experiment.  
1.3.6 Intracellular ROS production 
 The intracellular ROS was evaluated in duplicate, in cultures of each of the five 
treatments generated from two of the donors, after a period of seven days. Measurements 
were obtained from two independent experiments. Figure 10 shows the results from one of 
these two independent experiments. BSO induced in fibroblasts a significantly higher 
production of ROS compared to the control (p=0.033). The intracellular ROS content was 
similar in cells treated with all the other treatments and the control (p>0.2). The results of 
the second independent experiment displayed the same pattern.  
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Figure VI-9. The percentage of cells at any stage of apoptosis or necrosis in each treatment after 7 days of treatment. 
 
Due to the small number of measurements, normal distribution cannot be inferred. Thus, the graph represents median values, 
with inter-quartile range as error bars. 
*P value obtained from Kruskal-Wallis test. 
**Mann-Whitney tests between the percentages of apoptosis and necrosis in each of the treatments compared with the control 
were non-significant (p=0.121).  
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Figure VI-10. The intracellular ROS content of viable cells in each treatment after 7 days of treatment. 
 
 
Due to the small number of measurements, normal distribution cannot be inferred. Thus, the graph represents median values, 
with inter-quartile range as error bars.  
*P value obtained from Kruskal-Wallis test. 
**P value obtained from Mann-Whitney test. 
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1.3.7 Gene expression 
 TERT: Human skin fibroblasts do not normally express telomerase (Goldstein 1990). 
In order, to examine whether telomerase expression was induced by the different 
treatments, expression levels of TERT, the gene encoding the catalytic part of telomerase, 
were measured in each culture by RT-PCR. No quantifiable expression of TERT was 
detected before applying any treatment, nor at the first days of treatment (six days of 
treatment), or towards the end of the experiment (45 days of treatment), in any of the five 
treatments.  
 TFAM: In order to examine whether the increase in the mtDNA copies in the cells 
treated with BSO reflected an enhancement of mitochondria proliferation, I examined the 
expression of TFAM, the gene encoding the transcription factor responsible for 
mitochondria proliferation. TFAM mRNA levels from cells before any treatment were used 
as control, in order to calculate the relative change in expression of TFAM after six and 45 
days of treatment. The relative expression ratio of TFAM fell in the high glucose and IL1B 
treatments alone and in combination, but overall these differences were not statistically 
significant (Figure 11).  
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Figure VI-11. The change in TFAM expression levels after 45 days of treatment in 
each of the five conditions.  
 
 
Expression ratio was calculated using the REST software.  
The change in TFAM expression with each of the five treatments was calculated relatively 
to the levels of TFAM expression in each donor before the beginning of treatment.  
There were no significant differences in the changes in TFAM expression with each of the 
five treatments. 
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1.4 DISCUSSION  
1.4.1 Discussion of in vitro findings 
 The results of the present experiment suggest that pro-inflammatory conditioning with 
IL1B, which is implicated in the pathogenesis of both CVD (Galea et al. 1996) and T2D 
(Maedler et al. 2009), exacerbates the shortening of telomeres in an in vitro model of 
human cellular aging. This effect of IL1B on telomeres was only in part driven by higher 
cell turnover. In the present model, IL1B induced a moderate increase in cell turnover, and 
its effect on telomere shortening was only in part attenuated after adjustment for the 
number of cell divisions in the cultures. This is further supported by the fact that between 
the two donors‘ cultures, where the effect of IL1B on the cells‘ telomere shortening was 
more pronounced, only in one donor‘s cultures IL1B treatment led to an increased cell 
turnover. Thus, it can be speculated that pro-inflammatory conditioning with IL1B might 
exacerbate the shortening of telomeres through a still unknown pathway. The trigger of this 
proposed pathway may be a specific response to IL1B, or part of a general inflammatory 
response, such as is known to occur in early atherosclerosis and diabetes. Possibly IL1B 
deregulates the expression or the interplay of proteins essential for the protective structure 
of telomeres, the ―shelterin‖ complex, such as TRF2 (De Boeck et al. 2009). Further 
experiments are needed to explore the mechanism by which pro-inflammatory conditioning 
exacerbates the shortening of telomeres employing different inflammatory factors, or 
testing the reversibility of this phenomenon using anti-inflammatory agents such as aspirin 
and statins.  
 The effect of pro-oxidant treatment with BSO was also examined in the present 
experiment. BSO inhibits glutathione synthesis, a process essential for the intracellular 
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detoxification of peroxides (Griffith & Meister 1979). As expected, the cultures of 
fibroblasts treated with BSO exhibited a higher intracellular ROS production compared to 
control cultures; however, the high ROS levels in these cultures did not result in greater 
telomere shortening. ROS are known to cause single DNA strand breaks in G-rich 
overhangs of telomeres, which are prone to oxidative damage and which are considered to 
lead to greater telomere shortening in each cell division (von Zglinicki 2000). Such 
telomeric loss does not seem to have occurred here. Instead, the ROS-induced DNA 
damage appear to have led to a stress-associated, but telomere length-independent, arrest of 
the cell cycle (Petersen et al. 1998). This phenomenon has been described as ―stasis‖, 
where the cells are arrested at G1 phase and do not display genomic instability or critically 
short telomeres (Garbe et al. 2009). The occurrence of the phenomenon of ―stasis‖ is 
evident in the cultures generated from donor 2, where the increase in mtDNA copies was 
accompanied by a pronounced lowering of the growth rate in cultures treated with BSO 
compared to the control. In order to verify whether this increase was due to induced 
proliferation of the mitochondria, in an effort to compensate for the ROS increase (Ames et 
al. 1995), the expression of TFAM was examined. TFAM is the transcription factor 
regulating the mitochondria proliferation, and its expression was higher but not 
significantly so in BSO treated cultures compared to control cells. Thus, the observed 
increase in mtDNA content probably indicates an oxidative stress-induced cell cycle arrest 
at G1 phase rather than mitochondrial proliferation, as has been also described by Lee and 
colleagues (Lee et al. 2000). The present findings are also supported by the study of 
Ksiazek et al. (Ksiazek et al. 2008), which showed that high glucose–induced increase in 
ROS production was accompanied by double-stranded DNA breaks mainly localised to 
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non-telomeric regions of the genome. This provides a rational for the lack of effect on 
telomere length and the cell cycle arrest in cultures treated with BSO, which could have 
been caused by double stranded DNA breaks in non-telomeric regions. 
 In the present experiment high glucose concentration, alone, did not result in faster 
telomere shortening. This was not surprising given that glucose did not seem to have a 
significant effect on ROS levels in the present experiment. My hypothesis was that high 
glucose, as a substrate for the mitochondrial oxidative phosphorylation, would hasten the 
input of reducing equivalents into the electron transport chain and would thus increase the 
ROS production; apparently this did not occur in the present experimental model. The 
current literature provides conflicting evidence regarding this hypothesis. There are studies 
showing that hyperglycaemia elicits an increase in intracellular ROS production which is a 
trigger for pathways responsible for hyperglycaemia-induced cell damage (Nishikawa et al. 
2000; Piconi et al. 2006; Morgan et al. 2007). However, other studies have provided data 
arguing that high glucose induces an increase in ROS generation (Martens et al. 2005; 
Busik et al. 2008). The experiments of Busik et al. (Busik et al. 2008) demonstrated in 
endothelial cells that glucose consumption, and thus the generation of ROS, increases only 
when high glucose concentration is combined with pro-inflammatory conditioning with 
IL1B. However, in the present experiments with fibroblasts, the combination of high 
glucose and IL1B treatment did not result in higher intracellular ROS content. It is possible 
that the sensitivity to ROS generation, or the stimulus for higher consumption of nutrients, 
depends on the type of cell. In addition, although the main source of intracellular ROS in 
most cell types is the mitochondria (Lee et al. 2000), the actual substrate causing greater 
ROS generation during its catabolism in the mitochondria, might vary. For example, fatty 
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acids like palmitate have been shown to induce ROS generation in a variety of cells 
(Schonfeld 1990), thus experiments testing its effect on telomeres would be valuable. 
Besides the lack of effect on telomere length in high glucose concentration conditions has 
been observed previously by Ksiazek et al. (Ksiazek et al. 2008)where the vast majority of 
glucose-induced DNA damage was localised to non-telomeric regions of the genome.  
 The effect of the combination of high glucose and IL1B on telomere shortening was 
similar to the effect of IL1B treatment alone. High glucose did not result in higher ROS 
generation even in combination with IL1B, which could have had further aggravated 
telomere attrition. However, high glucose led to a lower cell turnover which might have 
caused a greater variation of telomere lengths in cultures treated with the combination. This 
variation is probably responsible for the decline in telomere length not being significantly 
different, when compared to the control. The lower growth rate observed in cultures treated 
with high glucose indicates that a telomere-independent cell cycle arrest must have 
occurred (Garbe et al. 2009).  
 Limitations of the present study need to be considered. The decline in mean telomere 
length of each culture was estimated here, but any elongation in specific chromosomes or in 
telomeres of subpopulations of cells would have diluted the observed effect on the rate of 
shortening. Human skin fibroblasts are considered a model of replicative senescence since 
they do not normally express telomerase (Goldstein 1990); thus the telomerase-mediated 
elongation of telomeres was not expected. In order to verify this in the present experiments, 
the expression of TERT was examined, and was undetectable both before and during the 
treatment in all cultures. Nonetheless, the possibility of alternative lengthening of telomeres 
by recombination (ALT), which was shown to occur in endothelial cells treated with BSO 
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in the study of Kruz et al. (Kurz et al. 2004), cannot be excluded. However, Kruz et al 
(Kurz et al. 2004) reported that ALT occurred only at late passages, after ~20 CPD, while 
in the present experiment the cultures treated with BSO were not grown beyond the 14 
CPD, and in general, no cultures were kept beyond the 19 CPD. A possibility which cannot 
be excluded is that the high ROS levels induced by BSO might have caused single DNA 
strand breaks or critically short telomere length in a subpopulation of cells in the culture or 
in specific chromosome arms. In this case the mean length measured in the present study 
would have been misleading. Thus, there is a possibility that oxidative stress affects the 
length of single telomeres and in this way leads to early senescence. On the other hand the 
present measurements show at least, that the mean telomere length does not gradually 
shorten under high oxidative stress levels, in contrast to high inflammatory status.   
 In conclusion, the present experiment showed that chronic inflammation, which 
characterises cardiovascular disease and diabetes before and after their onset, may 
exacerbate the shortening of telomeres and thus, result in premature senescence 
contributing to the disease development and/or progression. This observation is of 
particular importance also in the context of other clinical conditions exhibiting a chromic 
pro-inflammatory state, such as autoimmune diseases. Worthy of remark is that short 
telomeres has been observed in patients with T1D (relevant data are presented in the 
―Second result chapter‖, paragraph 3 (page 251) and in previous studies (Jeanclos et al. 
1998; Uziel et al. 2007)), rheumatoid arthritis (Steer et al. 2007) and systemic lupus 
erythematosus (Wu et al. 2007).  
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1.4.2 In vitro vs. epidemiological findings  
 The in vitro data of this chapter are not in full agreement with the epidemiological data 
of the previous chapter. The effect of inflammation on telomere length was not observed in 
the cross-sectional studies of Result Chapter 2, although the follow up data implied a role 
of inflammation in telomere length regulation. On the other hand the observed effect of 
oxidative stress on telomere length of patients in Result Chapter 2 was not supported by the 
present in vitro data; although previous in vitro studies have provided convincing data 
(Petersen et al. 1998; Serra et al. 2000; von Zglinicki 2000). Finally, the hypothesised role 
of high glucose on telomere length can be disputed, since both the epidemiological and the 
in vitro data indicate the absence of a detrimental effect.  
 The discrepancies between the epidemiological and the in vitro data of the present 
thesis could either be attributed to the poor performance of the inflammatory markers used 
in the epidemiological studies or to the fact that fibroblasts are not, physiologically, the 
most suitable cell type to use. The leukocyte mean telomere length, measured in the 
epidemiological studies, may be mainly determined by the hematopoietic stem cells or the 
differentiated leukocytes‘ telomere length, thus in vitro studies with these types of cells 
would be valuable. Additionally, the study of stress stimuli on the telomere dynamics of 
vascular endothelial cells or pancreatic cells would be more relevant to CVD and T2D 
pathogenesis, and thus more enlightening. Last but not least to consider is the selection of 
the most suitable method for measuring telomere length during in vitro experiments. A 
method which would provide us with the ability to determine the gradual mean telomere 
length changes -like the qPCR used here- but also with the ability to detect single critically 
short telomeres would be a valuable tool in similar experiments.   
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VII. GENERAL DISCUSSION 
 
Telomere length offers a novel insight into the basis of CVD and T2D 
predisposition, constituting a possibly inherited and early expressed risk factor. The work 
presented in this thesis explores the role of telomere length in relation to CVD, T2D and 
their common risk factors, as well as variation in relevant candidate genes. The majority of 
the work focused on factors associated with CVD and T2D development, such as oxidative 
stress and inflammation, and their role in determining the length of telomeres.  
 
1. CONCLUSIONS  
1.1 THE ROLE OF TELOMERE LENGTH IN CVD 
First, the data presented in this thesis showed that short telomere length is a marker 
of both monogenic and polygenic CVD, along with its complications, such as MI. The 
association of telomere length with CVD is now strongly confirmed by a large number of 
studies (Samani et al. 2001; Minamino et al. 2002; Brouilette et al. 2003; Matthews et al. 
2006; Brouilette et al. 2007; Fitzpatrick et al. 2007). The evidence so far suggests that in 
CVD, telomere length probably contributes as a primary abnormality. In support of this are 
data presented in this thesis showing that family history of CHD is in part inherited through 
short LTL (Brouilette et al. 2008; Salpea et al. 2008), most importantly, the prospective 
studies associating short baseline LTL with the risk to develop CVD (Brouilette et al. 2007; 
Fitzpatrick et al. 2007; Zee et al. 2009), and also the association of LTL with markers of 
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subclinical CVD, such as intima-media thickness (Adaikalakoteswari et al. 2007; 
Fitzpatrick et al. 2007). What remains to be determined is whether telomere length 
estimation is of clinical value; meaning whether it adds information for CVD risk 
estimation over and above the classical risk factors, currently used in risk algorithms. Also, 
information is needed on the race and ethnicity specific mean lengths and risk-effect size, 
as well as on the mean length of healthy individuals in various age groups.  
 
1.2 THE ROLE OF TELOMERE LENGTH IN T2D 
The data presented in this thesis on T2D, coupled with those from other smaller 
studies, show that T2D is also characterised by shorter telomeres (Sampson et al. 2006; 
Adaikalakoteswari et al. 2007; Olivieri et al. 2009; Salpea et al. 2009). It is not clear 
though, from the cross-sectional data available so far, whether the observed shorter 
telomeres in diabetes are a cause or consequence of the disease. Although the data are 
scarce, shorter telomeres have also been observed in type 1 diabetes patients here and 
elsewhere (Uziel et al. 2007). The aetiology of the disease in type 1 diabetes is in part 
different from that in type 2, although in both cases beta cell failure is the final event. Thus, 
one could speculate that critically short telomeres contribute to the onset of diabetes by 
eliciting senescent phenotypes in beta cells. However, in the case of type 1 diabetes again 
the data are cross-sectional, so the possibility that short telomeres are a result of the disease 
cannot be excluded.  
The epidemiology of cross-sectional telomere length estimations is different from 
the epidemiology of longitudinal telomere dynamics. The cross-sectional coupled with the 
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follow up data presented in this thesis suggest a bidirectional regulation of telomere length, 
where the single time point measurements reflect the lifelong effect of environmental 
factors in combination with the genetic effect, while telomere length trajectory is mainly 
driven by a negative feedback mechanism for protection of very short telomeres (Farzaneh-
Far et al. 2010).  
Nevertheless, telomere length seems like a useful marker for T2D since it is 
associated with disease progression or improvement. In the study of Adaikalakoteswari et 
al. telomeres were shorter in patients with impaired glucose tolerance only, compared to 
controls, and even shorter in T2D patients (Adaikalakoteswari et al. 2007). In addition, 
telomere shortening has been linked to diabetes complications, such as diabetic 
nephropathy (Verzola et al. 2008), microalbuminuria (Tentolouris et al. 2007) and 
epithelial cancers (Sampson & Hughes 2006), while it seems to be attenuated in patients 
with well-controlled diabetes (Uziel et al. 2007). The present thesis‘ follow up data showed 
that low baseline levels of CRP and short initial telomere length predicted the increase in 
telomere length. Thus, telomere length might be of use as a marker of biological age, 
providing a valuable tool in the management of T2D.  
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1.3 THE DETERMINANTS OF TELOMERE LENGTH 
The inter-individual differences in telomere length are documented to have a strong 
hereditary component (Graakjaer et al. 2004; Andrew et al. 2006) and, interestingly, the 
present thesis showed that paternal history of premature CVD, a major CVD risk factor, is 
partly expressed through inherited short LTL (Salpea et al. 2008). Thus, inheritance must 
play a major role in determining the telomere length of the embryo. Thereafter, the rate of 
shortening during life is mainly determined by the environmental factors and gene-
environment interactions (Huda et al. 2007). Even the in uterus environment influences the 
embryo‘s telomere length (Davy et al. 2009; Tarry-Adkins et al. 2009; Barnes & Ozanne 
2010). Recent population studies with follow up measurements of LTL, as well as the 
follow up data of the present thesis, suggest that baseline telomere length is associated with 
the rate of shortening (Chen et al. 2009; Nordfjall et al. 2009). More specifically, longer 
telomeres are inclined to faster shortening, whereas very short telomeres are preserved or 
even lengthened. The latter is possibly the result of stem/progenitor cells sensitization, or 
that of telomerase activation acting as a negative feedback mechanism for protection. These 
observations, though, are in contrast with the hypothesis that subjects predisposed to age-
related diseases, such as CVD, are born with shorter telomeres (Brouilette et al. 2008; 
Salpea et al. 2008). Perhaps the familial predisposition to shorter telomeres is not due to 
shorter lengths at birth, but rather due to a genetic predisposition to faster shortening. 
Experiments of in vitro ageing are needed in order to investigate whether baseline longer 
telomeres shorten faster under the effect of stress factors.  
Regarding the environmental factors determining telomere length during life, 
chronological age was shown to play a significant role, as expected. In most of the 
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individual studies employed in the present thesis, a negative correlation with age was 
observed. This is also evident in Figure 1, where the mean LTL is plotted against the mean 
age in each study sample.  
 
Figure VII-1. Mean leukocyte telomere length plotted against mean age in each of the 
study samples employed in the present thesis.  
 
 
 
More interestingly, the data so far suggest a contribution of oxidative stress. The 
present thesis showed a negative correlation with plasma oxidative stress and variation in 
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genes regulating reactive oxygen species levels (Salpea et al. 2009) and other studies have 
shown a negative correlation with a lipid peroxidation marker and oxidative DNA damage 
(Adaikalakoteswari et al. 2007; Satoh et al. 2008; Olivieri et al. 2009). What is not clear 
yet is which factors, and to what extent, contribute to the high levels of oxidative stress. 
The inverse correlation of LTL with variables reflecting the glycaemic state of patients in 
the study of Olivieri et al. (Olivieri et al. 2009) and the attenuation of telomere shortening 
in patients with good glycaemic control in the study by Uziel et al. (Uziel et al. 2007), 
suggest that hyperglycaemia might be driving the oxidative induced telomere loss in 
diabetes. However, the in vitro experiments and the epidemiological data of the present 
thesis, both cross-sectional and longitudinal, did not show any effect of high glucose on 
telomere length. Thus other risk factors, possibly linked to metabolic disorders, might be 
responsible for the oxidative induced telomere erosion.  
To this end, the contribution of inflammation should be discussed. Few studies, 
including the cross-sectional studies of this thesis, have failed to detect an association with 
inflammatory markers (Olivieri et al. 2009; Salpea et al. 2009). Nonetheless, the present 
thesis‘ follow up data showed that low grade of inflammation is an inpedent predictor of 
telomere elongation and the in vitro data showed that pro-inflammatory conditioning 
aggravates telomere shortening. Thus inflammation seems to be involved in the regulation 
of telomere length which deserves further investigation. The rate of telomere erosion and 
consequent uncapping might be regulated by factors affecting the expression of proteins 
(such as TRF2) essential for the protective shelterin complex (capping), or by factors 
affecting the activity of the enzyme telomerase. Thus, it is possible that high cellular 
metabolic rate or high inflammatory response or both might be contributing to vascular or β 
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cell senescence and decreased proliferative capacity of progenitor cells, not through 
oxidative stress, but by causing telomere uncapping or deregulation of telomerase 
expression.  
Ultimately, telomeres may offer the molecular mechanism linking the association of 
metabolic disorders and chronic inflammation with the development of premature ageing 
(De la Fuente & Miquel 2009) and age-related pathologies (Wilson et al. 2005), with 
telomere length registering the lifelong effect of environmental factors in combination with 
genetic factors. 
  
 362 
2. THE COMMON SOIL HYPOTHESIS 
The present thesis and several other studies (Adaikalakoteswari et al. 2007; Satoh et 
al. 2008; Olivieri et al. 2009) have provided data supporting the ―common soil‖ hypothesis. 
The observation that patients with diabetes, who also develop atherosclerotic CVD, have 
the shortest telomeres, suggests that the telomere-represented tissue ageing might provide 
the molecular basis to the ―common soil‖ hypothesis. In this case, the common factors 
giving rise to CVD and T2D also determine the shortening of telomeres and the subsequent 
tissue ageing underlying the pathogenesis of both diseases. Indeed, as the data of the 
present thesis‘ and other studies‘ suggest, genetic and environmental factors, common for 
T2D and CVD, play a role in determining the length of telomeres in patients. Such risk 
factors are oxidative stress, inflammation and functional SNPs in genes involved in ROS 
regulation. In order for this hypothesis, of telomere length contribution to the pathogenesis 
of CVD and T2D, to be confirmed it will require a prospective study design investigating 
the development of both diseases in the same study sample.  
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3. FUTURE WORK  
Telomere length may prove to be very useful in the management and possibly the 
prediction of CVD and diabetes, representing the contribution of tissue ageing to their 
pathology. During the past few years, significant advances have been accomplished in the 
research field that explores the role of telomeres in CVD and T2D; yet, in my opinion, there 
are key research question to be answered. The main question is whether telomere length is 
causally involved in CVD or T2D development, but also whether it can serve as a useful 
marker for the risk prediction and disease management, representing the premature 
biological ageing.  
Regarding this major research question there are convincing data for CVD but not 
for T2D. A prospective study where both the risk for CVD and T2D is examined would be 
the most useful tool for investigating the role of telomere length in risk prediction and the 
―common soil‖ hypothesis. Particularly enlightening would be studies with follow up 
measurements, since it has now become apparent that the trajectory of telomere length is 
different to its cross-sectional assessment. The few existing follow up studies have 
provided data suggesting that differentiated somatic cells are likely to have active or 
reactivated telomerase. In addition, it remains to be confirmed that LTL is a good surrogate 
measure of beta cells‘ telomere length, as it has been shown for the vascular wall cells, 
before examining whether it is a useful marker for T2D.  
To understand the connection of telomere biology with the pathogenesis of CVD 
and T2D, we need to shed light on how environmental and genetic factors predisposing to 
these diseases interact with telomere length. Epidemiological studies have shown an 
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association of CVD and T2D risk factors with LTL (Samani et al. 2001; Minamino et al. 
2002; Brouilette et al. 2003; Matthews et al. 2006; Brouilette et al. 2007; Fitzpatrick et al. 
2007; Wong et al. 2009). Although the role of oxidative stress had been shown in previous 
studies, the innovation of this thesis is the data provided supporting the role of chronic 
inflammation in the regulation of telomere length. It would be of great research interest to 
further investigate how chronic inflammation causes accelerated telomere shortening; 
whether it inhibits the protective mechanism of telomere elongation, what inflammatory 
molecules or pathways are involved and whether these interact with molecules of the 
shelterin complex, the telomerase or whether they exert their effect through an increase in 
ROS.  
On the other hand, a plausible mechanism leading to accelerated telomere 
shortening is that metabolic disorders related to CVD and T2D, which result in high 
concentration of certain nutrients, cause the oxidative-induced telomere shortening. Here 
we studied the role of hyperglycaemia which provided controversial data. The follow up 
study showed no association of well-controlled hyperglycaemia with telomere elongation, 
while the cross-sectional studies showed weak positive correlations with LTL and the in 
vitro data argued that high glucose concentration has no effect on telomere shortening. The 
data in the literature regarding the effect of high glucose levels on ROS production are also 
controversial. Thus, with the role of glucose being questioned, other nutrients involved in 
CVD and T2D pathogenesis such as the saturated fatty acids are a plausible candidate for 
examining their effect on telomere shortening. The possibly detrimental effect of chronic 
exposure to saturated fatty acids on telomere length is suggested by a study reporting that 
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omega-3 fatty acids are beneficial for telomere length preservation (Farzaneh-Far et al. 
2010) 
Of particular significance is the role of genetics in determining telomere length and 
its contribution to premature onset of age-related diseases. In this thesis it was shown that 
family history of premature CVD is associated with shorter telomeres in the offspring. On 
the other hand the follow up data of the present thesis and those of other studies support a 
negative feedback mechanism where short telomeres are preserved or lengthened, and long 
telomeres are rigorously shortened. Thus the hypothesis that those predisposed to an age-
related disease such as CVD are born with shorter telomeres is questioned. In my opinion, 
it is more likely that some individuals are genetically predisposed to develop conditions 
which lead to faster telomere shortening (e.g. high levels of oxidative stress), or that they 
have a genetic defect in the telomere protection mechanism (e.g. lower telomerase activity). 
As a result of this their telomeres get shorter faster under the burden of adverse 
environmental effects giving rise to age-related pathologies. The present thesis revealed 
genes having an effect on the telomere length which are involved in oxidative stress 
regulation and not in the telomere mechanism. On the other hand, a recent GWA study by 
Samani et al. has shown that the telomerase gene has a significant impact on the 
determination of telomere length. Therefore, it would be very interesting to study variants 
in all these candidate genes for association with telomere length in a large prospective 
cohort, with regard to CVD and T2D risk, in order to assess the significance of their effect. 
Also, birth cohort studies can prove useful for investigating the association of family 
history of age-related diseases with telomere length at birth, when the environment has not 
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yet exerted its effect. The latter is especially interesting regarding the family history of 
T2D, since there is no previous study examining its association with telomere length.  
Last but not least, there is a need to shed more light on the basic biological 
functions of telomeres, like the mechanism involved in the trigger of cell senescence by 
telomere length or structure, how this is regulated and the possible interactions of telomeres 
with other chromosome regions. 
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4. FUTURE PERSPECTIVES IN TELOMERE RESEARCH 
An important aspect of telomere biology is the hypothesis that its role in ageing and 
age-related diseases onset lies with the exhaustion of stem and progenitor cells causing 
limited regenerative capacity (Sahin & Depinho 2010). Especially in the era of stem cell 
therapy, it is mandatory to understand the mechanisms governing telomere dynamics, their 
interaction with CVD and T2D risk factors and their role in the exhaustion of progenitor 
cells. What factors determine the progenitor cells‘ proliferative capacity is crucial for 
optimizing these new promising regenerative therapies.  
Another interesting perspective of telomere research is to manage delay or prevent 
the telomere-dependent tissue senescence and exhaustion of progenitor cells with 
pharmacological agents. Telomere biology already offers therapeutic targets in the 
treatment of cancer, and it may also provide novel therapeutic targets for CVD and T2D. 
There is already evidence supporting the use of statins (Spyridopoulos et al. 2004; 
Mahmoudi et al. 2008; Satoh et al. 2009) for preventing telomere attrition, but other agents 
might be also worth testing, such as the antioxidant agent resveratrol (Li & Forstermann 
2009) or the peroxynitrite scavenger ebselen (Brodsky et al. 2004). On the other hand, 
merely identifying modifiable risk factors, which influence the longitudinal change of 
telomere length, may help us delay tissue ageing and consequently the onset of age-related 
pathologies. Improving the therapeutic strategies for ageing-related pathologies is very 
useful for an ageing population, such as that of our contemporary society.  
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VIII. APPENDICES 
APPENDIX I: THE EARSII GROUP 
EARS II Project Leader: D. St. J. O'Reilly, UK.  
EARS II Project Management Group: F. Cambien, France, G. De Backer, Belgium, D. 
St. J. O'Reilly, UK, M. Rosseneu, Belgium, J. Shepherd, UK, L. Tiret, France.  
The EARS II Group Collaborating Centres and their Associated Investigators:  
Austria: H. J. Menzel, Institute for Medical Biology and Genetics, University of Innsbruck, 
laboratory. 
Belgium: G. De Backer, S. De Henauw, Department of Public Health, University of Ghent, 
recruitment centre. 
Belgium: M. Rosseneu, Laboratorium voor Lipoproteïne Chemie/ Vakgroep Biochemie, 
University of Ghent, laboratory. Denmark: O. Faergeman, C. Gerdes, Medical Department 
I, Aarhus Amtssygehus, Aarhus, recruitment centre. 
Estonia: M. Saava, K. Aasvee, Department of Nutrition and Metabolism, Estonian Institute 
of Cardiology, Tallinn,recruitment centre. 
Finland: C. Ehnholm*, R. Elovainio**, J. Peräsalo, *National Public Health Institute, 
**The Finnish Student Health Service, Helsinki, recruitment centre. 
Finland: Y.A. Kesäniemi*, M.J. Savolainen*, P. Palomaa**, *Department of Internal 
Medicine and Biocenter, Oulu, **The Finnish Student Health Service, University of Oulu, 
recruitment centre. 
France: L. Tiret, V. Nicaud, O. Poirier, INSERM U525, Paris, EARS data centre, 
laboratory.France: S. Visvikis, Centre de Médecine Préventive, Nancy, laboratory. 
France: J. C. Fruchart, J. Dallongeville, Service de Recherche sur les Lipoprotéines et 
l'Athérosclérose (SERLIA), INSERM U325, Institut Pasteur, Lille, laboratory. 
Germany: U. Beisiegel, C. Dingler, Medizinische Klinik Universitäts-Krankenhaus 
Eppendorf, Hamburg, recruitment centre and laboratory. 
Greece: G. Tsitouris, N. Papageorgakis, G. Kolovou, Department of Cardiology, 
Evangelismos Hospital, Athens, recruitment centre. 
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Italy: E. Farinaro, Dept. of Medical Preventive Sciences, University ―Frederico II‖ of 
Naples, recruitment centre. The Netherlands: L. M. Havekes, IVVO-TNO Health Research, 
Gaubius Institute, Leiden, laboratory. 
Portugal: M. J. Halpern, J. Canena, Instituto Superior de Ciencas da Saude, Lisbon, 
recruitment centre. 
Spain: L. Masana, J. Ribalta, A. Jammoul, A. LaVille, Unitat Recerca Lipids, University 
Rovira i Virgili, Reus, recruitment centre and laboratory. 
Switzerland: F. Gutzwiller, B. Martin, Institute of Social and Preventive Medicine, 
University of Zurich, recruitment centre and laboratory. 
United Kingdom: D. St J. O'Reilly, M. Murphy, Institute of Biochemistry, Royal Infirmary, 
Glasgow, recruitment centre and laboratory. United Kingdom: S.E. Humphries, P.J. 
Talmud, V. Gudnason, R.M. Fisher, University College London School of Medicine, 
London, laboratory. 
United Kingdom: D. Stansbie, A. P. Day, M. Edgar, Department of Chemical Pathology, 
Royal Infirmary, Bristol, recruitment centre and laboratory.  
United Kingdom: F. Kee*, A. Evans**, *Northern Health and Social Services Board, 
**Department of Epidemiology and Public Health, the Queen's University of Belfast, 
Belfast, recruitment centre. 
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APPENDIX II: THE PRIMARY DATA PRODUCED BY THE IN VITRO 
EXPERIMENT PRESENTED IN THE FOURTH RESULT CHAPTER. 
 
Treatment 
Passag
e 
Dono
r 
Day of 
treatment 
Telomer
e length- 
T/S ratio 
mtDNA 
copy 
number/cel
l 
Cumulative 
population 
doublings 
CONTROL 4 3 1 1,36 3,1 1 
CONTROL 4 2 1 1,64 4,23 1 
CONTROL 4 4 1 1,65 3,89 1 
CONTROL 4 1 1 1,84 4,35 1 
BSO 4 3 1 1,36 3,1 1 
BSO 4 2 1 1,64 4,23 1 
BSO 4 4 1 1,65 3,89 1 
BSO 4 1 1 1,84 4,35 1 
D-GLUCOSE 4 3 1 1,36 3,1 1 
D-GLUCOSE 4 2 1 1,64 4,23 1 
D-GLUCOSE 4 4 1 1,65 3,89 1 
D-GLUCOSE 4 1 1 1,84 4,35 1 
IL1B 4 3 1 1,36 3,1 1 
IL1B 4 2 1 1,64 4,23 1 
IL1B 4 4 1 1,65 3,89 1 
IL1B 4 1 1 1,84 4,35 1 
IL1B+D-
GLUCOSE 
4 3 1 1,36 3,1 1 
IL1B+D-
GLUCOSE 
4 2 1 1,64 4,23 1 
IL1B+D-
GLUCOSE 
4 4 1 1,65 3,89 1 
IL1B+D-
GLUCOSE 
4 1 1 1,84 4,35 1 
CONTROL 6 2 12 1,31 3,43 3,19 
CONTROL 6 3 12 1,37 3,59 3,93 
BSO 6 2 12 2,82 4,34  
BSO 6 1 12 1,21  1,6 
D-GLUCOSE 6 1 12 1,27  2,12 
D-GLUCOSE 6 2 12 2,53 2,94 3,79 
IL1B 6 1 12 1,56 4,61 2,68 
IL1B 6 2 12 2,5 3,97 4,08 
IL1B 6 3 12 1,42 3,81 4,24 
IL1B 6 4 12 2,12 5,36 4,64 
IL1B+D- 6 1 12 2,28 5,48 2,12 
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GLUCOSE 
IL1B+D-
GLUCOSE 
6 2 12 2,05 3,35 3,83 
IL1B+D-
GLUCOSE 
6 4 12 1,92 4,65 4 
IL1B+D-
GLUCOSE 
6 3 12 1,43 4,9 4,06 
CONTROL 6 1 13 2,73 4,39 3,62 
BSO 6 4 14 1,6 4,5 3,54 
BSO 6 3 14 1,6 4,27 3,88 
D-GLUCOSE 6 4 14 1,32 3,59 3,19 
D-GLUCOSE 6 3 14 1,64 3,7 3,48 
CONTROL 7 2 15 1,26 2,87 5,05 
D-GLUCOSE 7 2 15 1,41 3,1 4,59 
IL1B 7 2 15 1,22 3,24 4,64 
IL1B+D-
GLUCOSE 
7 2 15 1,25 3,15 4,49 
CONTROL 7 3 19 1,18 5,03 5,56 
CONTROL 8 2 19 1,5 3,24 5,79 
BSO 7 3 19 1,6 4,51 5,14 
D-GLUCOSE 8 2 19 1,49 3,26 5,65 
IL1B 7 3 19 1,39 5,33 5,83 
IL1B+D-
GLUCOSE 
7 3 19 1,51 6,53 5,34 
CONTROL 7 1 20 1,71 5,07 4,35 
CONTROL 7 4 20 1,41 4,91 4,76 
D-GLUCOSE 7 1 20 1,75 3,82 4,19 
BSO 7 4 21 2,16  4,79 
D-GLUCOSE 7 3 21 1,52 6,89 5,1 
IL1B 7 1 21 1,53 3,95 3,26 
IL1B 8 2 21 1,56 5,08 5,61 
IL1B+D-
GLUCOSE 
8 2 21 1,62 4,95 5,4 
CONTROL 9 2 22 1,37 3,27 6,96 
CONTROL 8 3 24 1,23 3,92 6,11 
D-GLUCOSE 7 4 24 1,27 4,9 4,75 
CONTROL 8 4 25 2,27 3,7  
BSO 7 2 25 1,66 4,4 4,07 
BSO 8 3 25 1,68 4,26 5,38 
D-GLUCOSE 9 2 25 1,32 3,97 7,07 
IL1B 7 4 25 1,36 5,17 6,34 
IL1B+D-
GLUCOSE 
7 1 25 1,69 3,75 4,56 
IL1B+D-
GLUCOSE 
7 4 25 1,4 4,79 5,85 
D-GLUCOSE 8 3 26 1,07 3,61 6,02 
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IL1B+D-
GLUCOSE 
8 3 26 1,12 3,95 7,05 
CONTROL 8 1 27 1,71 3,85 5,53 
BSO 8 4 27 1,17 5,36 5,44 
IL1B 9 2 27 1,51 4,33 6,8 
CONTROL 10 2 28 1,25 3,67 7,99 
D-GLUCOSE 8 1 28 1,63 4,83 5,02 
IL1B+D-
GLUCOSE 
9 2 28 1,4 4,7 6,86 
BSO 8 1 29 2,15 6,22 4,54 
IL1B 8 1 29 1,85 4,82 4,23 
CONTROL 9 3 31 1,48 3,65 8,21 
CONTROL 9 4 33 1,36 3,08  
D-GLUCOSE 8 4 33 1,97 3,58  
D-GLUCOSE 9 3 33 1,37 4,07 8,25 
IL1B 9 3 33 1,52 4,32 9,46 
IL1B+D-
GLUCOSE 
8 1 34 1,76 4,19 6,06 
IL1B+D-
GLUCOSE 
8 4 34 2,23 6,69 7,93 
CONTROL 10 3 35 2,2 3,17 9,77 
CONTROL 11 2 35 1,41 4,62 10,27 
BSO 8 2 35 1,25 5,11 6,05 
BSO 9 3 35 1,5 6,2 8,16 
D-GLUCOSE 9 1 35 1,53 3,65 6,54 
IL1B 8 4 35 0,78 5,22 7,67 
IL1B 10 2 35 1,12 3,98 8,86 
IL1B+D-
GLUCOSE 
9 3 35 1,28 3,26 9,17 
CONTROL 9 1 36 2,42 5,56 7,44 
IL1B 9 1 36 1,03 5,59 5,53 
IL1B+D-
GLUCOSE 
10 2 36 1,86 3,8 8,8 
D-GLUCOSE 9 4 38 1,37 4,07 7,84 
D-GLUCOSE 10 3 38 2,08 2,88 9,48 
IL1B 9 4 38 1,44 5,25 7,84 
IL1B 10 3 38 0,38 3,29 10,65 
IL1B+D-
GLUCOSE 
10 3 38 1,57 3,29 10,23 
CONTROL 12 2 39 1,4 5,43 11,29 
CONTROL 11 3 40 1,65  11,16 
IL1B 11 2 41 1,59 4,87 9,75 
IL1B+D-
GLUCOSE 
11 2 41 0,61  9,79 
IL1B 11 3 42 1,1 3,87 11,2 
IL1B+D- 11 3 42 0,71 5,59 10,89 
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GLUCOSE 
IL1B 10 1 43 1,7 4,33 7,73 
IL1B+D-
GLUCOSE 
9 1 43 1,51 4,84 6,8 
CONTROL 11 4 46 1,49 6,7  
BSO 10 3 46 1,57 3,87 8,15 
D-GLUCOSE 10 4 46  3,24 8,87 
D-GLUCOSE 11 3 46 1,35  8,9 
IL1B 10 4 46 1,33 3,17 10,01 
IL1B+D-
GLUCOSE 
12 3 46  2,82 11,72 
CONTROL 13 2 47 1,01 5,37 11,59 
BSO 9 1 47  4,1 1,68 
BSO 9 2 47 1,14 7,6 6,74 
IL1B 12 2 47 1,06 6,83 11,3 
IL1B 12 3 47 0,83 4,07 12,15 
IL1B+D-
GLUCOSE 
12 2 47 0,78 5,43 10,91 
CONTROL 11 1 50 1,6 6,53 10,81 
IL1B 11 1 50 1,51 4,34 10,05 
IL1B 11 4 52 1,21 5,43 11,24 
IL1B+D-
GLUCOSE 
13 3 52 0,96 3,62 13,24 
IL1B 13 2 53 0,95 4,78 12,66 
IL1B+D-
GLUCOSE 
13 2 53 0,79 3,26 12,47 
D-GLUCOSE 11 4 54 1,13 6,69 10,23 
IL1B 13 3 54 1,06 3,76 13,81 
IL1B+D-
GLUCOSE 
10 1 55 1,75 6,98 7,75 
CONTROL 12 4 60 1,13 3,92  
IL1B 12 1 60 1,48 5,75 10,2 
IL1B 12 4 60 1,33 4,22 13,05 
IL1B 13 4 60 0,79 4,37 14,25 
IL1B 14 3 60 1,13 5,27 15,58 
BSO 10 1 61 1,66 5,17 7,91 
D-GLUCOSE 11 1 61  4,6 9,72 
IL1B 14 2 61 0,97 5,6 13,97 
IL1B+D-
GLUCOSE 
14 2 61 0,49 4,74 13,86 
CONTROL 13 3 63 1,26 4,46 12,15 
BSO 11 3 63 1,87 4,88 9,4 
IL1B 14 4 68 0,78 2,69 14,94 
IL1B 15 3 68 0,91 4,55 15,91 
IL1B+D-
GLUCOSE 
15 3 68 1,13 7,08 16,13 
 374 
IL1B 13 1 69 1,26  11,51 
IL1B+D-
GLUCOSE 
11 1 69 1,77 5,04 9,32 
D-GLUCOSE 12 4 70 0,95 3,67 11,47 
IL1B 15 2 71 1,39 6,41 15,41 
IL1B+D-
GLUCOSE 
15 2 71 1,26 5,58 15,17 
IL1B 16 3 77 0,8 4,14 18,22 
IL1B+D-
GLUCOSE 
16 3 77 0,79 4,26 17,93 
D-GLUCOSE 12 1 78 1,43 6,31 9,48 
IL1B 14 1 78 1,07 4,63 13,31 
IL1B 16 2 78 0,76 3,8 17,06 
BSO 12 3 80 2,12  11,97 
IL1B 17 3 80 0,85 4,27 16,8 
IL1B+D-
GLUCOSE 
17 3 80 0,71 4,15 17,71 
CONTROL 15 2 81 1,09 5,25 14,68 
BSO 11 2 81 1,61  8,19 
IL1B+D-
GLUCOSE 
12 1 81 1,39 5,28 10,96 
IL1B+D-
GLUCOSE 
16 2 81 0,85 3,93 17 
CONTROL 14 4 84 1,04 3,69  
IL1B 15 4 84 0,94 3,62 17,77 
CONTROL 13 1 85 1,41 3,73 12,89 
IL1B 15 1 85 0,53 4,92 14,24 
IL1B 17 2 85 0,87 5,1 17,9 
CONTROL 15 4 90 0,9 4,56  
CONTROL 14 1 90 0,82 4,18 13,97 
CONTROL 16 2 90 0,9 4,16 16,69 
CONTROL 15 3 90 1,26 3,94 17,57 
BSO 11 1 90 1,49 3,67 9,37 
BSO 13 3 90 0,96 4,13 14,02 
BSO 12 2 90 1,28 7,23  
D-GLUCOSE 13 1 90 1,04 3,61 12,54 
D-GLUCOSE 13 4 90 1,17 3,64 14,19 
IL1B 16 4 90 0,74 4,37 18,7 
IL1B 18 2 90 1,14 4,03 19,38 
IL1B 18 3 90 1,26 3,59 16,8 
IL1B+D-
GLUCOSE 
13 1 90 1,36 4,04 10,96 
IL1B+D-
GLUCOSE 
17 2 90 0,99 5,88 17 
IL1B+D-
GLUCOSE 
18 3 90 0,71 3,98 17,71 
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